WO2019108049A2 - Anticancer, antibacterial, alcohol-degrading, skin wound-healing, skin-regenerating, or antiasthmatic composition comprising mineral ion mixture - Google Patents

Anticancer, antibacterial, alcohol-degrading, skin wound-healing, skin-regenerating, or antiasthmatic composition comprising mineral ion mixture Download PDF

Info

Publication number
WO2019108049A2
WO2019108049A2 PCT/KR2018/015205 KR2018015205W WO2019108049A2 WO 2019108049 A2 WO2019108049 A2 WO 2019108049A2 KR 2018015205 W KR2018015205 W KR 2018015205W WO 2019108049 A2 WO2019108049 A2 WO 2019108049A2
Authority
WO
WIPO (PCT)
Prior art keywords
weight
composition
skin
cancer
mineral ion
Prior art date
Application number
PCT/KR2018/015205
Other languages
French (fr)
Korean (ko)
Other versions
WO2019108049A3 (en
Inventor
김광호
Original Assignee
(주)카데시인코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180086173A external-priority patent/KR101996383B1/en
Priority claimed from KR1020180107033A external-priority patent/KR101973198B1/en
Priority claimed from KR1020180107032A external-priority patent/KR101963614B1/en
Priority claimed from KR1020180135373A external-priority patent/KR102022671B1/en
Priority claimed from KR1020180152879A external-priority patent/KR102037431B1/en
Application filed by (주)카데시인코퍼레이션 filed Critical (주)카데시인코퍼레이션
Publication of WO2019108049A2 publication Critical patent/WO2019108049A2/en
Publication of WO2019108049A3 publication Critical patent/WO2019108049A3/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Definitions

  • the present invention relates to a composition for anticancer, antimicrobial use, alcohol decomposition, skin wound healing, skin regeneration or anti-asthmatic, which comprises a mineral ion mixture as an active ingredient. More particularly, the present invention relates to a biotite, kaolinite A mixture of mineral ions including kaolinite, Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite and Muscovite, Anticancer agents, alcohol decomposing agents, skin wound healing or skin regeneration agents, and anti-asthmatic agents.
  • chemotherapeutic agents used for treating malignant tumors are mainly used, and most of them exhibit anticancer activity by inhibiting the synthesis of nucleic acids.
  • paclitaxel, docetaxel, and other compounds have been approved by the US Food and Drug Administration (EPA) for use in clinical practice and have shown effects by over-stabilizing the microtubules of cells and inhibiting normal cell division.
  • EPA US Food and Drug Administration
  • these anticancer drugs are not only cancer cells but also normal cells, especially cell division-active normal tissues, resulting in adverse effects such as gastrointestinal mucosal damage, hair loss, abdominal pain and the like.
  • Factors such as age, early menarche, late menopause, kidney, postmenopausal obesity, family history of breast cancer, radiation exposure, oral contraceptive, hormone replacement therapy, density of breast tissue, genetic variation and benign tumors of breast Are associated with increased risk of breast cancer, among which dietary breast cancer is known to account for about 35% of all breast cancer incidences.
  • Preservatives that are safely used as conventional preservatives and are commonly used in cosmetics and medicines include preservatives such as skin allergens (Andrea Counti et al., Contact, Dermatitis, 1997, 37; 35-36) and potential as environmental hormones (Edwin et al , Toxicology and applied pharmacology, 1998, 153, 12-19) and resistance to inducing resistant bacteria.
  • preservatives such as skin allergens (Andrea Counti et al., Contact, Dermatitis, 1997, 37; 35-36) and potential as environmental hormones (Edwin et al , Toxicology and applied pharmacology, 1998, 153, 12-19) and resistance to inducing resistant bacteria.
  • Most cosmetics are suitable for the growth of microorganisms, and because of chemical changes, it is easy to decay products.
  • liver disease mortality rate is very high, 23.5 per 100,000 population (37.8 males and 9.0 females), and the number of deaths in South Korea is the highest (41.1 / 100,000) and the second highest among the 50 deaths (72.4 / 100,000) , The third leading cause of death in the 30s (10 people / 100,000 people), is the leading cause of death in the Korean middle-aged population.
  • alcoholic liver disease is a disease that can occur in most of chronic overdoses.
  • Liver is a very important organ in charge of metabolism, detoxification, degradation, synthesis and secretion in our body.
  • the liver has the function of managing the energy metabolism, and metabolizes all the nutrients absorbed from food into a substance capable of producing energy, and supplies or stores the whole body.
  • the liver has a function of synthesizing, storing and distributing fat of about 2,000 kinds of enzymes, albumin, serum proteins of bile coagulation factors, bile acid, phospholipid and cholesterol.
  • the liver has a function to excrete various metabolites through the bile duct into the duodenum, and it plays an important role in maintaining our life because of its immune function.
  • the liver has detoxification and decomposition functions to detoxify drugs, toxic substances and alcohol.
  • the hepatocyte detoxification function of this liver is likely to damage the drug, toxic and alcoholic liver disease can cause.
  • Alcoholic liver disease can be divided into alcoholic fatty liver disease, alcoholic hepatitis, and alcoholic cirrhosis according to the clinical symptoms and usually occurs when drinking 60 to 80g of alcohol per day for 10 years.
  • Alcoholic fatty liver is caused by accumulation of cholesterol and triglyceride in hepatocyte due to excessive alcohol consumption, and it can be recovered soon after this week, but if it continues drinking, it develops into hepatitis.
  • Alcoholic hepatitis is a condition of hepatocellular necrosis and inflammation, and has various symptoms such as fatigue, anorexia, weight loss, jaundice, fever, right upper abdominal pain, and about 40% of the patients develop alcoholic cirrhosis do.
  • Alcoholic cirrhosis is a condition that can not be recovered to the normal liver. It has various symptoms such as systemic fatigue, loss of appetite, ascites, esophageal varices, hemorrhage, hepatic encephalopathy and coma and has a worse prognosis than liver cirrhosis due to hepatitis virus. ), 50% of deaths from end-stage liver disease are known to be due to alcohol.
  • Wound healing is a tissue response to injury and is a process of tissue regeneration that involves the coalescence of several cell types, including keratinocytes, fibroblasts, endothelial cells, macrophages, and platelets.
  • This process involves cell proliferation and migration rates, collagen deposition and remodeling, wound contraction, and angiogenesis.
  • Skin fibroblasts play an important role in the wound healing process, where tissue function and structure are restored and regenerated. This cell moves other cells towards the wound area and regulates cell division at the edge of the wound area. In addition, it is the most important cell involved in the production and remodeling of extracellular matrix, and the proliferation and migration rate of fibroblasts play an important role in the formation of granulation tissue and later healing of wounds.
  • Cell migration to the wound is important for wound healing and regeneration, embryonic development, inflammation, and immune response.
  • the wound healing process is a complicated process of skin regeneration that occurs after the tissue is damaged, and the cell movement proceeds to the following four stages.
  • Skin wound healing is a complex process in which the skin or other organ or tissue restores itself after a wound.
  • the epidermis the outermost layer
  • the dermis the inner or deep layer
  • the protective barrier breaks, the normal physiological process of skin wound healing begins immediately.
  • the health of the injured, diseases such as age and diabetes the presence of this object or necrotic tissue can affect the rate of skin wound healing. If skin wound healing is slow, there is a risk of secondary infection through the wound site.
  • incomplete control of wound dissipation in some wounds results in excessive scar formation, leaving functional and cosmetically inferior scar tissues.
  • Asthma is a lung disease characterized by chronic airway inflammation and airway hyperresponsiveness. It is caused by air pollutants, dust, allergens, and the like. Asthma is known to be more prevalent in pediatric than adult, and is increasing with the change of diet and westernization. The pathogenesis of asthma is known to be very diverse. During this period, the immune response of the Th2 (T helper type 2) type is exaggerated to increase the secretion of interluenes -4, 5, and 13, , Many inflammatory cells including eosinophils migrate and invade into lung tissue.
  • Th2 T helper type 2
  • inflammatory cells release a variety of proinflammatory and chemoattractant factors to further exacerbate the inflammatory response, increase mucin secretion in the intratracheal goblet cells, and cause airway hyperresponsiveness. Because of this series of reactions, patients with asthma show clinical symptoms such as dyspnea, cyanosis, and chest pain. Drugs currently used to treat asthma include steroids, bronchodilators, and antibiotics. Steroids and antibiotics are used in the treatment of asthma through the suppression of immune and inflammatory responses. In the case of bronchodilators, they are used by offsetting clinical symptoms such as dyspnea.
  • these drugs have antimicrobial resistance including side effects such as immunosuppression, inhibition of bone marrow production, and adverse effects in long-term use, and thus they are very limited in use as asthma treatment agents. Therefore, the development of natural products or new compounds that overcome these side effects, have less toxicity, and have excellent therapeutic effects, are constantly under development.
  • the inventors of the present invention have been studying to develop a substance safe for human body while having an effect on anticancer, antibacterial, alcohol decomposition, skin wound healing or skin regeneration, asthma prevention and treatment, biotite, kaolinite
  • a mineral ion mixture comprising Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite and Muscovite is a cancer cell Inhibiting proliferation, exhibiting excellent antimicrobial activity, having an alcohol-decomposing effect, forming a neoplastic tissue at a skin incision site, reducing scarring, and having an anti-asthmatic effect and being safe for a human body.
  • a technical problem to be solved by the present invention is to provide a composition for anti-cancer using an effective ingredient of a mineral ion mixture having excellent anti-cancer effect and human safety.
  • Another object of the present invention is to provide a method for preventing, ameliorating or treating cancer by administering the composition for cancer therapy to a subject.
  • Another object of the present invention is to provide an antimicrobial composition comprising a mineral ion mixture having excellent antibacterial activity and excellent human safety as an active ingredient.
  • Another object of the present invention is to provide an antiviral agent comprising the antimicrobial composition.
  • Another object of the present invention is to provide a composition for alcohol decomposition which comprises a mineral ion mixture having an alcoholysis effect as an active ingredient.
  • Another object of the present invention is to provide a composition for the treatment or prevention of hangover, liver function, or alcoholic liver disease comprising the composition for alcoholysis.
  • Another object of the present invention is to provide a method for preventing, ameliorating or treating alcoholic liver disease by administering the composition for alcoholysis to an individual.
  • Another object of the present invention is to provide a composition for skin wound healing and skin regeneration comprising a mineral ion mixture as an active ingredient.
  • Another object of the present invention is to provide a method for preventing skin wounds, improving or treating skin wounds and regenerating skin by administering compositions for skin wound healing and skin regeneration to individuals.
  • Another object of the present invention is to provide an anti-asthmatic composition comprising a mineral ion mixture having an anti-asthmatic effect as an active ingredient.
  • Another object of the present invention is to provide a method for preventing, ameliorating or treating asthma by administering the composition for anti-asthma.
  • the present invention provides a method for producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegrad
  • the present invention provides a method for preventing, ameliorating or treating cancer by administering the anticancer composition to a subject.
  • the present invention provides a method of producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegrad
  • an antiviral agent comprising the antibiotic composition.
  • the present invention provides a method of producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegrad
  • the present invention provides a composition for alcohol treatment, prevention of hangover, prevention of liver function or composition for the treatment or prevention of alcoholic liver disease comprising the composition for alcoholysis.
  • the present invention provides a method for preventing, ameliorating or treating alcoholic liver disease by administering the composition for alcoholysis to an individual.
  • the present invention provides a method of producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegrad
  • the present invention provides a method for preventing skin wounds, improving or treating skin wounds and regenerating skin by administering compositions for skin wound healing and skin regeneration to individuals.
  • the present invention provides a method of producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegrad
  • the present invention provides a method for preventing, ameliorating or treating asthma by administering the composition for anti-asthma.
  • the mineral ion mixture of the present invention can be used in combination with human breast cancer cell line MDA-MB-231, human liver cancer cell line HepG2, human lung cancer cell line A549, human ovarian cancer cell line OVCA 429, human blood cancer cell line HL60, human skin cancer cell line A375, Can inhibit cancer cell proliferation of cell line RCC4 (-) and human colon cancer cell line HCT116, and thus can be usefully used as an anticancer composition; Excellent antimicrobial activity against various fungi; It is effective in reducing hangover in the short term due to its excellent alcohol-decomposing effect, and is effective in improving liver function when taken over a long period of time; It is free from skin irritation and cytotoxicity, has excellent human stability, but also forms new tissue at the wound area and reduces scars, and is effective for skin wound healing and skin regeneration; It inhibited or eliminated various asthma symptoms induced by ovalbumin.
  • IL-4 a cytokine associated with Th2 was induced.
  • the composition containing the mineral ion mixture of the present invention is safe as a human body and has anticancer, antibacterial, alcohol decomposition, skin wound healing or skin regeneration and anti-asthmatic effect, so that it is useful as a pharmaceutical, cosmetic and food composition Can be used.
  • FIG. 1 is a graph showing cell viability by culturing Raw264.7 cells for 24 hours in a mineral ion mixture (puritone) treated at different concentrations.
  • FIG. 2 is a photograph of cells cultured for 24 hours in the Raw264.7 cells treated with puritone by concentration.
  • FIG. 3 is a graph showing cell viability by culturing Raw264.7 cells for 48 hours after treating puritone by concentration
  • Fig. 4 is a photograph of cells cultured for 48 hours in the Raw264.7 cells treated with puritone by concentration.
  • FIG. 5 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human breast cancer cell line MDA-MB-231 for 24 hours after treatment with puritone by concentration.
  • FIG. 6 is a photograph of cells cultured for 24 hours in a human breast cancer cell line MDA-MB-231 treated with puritone by concentration.
  • FIG. 7 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human breast cancer cell line MDA-MB-231 at a concentration of puritone by concentration for 48 hours
  • FIG. 9 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human liver cancer cell line HepG2 for 24 hours after treatment with puritone by concentration.
  • FIG. 10 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human liver cancer cell line HepG2 at different concentrations of puritone for 48 hours.
  • FIG. 11 is a graph showing the effect of suppressing the proliferation of cancer cells by culturing the human lung cancer cell line A549 for 24 hours after treatment with puritone by concentration.
  • FIG. 12 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human lung cancer cell line A549 at a concentration of puritone by concentration for 48 hours.
  • FIG. 13 is a graph showing the inhibitory effect of cancer cell proliferation by culturing human ovarian cancer cell line OVCA 429 for 3 days after treatment with puritone.
  • FIG. 14 is a photograph of a cell cultured for 3 days after treatment with puritone at a concentration of human ovarian cancer cell line OVCA 429.
  • FIG. 14 is a photograph of a cell cultured for 3 days after treatment with puritone at a concentration of human ovarian cancer cell line OVCA 429.
  • Fig. 15 shows the result of culturing the human ovarian cancer cell line OVCA 429 for 3 days after treatment with 100% of puritone.
  • FIG. 16 is a graph showing the effect of inhibiting cancer cell proliferation by culturing human blood cancer cell line HL60 for 2 days after treatment with puritone.
  • FIG. 17 is a graph showing the effect of inhibiting cancer cell proliferation by culturing human skin cancer cell line A375 for 2 days after treatment with puritone.
  • Fig. 18 is a photograph of a cell cultured for 2 days after treatment with puritone at a concentration of human skin cancer cell line A375.
  • 19 is a graph showing the effect of inhibiting cancer cell proliferation by culturing human renal cancer cell line RCC4 (-) for 2 days after treatment with puritone.
  • FIG. 20 is a photograph of a cell cultured for two days after treatment of the human renal cell carcinoma cell line RCC4 (-) with puritone by concentration.
  • FIG. 21 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 24 hours after treatment with puritone by concentration.
  • FIG. 22 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 48 hours after treatment with puritone by concentration.
  • FIG. 22 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 48 hours after treatment with puritone by concentration.
  • Figure 24 shows the antimicrobial activity of puritone against Staphylococcus aureus .
  • Figure 26 shows the antimicrobial activity of puritone against Salmonella typhimurium .
  • Figure 27 shows the antimicrobial activity of puritone against Candida albicans .
  • FIG. 29 is a graph showing the result of color analysis of activity of aldehyde dehydrogenase by puritone.
  • FIG. 30 is a photograph of a cutaneous area reduction observed visually as a skin wound healing effect through an animal experiment of puritone.
  • FIG. 31 is a graph showing the cut-off area reduction by measuring the actual size as a skin wound healing effect through an animal experiment of purite.
  • WBC white blood cell
  • 33 is a graph showing neutrophil analysis results of BALF of puritone.
  • 34 is a graph showing the results of lymphocyte analysis of BALF of puritone.
  • 35 is a graph showing the results of IgE analysis of puritan BALF.
  • FIG. 36 shows changes in lung tissue due to puritone observed using H & E staining.
  • FIG. 37 shows changes in pulmonary tissue caused by puritone using PAS staining.
  • FIG. 38 shows the results of observing the degree of expression of IL-4 by puritone.
  • compositions of the present invention may be used in combination with biotite, kaolinite, montmorillonite, serpentine, mica, clinochlore, vermiculite and And a mineral ion mixture comprising Muscovite as an active ingredient.
  • the mineral ion mixture is selected from the group consisting of Brucite, Illite, Limestone, Zeolite, Orthoclase or Orthoclase feldspar, Nepheline, Palygorskite or Attapulgite, Magnesite, Sperrylite, Krennerite, Petzieite, and the like. But are not limited to, Petzite, Gibbsite, Allophane, Phlogopite, Lepidolite, Sylvanite, Glauconite, Dolomite, (Tourmaline), Carnallite, Andradite, and Humite. ≪ Desc / Clms Page number 2 >
  • an anticancer composition comprising the mineral ion mixture as an active ingredient.
  • the present invention provides a method for preventing, ameliorating or treating cancer by administering the composition for anti-cancer to the individual.
  • an antimicrobial composition comprising the mineral ion mixture as an active ingredient.
  • the present invention provides an antiviral agent comprising the above antimicrobial composition.
  • composition for alcoholysis comprising the mineral ion mixture as an active ingredient.
  • the present invention provides a composition for the treatment or prevention of hangover, liver function, or alcoholic liver disease comprising the composition for alcoholysis.
  • the present invention provides a method for preventing, ameliorating or treating alcoholic liver disease by administering the composition for alcoholysis as described above.
  • composition for skin wound healing and skin regeneration comprising the mineral ion mixture as an active ingredient.
  • the present invention provides a method for preventing, improving or treating skin wounds and regenerating skin by administering the skin wound healing and skin regeneration composition to an individual.
  • an anti-asthmatic composition comprising the mineral ion mixture as an active ingredient.
  • the present invention provides a method for preventing, ameliorating or treating asthma by regulating the composition for anti-asthma and for regenerating skin.
  • the mineral ion mixture is selected from the group consisting of Biotite, Kaolinite, Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite and Muscovite as main components and also contains Brucite, Illite, Limestone, Zeolite, For example, Orthoclase or Orthoclase feldspar, boehmite, Nepheline, Palygorskite or Attapulgite, Magnesite, Such as Sperrylite, Krennerite, Petzite, Gibbsite, Allophane, Phlogopite, Lepidolite, Sylvanite, Glauconite, dolomite (Dolo mite, Tourmaline, Carnallite, Andradite and Humite.
  • the mineral ion mixture is referred to as "purite" .
  • the mineral ion mixture comprises 15 to 25% by weight of kaolinite, 12 to 23% by weight of biotite, 15 to 25% by weight of montmorillonite, 10 to 13% by weight of serpentine, From 3 to 5% by weight of vermiculite, from 2 to 4% by weight of moscobite, from 2 to 5% by weight of clinocole, from 1 to 3% by weight of brucite, from 1 to 3% by weight of ilite, From 1 to 3% by weight of stones, from 0.5 to 1.5% by weight of zeolites, from 0.5 to 1.5% by weight of oligoclays or oloclayspull spores, from 0.8 to 1.0% by weight of boehmite, from 0.7 to 0.9% by weight of nephelins, 0.7 to 0.9% by weight of atropulgite, 0.6 to 0.8% by weight of magnesium, 0.5 to 0.7% by weight of spearylite, 0.5 to 0.7% by weight of crenellite,
  • Puritone is a natural, 100% mineral substance that has been researched and developed in the United States and Korea based on mineral medicine for more than 20 years. It has been approved by the US Food and Drug Administration (FDA) for its safety in all parts of the human body (eye, liver, skin) and its approval as a generic medicinal product (NDC) through its component analysis, toxicity analysis and nutritional analysis. Currently, there are 5 generic drugs. Puriton Eye Relief Drop, facial treatment, skin treatment, first-aid treatment such as burn-up, and women's clean treatment.
  • FDA US Food and Drug Administration
  • NDC generic medicinal product
  • Puriton Eye Relief Drop facial treatment, skin treatment, first-aid treatment such as burn-up, and women's clean treatment.
  • Puriton Eye Drop is known to have high therapeutic efficacy against dry eye syndrome, and is effective in treating diseases like cataracts, glaucoma, and insomnia, which are close to incurable diseases.
  • Puriton Intimate Disinfection Spray is a new concept medicine with maximal therapeutic efficacy by completely capturing the bacteria of the disease from vaginitis and cystitis which are mostly women's deep troubles and general hemorrhoids. can do.
  • a commercially available liquid form may be purchased or used directly.
  • purite is a natural mineral, which can be produced by using minerals such as kaolinite, bentonite, zeolite, calcium carbonate, and mica, which are clay materials.
  • the raw material is subjected to a grinding process to process the desired fine nano-particle minerals.
  • the pulverization may be carried out in a dry or wet process or a sequential mixing process.
  • the productivity of fine fine particles is low, and fine particles can be obtained in stages, but there is a limit in mass production and precision is poor.
  • the wet process can produce very fine and precise particles that can obtain fine powder by applying a suitable amount of water to the ball mill, .
  • the particle size of the minerals used for the preparation of the purite liquid phase is very fine powder of 5000 mesh (2 ⁇ m or less) corresponding to the nanoparticles.
  • the raw materials of puritone are mainly used as raw materials for food and pharmaceuticals, and stabilized clay minerals containing montmorillonites or bentonite, which contain many kinds of colloidal minerals.
  • the major elements of clay minerals are Si, Al, Na, K, and Ti, and trace elements are Fe, Ca, S, Mg, Ce, La, Zr, and P.
  • Bioceramic powders are Fe 2 O 3 , TiO 2 , Na 2 O, SiO 2 , P 2 O 5 , CeO 2 , K 2 O, MgO, and the like.
  • the product is a composite material containing a lot of trace minerals that are refined in a colloidal state after crushing clay minerals, which are montmorillonite (or bentonite), to a fine particle size. And a colloidal trace minerals minerals that are much smaller in particle size than blood cells.
  • clay minerals recognized in Medical Mineralogy as clay minerals are the main source of purite.
  • the pulverized minerals of the wet-pulverized nanoparticles are put into a closed open type mixer by putting an appropriate amount of mineral powder and distilled water into a high-temperature and high-pressure processing apparatus. It is a process of dissolving ionized minerals essential to the human body by reacting at a high temperature with the minerals and water which are added by applying heat of 100-300 °C or more. A large amount of mineral minerals are obtained. Minerals are extracted and then subjected to a mineral precipitation process. The duration of the process affects the particle size of the ionized minerals in the liquid phase. Approximately, the aging process requires aging time of 24 hours to a week or more depending on the desired product.
  • a filtering process is performed to separate the colloidal liquid phase and the fine powder of the precipitated minerals.
  • a precise filtering process can be used to produce an aqueous solution of the separated purite minerals.
  • an anticancer composition comprising the mineral ion mixture as an active ingredient.
  • the anticancer composition comprising the mineral ion mixture in the present invention may be a pharmaceutical composition or a food composition.
  • the cancer is exemplified by thyroid cancer, stomach cancer, colon cancer, lung cancer, ovarian cancer, breast cancer, rectal cancer, liver cancer, prostate cancer, pancreatic cancer, gallbladder cancer, blood cancer, skin cancer, kidney cancer or bile duct cancer. It is not.
  • the anticancer composition of the present invention comprises 17 wt% of montmorillonite, 23 wt% of kaolinite, 14 wt% of biotite, 12 wt% of serpentine, By weight of bismuth chloride, 4% by weight of vermiculite, 3% by weight of muskobite, 3% by weight of clinocore, 2% by weight of brucite, 2% by weight of dilite, 2% by weight of limestone, 1% by weight of oleic acid, 0.5% by weight of boehmite, 0.8% by weight of nephelin, 0.8% by weight of paliquochekate or atropulgite, 0.7% by weight of magnetite, 0.6% by weight of spearylite, 0.6 wt% of light, 0.5 wt% of petzite, 0.4 wt% of gibbsite, 0.4 wt% of allophane, 0.4 wt% of floplight, 0.3 wt% of light, 0.5 w
  • the anticancer composition of the present invention may contain 0.005 to 50 wt%, more preferably 0.01 to 30 wt%, and most preferably 0.1 to 10 wt% of the mineral ion mixture based on the total weight of the composition.
  • the content of the mineral ion mixture is less than 0.005 wt%, the cancer cell proliferation inhibitory effect of the present invention can not be obtained.
  • the content of the mineral ion mixture is more than 50 wt%, the effect is not proportional to the increase of the content, And the stability of the shape is not ensured.
  • the anticancer composition containing the mineral ion mixture of the present invention has the ability to inhibit proliferation of cancer cells and is safe for human body as a natural substance.
  • the mineral ion mixture is selected from human breast cancer cell line MDA-MB-231, human liver cancer cell line HepG2, human lung cancer cell line A549, human ovarian cancer cell line OVCA 429, human blood cancer cell line HL60, human skin cancer cell line A375, (-) and the human colon cancer cell line HCT116, respectively.
  • the present invention provides a method for preventing, ameliorating or treating cancer by administering the composition for anti-cancer to the individual.
  • an antimicrobial composition comprising the mineral ion mixture as an active ingredient.
  • the antimicrobial composition comprising the mineral ion mixture in the present invention may be a pharmaceutical composition or a cosmetic composition.
  • the present invention provides an antiviral agent comprising the above antimicrobial composition.
  • antimicrobial refers to the ability to resist bacteria and refers to all mechanisms that are performed to defend against the action of microorganisms such as bacteria, fungi, yeast, and the like. These antimicrobial effects lead to preservative effects that prevent microbial spoilage.
  • the antimicrobial composition of the present invention comprises 20 wt% of biotite, 17 wt% of kaolinite, 16 wt% of montmorillonite, 12 wt% of serpentine, 4 weight% of clinocole, 4 weight% of vermiculite, 3 weight% of moscobite, 2 weight% of brucite, 2 weight% of ilite, 2 weight% of limestone, 1 weight of zeolite, 1% by weight of oleic acid, 0.5% by weight of boehmite, 0.8% by weight of nephelin, 0.8% by weight of paliquochekate or atropulgite, 0.7% by weight of magnetite, 0.6% by weight of spearylite, 0.6 wt% of light, 0.5 wt% of petzite, 0.4 wt% of gibbsite, 0.4 wt% of allophane, 0.4 wt% of floplight, 0.3 wt% of rec
  • the antimicrobial composition of the present invention may contain 0.005 to 50 wt%, more preferably 0.01 to 30 wt%, and most preferably 0.1 to 10 wt% of the mineral ion mixture based on the total weight of the composition. If the content of the mineral ion mixture is less than 0.005% by weight, the antimicrobial effect of the present invention can not be obtained. If the content of the mineral ion mixture exceeds 50% by weight, the effect may not be proportional to the content, There is a problem that the stability of the shape is not ensured.
  • composition for alcoholysis comprising the mineral ion mixture as an active ingredient.
  • the present invention provides a composition for alcohol treatment, prevention of liver function, or a composition for the treatment or prevention of alcoholic liver disease comprising the composition for alcoholysis.
  • the composition for alcoholysis comprising a mineral ion mixture in the present invention may be a pharmaceutical composition or a food composition.
  • alcoholic liver diseases include, but are not necessarily limited to, alcoholic fatty liver disease, alcoholic hepatitis, or alcoholic cirrhosis.
  • the antimicrobial composition of the present invention comprises 24% by weight of montmorillonite, 16% by weight of kaolinite, 15% by weight of biotite, 11% by weight of serpentine, By weight of bismuth chloride, 4% by weight of vermiculite, 3% by weight of muskobite, 3% by weight of clinocore, 2% by weight of brucite, 2% by weight of dilite, 2% by weight of limestone, 1% by weight of oleic acid, 0.5% by weight of boehmite, 0.8% by weight of nephelin, 0.8% by weight of paliquochekate or atropulgite, 0.7% by weight of magnetite, 0.6% by weight of spearylite, 0.6 wt% of light, 0.5 wt% of petzite, 0.4 wt% of gibbsite, 0.4 wt% of allophane, 0.4 wt% of floplight, 0.3 wt% of rec
  • the composition for alcoholysis of the present invention may contain 0.005 to 50 wt%, more preferably 0.01 to 30 wt%, and most preferably 0.1 to 10 wt% of a mineral ion mixture based on the total weight of the composition . If the content of the mineral ion mixture is less than 0.005% by weight, the alcohol decomposition effect of the present invention can not be obtained. If the content of the mineral ion mixture is more than 50% by weight, the effect may not be proportional to the content, There is a problem that the stability of the shape is not ensured.
  • the mineral ion mixture is excellent in the alcohol decomposing effect and can exhibit the hangover resolution effect in the short term, and it is expected that the long-term administration will be effective for improving the liver function.
  • the present invention provides a method for preventing, ameliorating or treating alcoholic liver disease by administering the composition for alcoholysis as described above.
  • composition for promoting skin wound healing or skin regeneration comprising the mineral ion mixture as an active ingredient.
  • the skin wound healing or skin regeneration promoting composition comprising a mineral ion mixture in the present invention may be a pharmaceutical composition or a cosmetic composition.
  • wound means a physical rupture of continuity or completeness of tissue structure
  • skin wound healing means restoration of tissue integrity. This may mean a partial or complete restoration of tissue integrity, and thus wound treatment refers to the promotion, improvement, progression, acceleration or progress of one or more steps or processes involved in the skin wound healing process.
  • the wound may be any internal wound or external wound, particularly a skin wound, where the external structural integrity of the skin is maintained, such as, for example, bruising or internal ulceration, and thus the tissue may be internal or external body tissue.
  • the tissue is skin (e.g., human skin) and the wound may be a skin wound, such as a dermal or epidermal wound.
  • skin regeneration is a tissue regeneration process for damage, which includes chemotaxis, differentiation and replication of cells, synthesis of matrix proteins, And the rest of the biological process.
  • the types of wounds to which the skin wound healing or skin regeneration composition of the present invention can be applied include, but are not limited to, veneer wounds and lacerations, surgical incisions or wounds, punctures, grazes, scratched wounds, (Eg, pressure sores), pressure sores (eg diaper rashes, frictional blisters), pressure ulcers (eg pressure sores or windows), wounds caused by heat (direct or indirect sources of heat, Bacterial or fungal infections), ulcers, chronic wounds (including, but not limited to, burns), chemical wounds (such as acid or alkaline burns) or open or intact boils, skin rashes, scratches and acne -Related injuries such as lower leg and foot ulcers, venous leg ulcers, and pressure ulcers).
  • veneer wounds and lacerations surgical incisions or wounds, punctures, grazes, scratched wounds, (Eg, pressure sores), pressure sores (eg diaper rashes, frictional blisters), pressure ulcers
  • the skin wound healing or skin regeneration promoting composition of the present invention comprises 24% by weight of montmorillonite, 16% by weight of kaolinite, 15% by weight of biotite, 11 weight%, mica 8 weight%, vermiculite 4 weight%, moscobite 3 weight%, clinocole 3 weight%, brucite 2 weight%, ilite 2 weight%, limestone 2 weight%, zeolite 1% by weight of silica gel, 1% by weight of oligo-clay or oloclayspherd spar, 0.9% by weight of boehmite, 0.8% by weight of nephelin, 0.8% by weight of paliquochetite or atropulgite, 0.7% 0.6% by weight of crenellite, 0.5% by weight of petzite, 0.4% by weight of gibbsite, 0.4% by weight of allophane, 0.4% by weight of floplight, 0.3% by weight of recrystallized silica, 0.3% 0.3% by weight
  • the skin wound healing or skin regeneration promoting composition of the present invention may contain 0.005 to 50 wt.%, More preferably 0.01 to 30 wt.%, Most preferably 0.1 to 10 wt.% Of a mineral ion mixture based on the total weight of the composition. As shown in FIG. If the content of the mineral ion mixture is less than 0.005% by weight, the effect of promoting skin wound healing and skin regeneration, which is the object of the present invention, can not be obtained. If the content exceeds 50% by weight, the effect is proportionate There is a problem that the stability of the shape can not be secured.
  • the mineral ion mixture is free from skin irritation and cytotoxicity and has excellent human stability, but also forms new tissue at the wound area and reduces scars to provide cosmetic or pharmaceutical compositions for skin wound healing and skin regeneration It can be safely used as an active ingredient.
  • the present invention provides a method of preventing skin wounds, improving or treating skin wounds and regenerating skin by administering compositions for skin wound healing and skin regeneration to individuals.
  • composition for preventing or treating asthma comprising the mineral ion mixture as an active ingredient.
  • the composition for preventing or treating asthma comprising a mineral ion mixture in the present invention may be a pharmaceutical composition or a food composition.
  • the term "asthma” refers to a disease in which the bronchus in the lung is very sensitive, sometimes the bronchus narrows, and the breathing, It is caused by allergic diseases.
  • the most common symptoms of asthma include dyspnea, cough, wheezing (whez breathing), a symptom reliever (bronchodilator) that alleviates the narrowed bronchus in a short time, or a disease modifier that prevents asthma attacks by inhibiting bronchial allergic inflammation Anti-inflammatory agents, and leukotriene modulators).
  • the asthma may be, but not limited to, bronchial asthma, allergic asthma, atopic asthma, non-atopic asthma, exercise induced asthma, aspirin asthma, cardiogenic asthma or alveolar asthma.
  • the composition for preventing or treating asthma according to the present invention comprises 19% by weight of kaolinite, 18% by weight of biotite, 17% by weight of montmorillonite, 12% % Mica, 4% by weight of vermiculite, 3% by weight of moscobite, 3% by weight of clinocore, 2% by weight of brucite, 2% by weight of ilite, 2% by weight of limestone and 1% by weight of zeolite 1% by weight, oloclase or oloclayspherd spar, 0.9% by weight boehmite, 0.8% by weight nephelin, 0.8% by weight of palycorhkate or atropulgite, 0.7% by weight of magnesium, 0.6% by weight of spearylite 0.6% by weight of crenellite, 0.5% by weight of petzite, 0.4% by weight of gibbsite, 0.4% by weight of allophane, 0.4% by weight of floplight, 0.3% by weight of recry
  • Kaolinite A1 2 Si 2 O 5 ( OH) 4) 19 Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 18 ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 17 Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 12
  • Mica AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 8 (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 4 Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 3 (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 3 Brucite (Mg (OH) 2 ) 2 Illite (KAl 1.
  • the composition for preventing or treating asthma according to the present invention contains 0.005 to 50% by weight, more preferably 0.01 to 30% by weight, most preferably 0.1 to 10% by weight, based on the total weight of the composition, of a mineral ion mixture can do. If the content of the mineral ion mixture is less than 0.005% by weight, the anti-asthmatic effect of the present invention can not be obtained. If the content of the mineral ion mixture is more than 50% by weight, the effect may not be proportional to the content, There is a problem that the stability of the shape is not ensured.
  • the mineral ion mixture can reduce the number of inflammatory cells around the bronchi or the blood vessels or reduce the mucus secretion of the bronchial goblet cells.
  • Bronchoalveolar lavage was performed in patients with asthma, and airway inflammation was confirmed.
  • lymphocytes, mast cells, eosinophils and activated macrophages were increased in bronchoalveolar lavage fluid.
  • asthma is generalized as airway inflammation disease, and most inflammatory cells are activated and secrete various mediators to induce asthma, and reduction of inflammatory cells is known to be related to the treatment of asthma (Haley KJ , et al., Am J Respir Crit Care Med, 1998; 158: 565-72).
  • asthma is a kind of asthmatic symptom, because airway stenosis and infiltration of inflammatory cells into the bronchi, goblet cells are formed, secretion of mucus is prominent, and collagen deposition is prominent. It is known.
  • the present invention provides a method for preventing, ameliorating or treating asthma by administering the composition for anti-asthma to the individual.
  • the above-mentioned "active ingredient” means a component that exhibits the desired activity alone or can exhibit activity together with a carrier which is itself inactive.
  • a pharmaceutical composition comprising a mineral ion mixture as an active ingredient.
  • the pharmaceutical composition may be any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, sterilized aqueous solutions, nonaqueous solvents, suspensions, emulsions, And may be oral or parenteral formulations of various forms.
  • a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.
  • Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used.
  • Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like.
  • excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have.
  • Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent.
  • Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
  • composition of the present invention may be administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will vary depending on the species and severity, age, sex, , The activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts.
  • the composition of the present invention may be administered as an individual therapeutic agent or in combination with another therapeutic agent, and may be administered sequentially or simultaneously with a conventional therapeutic agent. And can be administered singly or multiply.
  • administering means introducing the pharmaceutical composition of the present invention into a subject by any suitable method, and the administration route can be administered through various routes of oral or parenteral administration as long as it can reach the target tissues .
  • the specific therapeutically effective amount for a particular patient will depend upon the nature and extent of the reaction to be achieved, the particular composition, including whether or not other agents are used, the age, weight, Sex and diet of the patient, the time of administration, the route of administration and the rate of administration of the composition, the duration of the treatment, the drugs used or concurrently used with the specific composition, and similar factors well known in the medical arts.
  • the preferred dosage of the composition of the present invention will depend on the condition and the weight of the patient, the severity of the disease, the type of drug, the route of administration and the period of time, and the appropriate total daily dose can be determined by treatment However, it is generally administered in an amount of 0.001 to 1000 mg / kg, preferably 0.05 to 200 mg / kg, more preferably 0.1 to 100 mg / kg, once or several times a day.
  • the composition is not particularly limited as long as it is a target object, and any object can be applied.
  • any non-human animal such as a monkey, a dog, a cat, a rabbit, a guinea pig, a rat, a mouse, a cattle, a sheep, a pig, Including but not limited to, For example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
  • a cosmetic composition comprising a puritone as an active ingredient.
  • the cosmetic composition according to one embodiment of the present invention may contain, in addition to the friton as an active ingredient, conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, May be further added.
  • conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, May be further added.
  • the cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be prepared as a nutritional cream, a convergent lotion, a soft lotion, a lotion, an essence, a nutritional gel or a massage cream.
  • the formulation of the present invention is a paste, cream or gel
  • tosse When the formulation of the present invention is a powder or a spray, tosse, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component.
  • a spray in particular, chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
  • a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
  • the formulation of the present invention is a suspension
  • a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Castellulose, aluminum metahydroxide, bentonite, agar or tracert, etc.
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Castellulose, aluminum metahydroxide, bentonite, agar or tracert, etc.
  • the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
  • a food composition comprising a mineral ion mixture as an active ingredient.
  • the composition of the present invention When the composition of the present invention is used as a food, the composition may be added as it is or may be used in combination with other health food, health functional food or health functional food component, and may be appropriately used according to a conventional method.
  • the amount of the active ingredient to be mixed can be appropriately determined depending on the purpose of use.
  • the composition of the present invention may be added in an amount of preferably not more than 15 parts by weight, more preferably not more than 10 parts by weight, based on the raw material, in the production of food or beverage.
  • the amount may be less than the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount in the above range.
  • composition of the present invention is not particularly limited, and examples thereof include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramie noodle, other noodles, gum, ice cream , Various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and may include all foods in the conventional sense, and foods used as feed for animals.
  • the food composition of the present invention when used in the form of a drink, it may contain various sweetening agents, flavoring agents, or natural carbohydrates as additional components such as ordinary beverages.
  • the natural carbohydrates may be polysaccharides such as disaccharides such as monosaccharides such as glucose and fructose, maltose, sucrose, dextrin, cyclodextrins, and sugar alcohols such as xylitol, sorbitol and erythritol.
  • the ratio of the natural carbohydrate is not limited thereto, but may be about 0.01 to 0.04 g, and more preferably 0.02 to 0.03 g per 100 ml of the composition of the present invention.
  • the sweeteners may be natural sweeteners such as tau martin and stevia extract, and synthetic sweeteners such as saccharin and aspartame.
  • the food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
  • the puritone of the present invention is a natural substance which is harmless to the human body, has little toxicity and side effects, and can be safely used for a long time, and can be safely applied to pharmaceuticals, cosmetics and food compositions as described above.
  • MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphinyltetrazolium bromide) solution (storage concentration: 5 mg / ml) was added and further reaction was induced for 3 hours.
  • the cell viability was calculated from the OD value obtained by measuring the absorbance at 570 nm using a spectrophotometer (Molecular Device, CA, USA) in which the amount of MTT reduced to formazan was measured.
  • FIG. 1 is a graph showing the cell survival rate by culturing Raw264.7 cells in a concentration-dependent manner for 24 hours.
  • FIG. 2 is a graph showing the cell survival rate of Raw264.7 cells treated with puritone It is a photograph. As shown here, cell proliferation was observed at 0.5 to 25% for 24 hours in the cell culture, and there was little decrease in cell survival rate in RAW264.7 cells, and it was confirmed that there was no cytotoxicity.
  • FIG. 3 is a graph showing cell viability by culturing Raw264.7 cells in a concentration-dependent manner at a concentration of puritone for 48 hours.
  • FIG. 4 is a graph showing the cell viability of Raw264.7 cells after 48 hours of treatment with puritone It is a photograph. As shown here, cell proliferation was observed at 0.5 to 25% for 48 hours in the cell culture, and there was little decrease in cell survival rate in RAW264.7 cells, confirming no cytotoxicity.
  • the human breast cancer cell line MDA-MB-231 was suspended in DMEM medium (Dulbecco's Modified Eagle Medium, Gibco) supplemented with 10% fetal bovine serum and 1% penicillin at a concentration of 1 x 10 4 / Inoculated on a 96-well plate and allowed to attach for 12 hours. Puritone was treated with concentrations (0, 1, 2, 5, 10, 50, 100 ⁇ l / 200 ⁇ l (0 - 55%)) and cultured for 24 and 48 hours.
  • DMEM medium Dulbecco's Modified Eagle Medium, Gibco
  • MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphinyltetrazolium bromide) solution (storage concentration: 5 mg / ml) was added and further reaction was induced for 3 hours.
  • the cell viability was calculated from the OD value obtained by measuring the absorbance at 570 nm using a spectrophotometer (Molecular Device, CA, USA) in which the amount of MTT reduced to formazan was measured.
  • FIG. 5 is a graph showing the effect of inhibiting the proliferation of cancer cells by culturing the human breast cancer cell line MDA-MB-231 for 24 hours after treatment with puritone by concentration;
  • FIG. 6 is a graph showing the effect And then cultured for 24 hours. As shown here, it was found that the cell growth inhibition effect was 25 to 50% for 24 hours.
  • FIG. 7 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human breast cancer cell line MDA-MB-231 at a concentration of puritone by concentration for 48 hours
  • FIG. 8 is a graph showing the effect of suppressing the proliferation of human breast cancer cell line MDA- And then cultured for 48 hours. As shown here, it was found that the cell growth inhibitory effect was 25 to 50% during cell culture.
  • Puritone was tested by the following method in order to confirm the inhibitory effect of cancer cell growth on liver cancer cell line HepG2.
  • Human liver cancer cell line HepG2 was suspended in DMEM medium (Dulbecco's Modified Eagle Medium, Gibco) supplemented with 10% fetal bovine serum and 1% penicillin at a concentration of 1 x 10 4 / ml, And inoculated for 12 hours. Puritone was treated with concentration (0, 1, 2, 5, 10, 50, 100, 150 ⁇ l / 200 ⁇ l (0 - 75%)) and cultured for 24 hours and 48 hours.
  • DMEM medium Dulbecco's Modified Eagle Medium, Gibco
  • concentration 0., 1, 2, 5, 10, 50, 100, 150 ⁇ l / 200 ⁇ l (0 - 75%)
  • MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphinyltetrazolium bromide) solution (storage concentration: 5 mg / ml) was added and further reaction was induced for 3 hours.
  • the cell viability was calculated from the OD value obtained by measuring the absorbance at 570 nm using a spectrophotometer (Molecular Device, CA, USA) in which the amount of MTT reduced to formazan was measured.
  • FIG. 9 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human liver cancer cell line HepG2 for 24 hours after treatment with puritone by concentration. As shown here, it was found that the cell growth inhibition effect was 50 to 70% for 24 hours.
  • FIG. 10 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human liver cancer cell line HepG2 at different concentrations of puritone for 48 hours. As shown here, it was found that the cell growth inhibition effect was 50 to 75% for 48 hours.
  • Puritone was tested by the following method to confirm the inhibitory effect of cancer cell line A549 on cancer cell proliferation.
  • Human lung cancer cell line A549 was suspended in RPMI 1640 medium supplemented with 10% fetal bovine serum (Fetal Bovine Serum) and 1% penicillin at a concentration of 1x10 4 / ml, and 200 ⁇ l of each was inoculated in a 96-well plate and adhered for 12 hours . Puritone was treated with concentration (0, 1, 2, 5, 10, 50, 100, 150 ⁇ l / 200 ⁇ l (0 - 75%)) and cultured for 24 hours and 48 hours.
  • MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphinyltetrazolium bromide) solution (storage concentration: 5 mg / ml) was added and further reaction was induced for 3 hours.
  • the cell viability was calculated from the OD value obtained by measuring the absorbance at 570 nm using a spectrophotometer (Molecular Device, CA, USA) in which the amount of MTT reduced to formazan was measured.
  • FIG. 11 is a graph showing the effect of suppressing the proliferation of cancer cells by culturing the human lung cancer cell line A549 for 24 hours after treatment with puritone by concentration. As shown here, it was found that the cell growth inhibition effect was 50 to 70% for 24 hours.
  • FIG. 12 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human lung cancer cell line A549 at a concentration of puritone by concentration for 48 hours. As shown here, it was found that the cell growth inhibition effect was 50 to 75% for 48 hours.
  • Puritone inhibited cancer cell proliferation in ovarian cancer cell OVCA 249 by the following method.
  • FIG. 13 is a graph showing inhibitory effect on cancer cell proliferation by culturing human ovarian cancer cell line OVCA 429 for 3 days after treatment with puritone
  • FIG. 14 is a graph showing the effect of puritone treatment on human ovarian cancer cell line OVCA 429 Cell culture. As shown here, the puritone treated at a concentration of 70% showed 99% inhibition of OVCA429 cell growth.
  • Fig. 15 shows the result of culturing the human ovarian cancer cell line OVCA 429 for 3 days after treatment with 100% of puritone. As shown here, the puritone showed 99% inhibition of OVCA429 cell growth.
  • FIG. 16 is a graph showing the inhibitory effect of cancer cell proliferation by culturing human blood cancer cell line HL60 for 2 days after treatment with puritone. As shown here, HL60 cell growth inhibition was 70% at 50% puritone treatment and 99% HL60 cell growth inhibition at 70% puritone treatment.
  • FIG. 17 is a graph showing the inhibitory effect of cancer cell proliferation inhibition by culturing human skin cancer cell line A375 for 2 days after treatment with puritone.
  • FIG. 19 is a graph showing the effect of puritone treatment on human skin cancer cell line A375 It is a photograph. As shown here, A375 cell growth inhibition was 20% at 50% puritone treatment and 99% HL60 cell growth inhibition at 70% puritone treatment.
  • Puritone inhibited the cancer cell proliferation inhibition in the renal cancer cell RCC4 (-) as described above.
  • FIG. 19 is a graph showing the cancer cell proliferation inhibitory effect by culturing the human renal cell carcinoma cell line RCC4 (-) for 2 days after treatment with puritone.
  • FIG. 20 is a graph showing the effect of treating the human renal cancer cell line RCC4 And then cultured for 2 days. As shown here, the inhibition of RCC4 (-) cell growth by 70% puritone treatment was 99%.
  • FIG. 21 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 24 hours after treatment with puritone by concentration. As shown here, the inhibitory effect on cancer cell proliferation was shown to be 50 to 90% for 24 hours of cell culture.
  • FIG. 22 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 48 hours after treatment with puritone by concentration.
  • FIG. As shown here, it was found that the cell growth inhibition effect was 50 to 60% for 48 hours.
  • the puritone liquid was diluted to 50% in water. 1 mL of each sample dilution was added to the tube three times at each time point and each virus was tested. A negative control (water) and a positive control (70% ethanol) were included in each replicate.
  • One set of toxic control tubes was prepared in the same manner without the addition of virus. Virus was added to the tube at each time point (4 hours and 18 hours). 10 ⁇ l of Zika virus stock and 100 ⁇ l of influenza A (H5N1) viral stock were added to each tube and mixed thoroughly. The activity of the H5N1 strain was low and the volume required for the test was increased. Thus, the highest concentration of tested drug after virus addition was 90%, but Zika was 99%. The tubes were incubated at room temperature for 4 hours or 18 hours.
  • Virus (30 CCID50 / well) was added to monitor the antiviral activity (neutralization regulation) of intracellular compounds in half of the uninfected control. The plates were incubated at 5% CO 2 at 37 ⁇ 2 °C. Cultures were scored for the presence or absence of cytopathic effect (CPE) on day 3 for H5N1 and on day 6 for Zika virus. The endpoint titer of the sample (50% cell culture infectious dose, CCID50) was determined using the Reed-Muench method and the log reduction value (LRV) of the compound compared to the negative (water) control was calculated.
  • CPE cytopathic effect
  • Tables 8 and 9 below show the virucidal activity of puritone against Zicca virus and influenza A, respectively.
  • the neutralized control group showed that the virus was effectively detected in the titer assay.
  • the titer plate was valid and toxicity was not observed on the test plate.
  • influenza A H5N1
  • 70% ethanol was completely effective and the control group with no virus treatment was as expected.
  • the undiluted compound showed effective viral activity at contact times of 4 and 18 hours, while the 50% solution was effective at contact times of 18 hours, but less effective at contact times of 4 hours.
  • E. coli targeting component reported to have antibacterial efficacy (Escherichia coli), Staphylococcus brother, Les (Staphylococcus aureus), Pseudomonas rugi Ah Labor (Pseudomonas aeruginosa), Candida albicans (Candida albicans) and Salmonella typhimurium bunch was measured an antibacterial effect for help (Salmonella typhimurium).
  • Each microorganism was grown to 1,000,000 CFU / ml and added to each sample and purified water. After 24 hours and 7 days, the number of microorganisms in the plate was recovered. The results are shown in Table 10 and FIG. 23 to FIG.
  • Figure 24 shows the antimicrobial activity of puritone against Staphylococcus aureus .
  • Figure 26 shows the antimicrobial activity of puritone against Salmonella typhimurium .
  • Figure 27 shows the antimicrobial activity of puritone against Candida albicans .
  • 6-week-old ICR mice 24 rats
  • 400 ⁇ l and 800 ⁇ l of puritone were orally administered to the two groups one hour before autopsy.
  • Acetaldehyde Assay kit [BioAssay Systmes, Cat. No. EACT-100] was used to analyze the acetaldehyde content.
  • Standard and sample were added to each well of a 96-well plate in an amount of 20 ⁇ l, and then 80 ⁇ l of Working Reagent was added to each well, followed by reaction at room temperature for 30 minutes. The absorbance was then measured at 562 nm and the content of acetaldehyde was analyzed. As a control, tap water was used.
  • acetaldehyde content was high due to alcohol degradation by puritone from 0 hours to 3 hours after alcohol administration, but acetaldehyde content rapidly decreased after 3 hours.
  • Acetaldehyde Assay kit [BioAssay Systmes, Cat. No. EACT-100] was used to analyze the activity colorimetry of aldehyde dehydrogenase.
  • FIG. 29 is a graph showing the result of color analysis of activity of aldehyde dehydrogenase by puritone.
  • FIG. As shown here, after 3 hours of alcohol administration by puritone, ALDH increased and acetaldehyde, a causative agent of hangover, was decreased.
  • Puritone and Band-Aid Brand First Aid Hurt Free Antiseptic Liquid were sprayed 3-4 times daily for 15 days in an amount of 100 mg / kg per mouse total weight, respectively, on the incision sites of the puritone-treated group and the positive control group .
  • the incision was photographed at a constant distance from each group using a digital camera every day after incision, and the change of the wound was visually observed.
  • the area of the incision was measured , H & E staining, or M & T staining.
  • FIG. 30 is a photograph of a cut-off healing effect through an animal experiment of puritone, and a visual reduction of the incision area.
  • FIG. 31 is a graph showing an actual size of the incision area reduction as an incision healing effect through an animal experiment of puritone.
  • the wound area showed a tendency to decrease during the treatment period.
  • the wound size was larger in the puritanthus females than in the positive control group, but from the 2nd day, And it was confirmed that the size difference of about 1 mm was caused by the largest size difference between 6 days and 11 days from the wound. From this, it can be seen that the puritone significantly reduces the wound area.
  • Kaolinite A1 2 Si 2 O 5 ( OH) 4) 19 Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 18 ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 17 Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 12
  • Mica AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 8 (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 4 Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 3 (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 3 Brucite (Mg (OH) 2 ) 2 Illite (KAl 1.
  • the experimental animals used in the experiments have accumulated abundant test data and can be used for the interpretation and evaluation of the test results.
  • a specific pathogen member (SPF) mouse BALB / c mouse, was selected.
  • the number of animals was calculated as the minimum number sufficient to interpret the test results and divided into 6 groups according to the substance to be administered, and 8 animals per group were calculated.
  • the criteria for the calculation are 4 BALF samples for autopsy and 4 lungs for lung tissue.
  • the animal test schedule was observed at least once a day with a purifying period in the animal room where animals were tested after they were received.
  • the weight of the animals determined to be healthy during the refinement period was measured and ranked, and the test groups were randomly distributed so that the average weight of each group was uniformly distributed.
  • Each group was set up as a total of 5 groups: control group, ovarian albumin-induced control group (OVA), positive control group (Dexamethasone, Dex), 700 ⁇ l of purite and 1400 ⁇ l.
  • OVA ovarian albumin-induced control group
  • Dex positive control group
  • the experiment sensitizes OVA by intraperitoneal injection once a week for 2 weeks after the purifying period.
  • Positive control substances and puritone were orally administered in the morning for 5 days from the third week, and 5% OVA solution was administered in the afternoon.
  • the dose was orally administered to 28 [mu] l per body weight (g) of the experimental animals. After 5 days of administration, autopsy was performed the next day.
  • OVA ovalbumin
  • the first BALF was taken in tube # 1, the second, and the third BALF taken in tube # 2. After centrifugation at 3000 rpm for 5 minutes, the supernatant was transferred to No. 3, and the remaining pellet was mixed with 20 ⁇ l of PBS. After centrifugation at 3000 rpm for 5 minutes, the supernatant was discarded and the pellet and PBS (60 ⁇ l) were added and mixed. One 20 ⁇ l of the mixture was mixed with a total of 80 ⁇ l using a hematology analyzer (Hemavet 950FS, Drew Scientific Inc, Korea) And blood cell counts were analyzed.
  • Hemavet 950FS Hemavet 950FS, Drew Scientific Inc, Korea
  • FIG. 33 is a graph showing the result of neutrophil analysis of puritan BALF
  • FIG. 34 is a graph showing the results of lymphocyte analysis of BALF of purite.
  • FIG. 32 is a graph showing the results of white blood cell (WBC) analysis of puritan BALF
  • FIG. CON is a normal animal group
  • DEX is a dexamethasone treatment group which is an asthma treatment drug
  • 700 ⁇ l of purite is 700 ⁇ l treated with purite
  • 1400 of purite is treated with 1400 of purite.
  • FIG. 35 is a graph showing the results of IgE analysis of Puritone BALF. After completion of the treatment, an autopsy was performed to obtain serum, and immunoglobulin E (IgE) was confirmed. Immunoglobin is an antibody that is classified into five types of IgA, IgM, IgE, IgD and IgG. When parasite infections and irritable immune reactions occur, the amount of IgE increases sharply. Asthma is one of the irritable immune responses, and IgE is one of the indicators to check the occurrence and treatment of asthma. As shown here, the amount of IgE in the puritone treated group was dose-dependently decreased.
  • H & E staining is the most widely used staining method in tissue staining with hematoxylin and eosin staining.
  • Hematoxylin is used to stain nuclei containing a large amount of phosphoric acid in tissues.
  • Eosine binds with acidic and basic atomic groups to produce color, which stains the outer structure of cells such as cytoplasm and cell walls.
  • FIG. 36 shows changes in lung tissue due to puritone observed using H & E staining.
  • a is the normal group
  • b is the asthma induction group
  • c is the dexamethasone treatment group
  • d is the treatment group of 700 ⁇ l of purite
  • e is the treated group of 1400 ⁇ of purite.
  • e bronchiolar epithelial cells (hyperplasia)
  • bronchioles are filled with musos, and many inflammatory cells around bronchioles and vessels And infiltration was observed.
  • the dexamethasone treatment group (c) and the puritane treatment group (d and e) of the present invention inhibit the proliferation of bronchial epithelial cells, reduce the amount of musos in the bronchioles, and stimulate many inflammatory cells around the bronchioles and vessels ) was able to confirm a dose-dependent manner of infiltration.
  • polysaccharides, mucopolysaccharides, mucopolysaccharides and glycoproteins are present in the tissues.
  • the carbohydrate groups bound to these proteins are oxidized by periodic acid to produce aldehyde groups, Schiff's reagent) and is a purple-red principle.
  • Paraffin removal and hydration were carried out with 15 minutes of xylene, 1 minute of 80% alcohol, 1 minute of 90% alcohol and 1 minute of 100% alcohol.
  • the tissues were oxidized by soaking in 0.5% iodine solution for 10 minutes. After the oxidation, tap water flowing for 5 minutes was washed with water and lightly rinsed with primary distilled water for 3 minutes. After washing with water, the reaction solution was immersed in a Sip reagent for 10 minutes and then washed with running tap water for 5 minutes. After washing with water, it was stained with hematoxylin for 1 minute and 30 seconds and then rinsed with water for 10 minutes. After washing with water, the tissue was sealed by a mounting process and observed with a microscope.
  • FIG. 37 shows changes in pulmonary tissue caused by puritone using PAS staining.
  • the musculoskeleton was filled in the bronchus.
  • the dexamethasone treatment group (c) and the puritin treatment group (d and e) of the present invention It is possible to confirm the reduction.
  • OptEIA mouse ELISA was purchased from BD Biosciences. All analyzes were performed according to the manufacturer's instructions. All lung samples were prepared with protease inhibitor cocktail and lysis buffer prepared with RIPA buffer (Thermo Fisher Scientific). Lung tissue aliquots from all groups were weighed and homogenized with lysis buffer. The centrifuge was centrifuged at 8200 rpm for 15 minutes and the supernatant was collected and measured using a microplate reader (EZ Read 400, Biochrom, Cambourne, UK).
  • Asthma is a disease caused by an imbalance of Th1 and Th2 due to an irritable immune response, especially the IL-4 related to Th2.
  • FIG. 38 shows the results of observing the degree of expression of IL-4 by puritone.
  • CON is a normal animal group
  • OVA is an egg white albumin-induced control group
  • DEX is treated with dexamethasone, which is a therapeutic agent for asthma
  • 700 ⁇ l of purite is treated with 700 ⁇ l of purite
  • 1400 ⁇ l of purite is treated with 1400 ⁇ l of purite It means a group.
  • the expression of IL-4 was found to be decreased in dependence on the purite concentration.
  • the composition containing the mineral ion mixture of the present invention is safe as a human body and has anticancer, antibacterial, alcohol decomposition, skin wound healing or skin regeneration and anti-asthmatic effect, so that it is useful as a pharmaceutical, cosmetic and food composition Can be used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to an anticancer, antibacterial, alcohol-degrading, skin wound-healing or skin-regenerating, and antiasthmatic composition comprising a mineral ion mixture as an effective ingredient. A mineral ion mixture comprising biotite, kaolinite, montmorillonite, serpentine, mica, clinochlore, vermiculite, and muscovite can inhibit the proliferation of the human breast cancer cell line MDA-MB-231, the human liver cancer cell line HepG2, the human lung cancer cell line A549, the human ovarian cancer cell line OVCA 429, the human blood cancer cell line HL60, the human skin cancer cell line A375, the human renal cancer cell line RCC4(-), and the human colon cancer cell line HCT116 and thus can be useful as an anticancer composition; exhibits excellent antibacterial activity against various bacteria; can degrade alcohol at superb efficiency, thus quickly mitigating hangovers, and is effective for improving liver functions when ingested over a long period of time; is free of skin irritation and cytoxicity, is highly stable in humans, and is effective for skin wound healing and skin regeneration thanks to acting to form new tissue at a wound region and to reduce scars; and plays a role in suppressing or removing various ovalbumin-derived asthmatic symptoms, restrains the proliferation of white blood cells, neutrophils, and lymphocytes in BALF and serum, inhibits the proliferation of bronchial epithelial cells, and is found to reduce mucus in the bronchiole and to decrease the infiltration of many inflammatory cells around the bronchiole and vessels in a dose-dependent manner. In addition, the composition induced the reduction of the Th2 cell-related cytokine IL-4. Therefore, a composition comprising the mineral ion mixture of the present invention can be useful as a pharmaceutical, cosmetic, and food composition because it is a natural material safe to the human body and exhibits anticancer, antibacterial, alcohol-degrading, skin wound-healing or skin-regenerating, and antiasthmatic effects.

Description

미네랄 이온 혼합물을 포함하는 항암용, 항균용, 알콜분해용, 피부상처 치유, 피부재생용 또는 항천식용 조성물Anti-cancer, antimicrobial, alcohol decomposition, skin wound healing, skin regeneration or anti-asthmatic composition containing a mineral ion mixture
본 발명은 미네랄 이온 혼합물을 유효성분으로 포함하는 항암용, 항균용, 알콜분해용, 피부상처 치유, 피부재생용 또는 항천식용 조성물에 관한 것으로서, 보다 상세하게는 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물을 유효성분으로 포함하는 항암용, 항균용, 알콜분해용, 피부상처 치유 또는 피부재생용, 항천식용 조성물에 관한 것이다. The present invention relates to a composition for anticancer, antimicrobial use, alcohol decomposition, skin wound healing, skin regeneration or anti-asthmatic, which comprises a mineral ion mixture as an active ingredient. More particularly, the present invention relates to a biotite, kaolinite A mixture of mineral ions including kaolinite, Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite and Muscovite, Anticancer agents, alcohol decomposing agents, skin wound healing or skin regeneration agents, and anti-asthmatic agents.
항암제는 악성종양을 치료하기 위해 사용하는 방법들 중 수술이나 방사선 요법을 제외한 화학요법제를 총칭하는 것으로, 주로 핵산의 합성을 저해하여 항암활성을 나타내는 물질이 대부분이다. 그 예로, 파클리탁셀(paclitaxel), 도세탁셀(docetaxel) 등의 화합물은 미국 식품의약국의 승인을 받아 실제 임상에서 사용되고 있으며, 세포의 미세소관을 과도하게 안정화하여 정상적인 세포 분열을 억제함으로써 그 효과를 나타낸다. 하지만, 이들 항암제는 암세포 외에도 정상세포, 특히 세포분열이 활발한 정상 조직에도 손상을 입혀 위장관 점막 손상, 탈모, 복통 등의 부작용을 나타내며, 약물 자체의 심각한 독성뿐만 아니라 수용액 상에서의 낮은 용해도로 인하여 그 치료효능이 반감되는 결과를 가져온다. 따라서, 이러한 약물의 부작용을 최소화하고 암세포에서 효과를 극대화할 수 있는 새로운 암 치료제의 개발이 요구되고 있다. 유방암은 미국을 비롯한 서구 국가에서 발병률이 가장 높은 암으로 한국을 포함한 동양인에서는 발생이 다소 낮은 편이었지만, 식생활의 변화와 환경의 변화로 인해 한국인 여성에서의 발생률은 매년 증가하고 있는 추세이다. 유방암을 일으키는 여러 가지 요인으로는 연령, 이른 초경, 늦은 폐경, 신장, 폐경 후 비만, 유방암 가족력, 방사선 노출, 경구피임약, 호르몬 대체 치료법, 유방 조직의 밀도, 유전자 변이 및 유방의 양성종양과 같은 요인들이 유방암의 발생 위험을 증가시키며 그 중에서도 식생활에 의한 유방암 발생이 전체 유방암 발생률 중 약 35%를 차지한다고 알려져 있다.Among chemotherapeutic agents used for treating malignant tumors, chemotherapeutic agents other than surgery and radiation therapy are mainly used, and most of them exhibit anticancer activity by inhibiting the synthesis of nucleic acids. For example, paclitaxel, docetaxel, and other compounds have been approved by the US Food and Drug Administration (EPA) for use in clinical practice and have shown effects by over-stabilizing the microtubules of cells and inhibiting normal cell division. However, these anticancer drugs are not only cancer cells but also normal cells, especially cell division-active normal tissues, resulting in adverse effects such as gastrointestinal mucosal damage, hair loss, abdominal pain and the like. In addition to the serious toxicity of the drug itself and low solubility in the aqueous solution, Resulting in half the efficacy. Therefore, there is a need to develop a novel cancer treatment agent that can minimize the side effects of such drugs and maximize the effects of the cancer cells. Breast cancer has the highest incidence rate in Western countries including the United States, and it has been reported to be slightly lower in Asians, including Koreans. However, the incidence in Korean women is increasing every year due to changes in diet and environment. Factors such as age, early menarche, late menopause, kidney, postmenopausal obesity, family history of breast cancer, radiation exposure, oral contraceptive, hormone replacement therapy, density of breast tissue, genetic variation and benign tumors of breast Are associated with increased risk of breast cancer, among which dietary breast cancer is known to account for about 35% of all breast cancer incidences.
한편, 생활주변에서 널리 이용되는 식품, 의약품, 화장품 등의 많은 제품에는 내부 물성의 변화를 방지하고, 일정기간 동안의 보존을 위해서 인체에 무익한 방부제가 첨가되어 있다. 기존의 방부제로서 가장 안전하며 화장품, 의약품에 범용적으로 사용되는 파라벤류의 방부제들은 피부 알러지 (Andrea Counti et al., Contact Dermatitis, 1997, 37; 35-36)와 환경호르몬으로서의 가능성 (Edwin et al., Toxicology and applied pharmacology, 1998, 153; 12-19) 및 내성균 유발이라는 문제점을 가지고 있다. 대부분의 화장품은 미생물의 성장에 적합한 상태이고 화학적 변화로 인해 제품의 부패가 쉬우므로 이를 방지하기 위해 인공방부제인 값싼 파라벤류, 이미다졸리디닐 우레아, 디아졸리디닐우레아, 페녹시에탄올 등이 사용되고 있다. 최근에는 단백질, 검, 비타민, 약용식물 등 새로운 첨가물이 추가되면서 미생물의 작용으로 생기는 변화도 다양해지고 있으므로, 이로 인한 방부기능의 약화로 인하여 첨가되는 방부제의 함량은 증가하고 있는 추세이다. 방부제의 사용량이 증가함에 따라, 피부에 대한 자극 및 알러지 증상이 유발될 위험성도 증가하고 있다. 또한, 천연활성 물질들의 경우, 대부분 색취, 안정성 저하, 제형상의 문제점 등으로 인하여 상용화되지 못하고 있으며, 편백 추출물인 히노키티올 (hinokitiol)과 목련 추출물인 마그놀롤 (magnolol), 자몽추출물인 DF-100 등 극히 일부만이 상용화되고 있는 실정이다. 따라서, 기존의 합성방부제의 부작용을 줄이고, 제형상의 안정성 등을 보유한 항바이러스제에 관한 연구가 활발히 진행되고 있다.On the other hand, many products such as foods, medicines, cosmetics, etc., widely used in daily lives, have added preservatives that are useless to the human body to prevent changes in internal properties and to preserve them for a certain period of time. Preservatives that are safely used as conventional preservatives and are commonly used in cosmetics and medicines include preservatives such as skin allergens (Andrea Counti et al., Contact, Dermatitis, 1997, 37; 35-36) and potential as environmental hormones (Edwin et al , Toxicology and applied pharmacology, 1998, 153, 12-19) and resistance to inducing resistant bacteria. Most cosmetics are suitable for the growth of microorganisms, and because of chemical changes, it is easy to decay products. To prevent this, artificial preservatives such as cheap parabens, imidazolidinyl urea, diazolidinyl urea, phenoxyethanol etc. are used . In recent years, the addition of new additives such as proteins, gums, vitamins and medicinal plants has been accompanied by various changes caused by the action of microorganisms. As a result, the preservative content to be added is increasing due to the deterioration of the preservative function. As the use of preservatives increases, the risk of skin irritation and allergic symptoms is also increasing. In addition, the natural active materials are not commercialized because of coloration, poor stability, poor shape, and the like. In addition, hinokitiol, magnolia, Magnolia extract, and grapefruit extract, DF-100 And so on. Accordingly, researches on antiviral agents having a stabilized form and reducing the side effects of existing synthetic preservatives have been actively conducted.
우리나라 간질환 사망률은 인구 십만명 당 23.5명(남자 37.8명, 여자 9.0명)으로 매우 높으며, 40대 사망원인 1위(41.1명/10만명), 50대 사망원인 2위(72.4명/10만명), 30대 사망원인 3위(10명/10만명)를 차지하는 등 간질환은 한국 중년층 인구의 주요 사망원인이다. 특히 알콜성 간질환은 만성과다 음주자의 대부분에서 나타날 수 있는 질환이다. 간은 우리 몸에서 각종 대사 작용, 해독, 분해, 합성 및 분비를 담당하는 매우 중요한 장기로, 그 기능을 자세히 살펴보면 다음과 같다. 첫째, 간은 에너지 대사를 관리하는 기능이 있어 음식물에서 흡수된 모든 영양소들을 에너지를 생산할 수 있는 물질로 대사시켜 전신에 공급하거나 저장한다. 둘째, 간은 약 2,000여종의 효소, 알부민, 응고인자들의 혈청단백, 담즙산, 인지질, 콜레스테롤 등의 지방을 합성하고 저장하며 분배하는 기능이 있다. 셋째, 간은 각종 대사산물을 담관을 통해 십이지장으로 배설하는 기능이 있으며, 면역기능이 있어서 우리의 생명유지에 중요한 역할을 한다. 마지막으로, 간은 해독 및 분해 기능이 있어 약물, 독성물질, 술 등을 해독시킨다. 하지만 이러한 간의 해독기능은 간세포를 손상시키기 쉬워 약물성, 독성, 알콜성 간질환 등을 유발시킬 수 있다. 알콜성 간질환은 임상증상에 따라 알콜성 지방간, 알콜성 간염, 알콜성 간경변증으로 크게 나눌 수 있고 대개 하루 60-80g의 알콜을 10년 정도 마실 때 발생한다. 알콜성 지방간은 과다한 알콜 섭취로 인해 간세포 안에 콜레스테롤과 중성지방이 축적되어 발생하는 것으로 금주만 하게 되면 곧 회복할 수 있으나, 계속 음주하게 되면 간염으로 발전하게 된다. 알콜성 간염은 간세포의 괴사와 염증이 발생한 상태로, 피로감, 식욕부진, 체중감소, 황달, 발열, 우상복부통증 등의 다양한 증상을 보이며, 이를 앓는 환자 중 약 40%는 알콜성 간경변증으로 발전하게 된다. 알콜성 간경변증은 정상 간으로 회복이 불가능한 상태로, 전신 피로감, 식욕감퇴, 복수, 식도정맥류, 출혈, 간성뇌증, 혼수 등의 다양한 증상을 보이며, 간염 바이러스에 의한 간경변증보다 예후가 불량하여 구미(歐美)에서는 말기 간질환으로 인한 사망의 50%가 알콜에 의한 것으로 알려져 있다.In Korea, liver disease mortality rate is very high, 23.5 per 100,000 population (37.8 males and 9.0 females), and the number of deaths in South Korea is the highest (41.1 / 100,000) and the second highest among the 50 deaths (72.4 / 100,000) , The third leading cause of death in the 30s (10 people / 100,000 people), is the leading cause of death in the Korean middle-aged population. Especially alcoholic liver disease is a disease that can occur in most of chronic overdoses. Liver is a very important organ in charge of metabolism, detoxification, degradation, synthesis and secretion in our body. First, the liver has the function of managing the energy metabolism, and metabolizes all the nutrients absorbed from food into a substance capable of producing energy, and supplies or stores the whole body. Second, the liver has a function of synthesizing, storing and distributing fat of about 2,000 kinds of enzymes, albumin, serum proteins of bile coagulation factors, bile acid, phospholipid and cholesterol. Third, the liver has a function to excrete various metabolites through the bile duct into the duodenum, and it plays an important role in maintaining our life because of its immune function. Finally, the liver has detoxification and decomposition functions to detoxify drugs, toxic substances and alcohol. However, the hepatocyte detoxification function of this liver is likely to damage the drug, toxic and alcoholic liver disease can cause. Alcoholic liver disease can be divided into alcoholic fatty liver disease, alcoholic hepatitis, and alcoholic cirrhosis according to the clinical symptoms and usually occurs when drinking 60 to 80g of alcohol per day for 10 years. Alcoholic fatty liver is caused by accumulation of cholesterol and triglyceride in hepatocyte due to excessive alcohol consumption, and it can be recovered soon after this week, but if it continues drinking, it develops into hepatitis. Alcoholic hepatitis is a condition of hepatocellular necrosis and inflammation, and has various symptoms such as fatigue, anorexia, weight loss, jaundice, fever, right upper abdominal pain, and about 40% of the patients develop alcoholic cirrhosis do. Alcoholic cirrhosis is a condition that can not be recovered to the normal liver. It has various symptoms such as systemic fatigue, loss of appetite, ascites, esophageal varices, hemorrhage, hepatic encephalopathy and coma and has a worse prognosis than liver cirrhosis due to hepatitis virus. ), 50% of deaths from end-stage liver disease are known to be due to alcohol.
한편, 피부의 손상은 심각한 정도에 따라 화상, 창상, 찰과상, 궤양의 결과로 발생할 수 있다. 만약 피부 손상이 회복되지 않는다면 피부장벽으로서의 기능을 손실하여 미생물감염에 피부조직이 노출되어 피부를 더 심각하게 손상시킬 수 있다. 그러나 최근 창상 치유에 관한 연구는 세포생물학적, 분자생물학적 분야로 더욱 세분화되고 있고, 창상 치유 촉진에 관한 임상적 적용 또한 더욱 광범위해지고 있음에도 불구하고, 피부 창상 치유에 대한 세포생물학, 분자생물학적 기전에는 의문점들이 많다. 창상 치유는 손상에 대한 조직의 반응이며 조직 회복의 과정으로 몇몇 세포유형들의 합동으로 이루어지는데 이 중에는 각질세포, 섬유아세포, 내피세포, 대식세포, 혈소판을 포함한다. 이 과정은 세포의 증식률과 이동률, 콜라겐 침적과 리모델링, 창상수축, 혈관형성을 포함한다. 피부 섬유아세포는 조직의 기능과 구조가 다시 복구되고 재생되는 창상치유과정에서 매우 중요한 역할을 담당한다. 이 세포는 창상 부위 쪽으로 다른 세포들을 이동시키고 창상 부위의 가장자리에서 세포의 분열을 조절한다. 또한, 세포외기질을 생산하고 리모델링에 연루되는 가장 중요한 세포이며 섬유아세포의 증식률과 이동률은 육아조직의 형성과 후에 창상 치유에 중요한 역할을 한다. 창상으로의 세포이동은 창상 치유와 재생, 배아 발달, 염증, 면역반응에 중요하다. 창상 치유 과정은 조직이 손상을 입게 된 후, 일어나는 피부재생의 복잡한 과정으로 세포의 이동은 다음의 4단계로 진행된다. (1) 세포의 leading edge에서 세포의 projections의 형성이 액틴의 안정성에 의해서 제공된다. (2) 이동과정동안, 인테그린 (integrin)이 세포의 안쪽에 액틴의 세포골격과 세포의 바깥쪽에 세포외기질을 결합시켜 substrate와 접촉을 형성한다. (3) 세포체 수축(retraction)은 스트레스섬유의 수축(contraction) 때문에 발생한다. 스트레스 섬유는 비근육세포에서 수축구조(contractile structure)의 주요유형이다. (4) 기질로부터 트레일링 에지(trailing edge)의 탈부착이 진행된다. 성공적인 창상 치유는 세포 증식, 이동 그리고 세포외기질의 많은 생물학적 과정이 관여한다. 특히, 세포 증식과 이동은 창상부위에서 분비되는 성장인자에 의해 조절되고 이들은 세포 성장과 증식, 분화, 이동을 자극시키는 단백질 같은 거대분자이거나 호르몬 같은 소분자일 수 있다. 상처치유에 연루되는 많은 단백질들 중 일부는 액틴 리모델링과 관련이 있다. 피부상처 치유는 피부 또는 다른 기관 또는 조직이 상처 후 자신을 수복하는 복잡한 공정이다. 정상 피부에서 표피(최외각 층) 및 진피(내부 또는 심부 층)는 외부 환경에 대하여 보호 장벽을 형성한다. 일단 보호 장벽이 깨지면 피부상처 치유의 정상적인 생리적 공정이 즉시 가동된다. 다만, 부상자의 건강, 연령 당뇨와 같은 질환, 이물체 또는 괴사 조직의 존재가 피부상처 치유의 속도에 영향을 미칠 수 있다. 피부상처 치유의 속도가 느릴 경우, 상처 부위를 통해 2차 감염의 위험성이 존재한다. 또한, 일부 상처들에서 상처 소산의 불완전한 조절은 과도한 흉터 생성을 초래하여 기능적 및 미용적으로 열등한 흉터 조직을 남기는 문제점이 있다. 따라서 상처가 발생할 경우, 신속하고 부작용 없이 상처를 치유하는 것이 중요하다. 현재 피부상처 치유를 위해 사용되는 상용화된 제품에는 대표적으로 주식회사 동화약품의 후시딘과 주식회사 동국제약의 마데카솔 등이 있다. 다만 후시딘의 주성분인 푸시딘산(fucidic acid)에 대해 내성을 갖는 황색포도상구균(Staphylococcus aureus)이 늘고 있다는 연구가 보고되고 있다(Arch Dis Child 2004;89:74-44). 또한, 후시딘과 마데카솔의 사용시 알레르기 반응, 발진 등의 부작용이 꾸준히 보고되고 있어 새로운 약학에 대한 연구의 필요성이 대두되고 있다.On the other hand, skin damage can occur as a result of burns, wounds, abrasions and ulcers, depending on severity. If the skin damage is not restored, it can lose its function as a skin barrier, exposing the skin tissue to microbial infections and damaging the skin more severely. Recently, however, studies on wound healing have been subdivided into the fields of cell biology and molecular biology, and although the clinical application of wound healing has been broadened, questions on cell biology and molecular biology of wound healing have been questioned many. Wound healing is a tissue response to injury and is a process of tissue regeneration that involves the coalescence of several cell types, including keratinocytes, fibroblasts, endothelial cells, macrophages, and platelets. This process involves cell proliferation and migration rates, collagen deposition and remodeling, wound contraction, and angiogenesis. Skin fibroblasts play an important role in the wound healing process, where tissue function and structure are restored and regenerated. This cell moves other cells towards the wound area and regulates cell division at the edge of the wound area. In addition, it is the most important cell involved in the production and remodeling of extracellular matrix, and the proliferation and migration rate of fibroblasts play an important role in the formation of granulation tissue and later healing of wounds. Cell migration to the wound is important for wound healing and regeneration, embryonic development, inflammation, and immune response. The wound healing process is a complicated process of skin regeneration that occurs after the tissue is damaged, and the cell movement proceeds to the following four stages. (1) formation of cell projections at the leading edge of the cell is provided by the stability of actin. (2) During the migration process, integrin binds the extracellular matrix on the inside of the cell with the actin cytoskeleton and the outside of the cell to form contact with the substrate. (3) Cellular body retraction is caused by the contraction of stress fibers. Stress fibers are a major type of contractile structure in non-muscle cells. (4) detachment of the trailing edge from the substrate proceeds. Successful wound healing involves many biological processes of cell proliferation, migration, and extracellular quality. In particular, cell proliferation and migration are regulated by growth factors secreted at the wound site, which can be macromolecules such as proteins that stimulate cell growth and proliferation, differentiation, migration, or small molecules such as hormones. Some of the many proteins involved in wound healing are related to actin remodeling. Skin wound healing is a complex process in which the skin or other organ or tissue restores itself after a wound. In normal skin, the epidermis (the outermost layer) and the dermis (the inner or deep layer) form a protective barrier against the external environment. Once the protective barrier breaks, the normal physiological process of skin wound healing begins immediately. However, the health of the injured, diseases such as age and diabetes, the presence of this object or necrotic tissue can affect the rate of skin wound healing. If skin wound healing is slow, there is a risk of secondary infection through the wound site. In addition, incomplete control of wound dissipation in some wounds results in excessive scar formation, leaving functional and cosmetically inferior scar tissues. Thus, if a wound occurs, it is important to heal the wound quickly and without side effects. Currently commercialized products used for skin wound healing include Foshidan of Donghwa Pharmaceutical Co., Ltd. and Madecasol of Dongkuk Pharmaceutical Co., Ltd. However, studies have been reported that Staphylococcus aureus resistant to fucidic acid, a major component of fucidin, is increasing (Arch Dis Child 2004; 89: 74-44). In addition, when fucidine and madecasol are used, side effects such as allergic reactions and rashes are reported steadily, necessitating research on new pharmacology.
또한, 급속한 산업발전에 따라 최근 생활환경이 오염되고 식생활이 변화되면서 다양한 알레르기성 질환들이 증가하고 있으며, 이러한 알레르기성 질환 중에서도 특히 천식의 발병률이 크게 증가하고 있는 실정이다. 천식은 만성 기도염증 및 기도과민성을 특징으로 하는 폐질환으로, 대기오염물질, 황사, 알러젠(allergen) 등에 의하여 발생한다. 천식은 성인보다는 소아에서 발병률이 높은 것으로 알려져 있으며, 식습관의 변화 및 서구화에 따라 증가하고 있는 추세이다. 천식이 발병하는 기전은 매우 다양한 것으로 알려져 있으며, 이러한 기전 중에 Th2(T helper type 2) 타입의 면역반응이 항진되어 이에 따라 인터루킨(interluekin)-4, 5, 13 등의 분비가 증가하며, 이러한 반응과 연계하여 호산구를 비롯한 많은 염증세포들이 폐조직 내로 이동 및 침윤하게 된다. 또한 염증세포들은 다양한 전염증인자 및 화학주성인자들을 방출하여 염증반응을 더욱 악화시키며, 기도 내 배상세포의 점액분비를 증가시키고, 기도과민성을 야기하게 된다. 이러한 일련의 반응으로 인하여 천식환자들은 호흡곤란, 청색증, 및 흉통 등의 임상증상을 나타내게 된다. 현재 천식의 치료에 사용되고 있는 약물은 스테로이드제제, 기관지확장제 또는 항생제 등이 있다. 스테로이드 제제와 항생제의 경우, 면역반응 및 염증반응 억제를 통하여 천식치료에 사용되고 있으며, 기관지 확장제의 경우, 호흡곤란 등의 임상증상 발현 시에 이를 상쇄시킴으로써 사용되고 있다. 그러나, 이러한 약물은 면역억압, 골수생성억제 등의 부작용을 비롯한 항생제 내성, 그리고 장기사용 시 부작용이 발견되어 천식치료제로서 사용이 매우 제한적이다. 따라서 이러한 부작용들을 극복하고 독성이 적으며, 치료효과가 탁월한 천연물 혹은 새로운 화합물의 개발이 끊임없이 진행되고 있다. In addition, as a result of rapid industrial development, recent living environments have been contaminated and dietary habits have changed, and various allergic diseases have been increasing. Among these allergic diseases, the incidence of asthma is particularly increasing. Asthma is a lung disease characterized by chronic airway inflammation and airway hyperresponsiveness. It is caused by air pollutants, dust, allergens, and the like. Asthma is known to be more prevalent in pediatric than adult, and is increasing with the change of diet and westernization. The pathogenesis of asthma is known to be very diverse. During this period, the immune response of the Th2 (T helper type 2) type is exaggerated to increase the secretion of interluenes -4, 5, and 13, , Many inflammatory cells including eosinophils migrate and invade into lung tissue. In addition, inflammatory cells release a variety of proinflammatory and chemoattractant factors to further exacerbate the inflammatory response, increase mucin secretion in the intratracheal goblet cells, and cause airway hyperresponsiveness. Because of this series of reactions, patients with asthma show clinical symptoms such as dyspnea, cyanosis, and chest pain. Drugs currently used to treat asthma include steroids, bronchodilators, and antibiotics. Steroids and antibiotics are used in the treatment of asthma through the suppression of immune and inflammatory responses. In the case of bronchodilators, they are used by offsetting clinical symptoms such as dyspnea. However, these drugs have antimicrobial resistance including side effects such as immunosuppression, inhibition of bone marrow production, and adverse effects in long-term use, and thus they are very limited in use as asthma treatment agents. Therefore, the development of natural products or new compounds that overcome these side effects, have less toxicity, and have excellent therapeutic effects, are constantly under development.
이에 본 발명자들은 항암, 항균, 알콜분해, 피부상처 치유 또는 피부재생, 천식 예방 및 치료에 효과를 가지면서 인체에 안전한 물질을 개발하기 위해 계속 연구를 진행하던 중 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물이 암세포 증식을 억제하고, 우수한 항균활성을 나타내며, 알콜분해 효과가 있으면서 피부 절개 부위에서 신생조직을 형성하고 반흔이 감소될 뿐만 아니라 항천식 효과를 가지면서 인체에 안전하다는 것을 확인함으로써 본 발명을 완성하였다.Accordingly, the inventors of the present invention have been studying to develop a substance safe for human body while having an effect on anticancer, antibacterial, alcohol decomposition, skin wound healing or skin regeneration, asthma prevention and treatment, biotite, kaolinite A mineral ion mixture comprising Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite and Muscovite is a cancer cell Inhibiting proliferation, exhibiting excellent antimicrobial activity, having an alcohol-decomposing effect, forming a neoplastic tissue at a skin incision site, reducing scarring, and having an anti-asthmatic effect and being safe for a human body.
따라서, 본 발명에서 해결하고자 하는 기술적 과제는 항암효과를 가지는 인체 안전성이 우수한 미네랄 이온 혼합물을 유효성분으로 항암용 조성물을 제공하기 위한 것이다.Accordingly, a technical problem to be solved by the present invention is to provide a composition for anti-cancer using an effective ingredient of a mineral ion mixture having excellent anti-cancer effect and human safety.
또한, 본 발명에서 해결하고자 하는 다른 기술적 과제는 상기 항암용 조성물을 개체에 투여하여 암을 예방, 개선 또는 치료하는 방법을 제공하기 위한 것이다.Another object of the present invention is to provide a method for preventing, ameliorating or treating cancer by administering the composition for cancer therapy to a subject.
본 발명에서 해결하고자 하는 다른 기술적 과제는 우수한 항균활성을 가지면서 인체 안전성이 우수한 미네랄 이온 혼합물을 유효성분으로 포함하는 항균용 조성물을 제공하기 위한 것이다.Another object of the present invention is to provide an antimicrobial composition comprising a mineral ion mixture having excellent antibacterial activity and excellent human safety as an active ingredient.
또한, 본 발명에서 해결하고자 하는 다른 기술적 과제는 상기 항균용 조성물을 포함하는 항바이러스제를 제공하기 위한 것이다.Another object of the present invention is to provide an antiviral agent comprising the antimicrobial composition.
본 발명에서 해결하고자 하는 다른 기술적 과제는 알콜분해 효과를 가지는 미네랄 이온 혼합물을 유효성분으로 포함하는 알콜분해용 조성물을 제공하기 위한 것이다.Another object of the present invention is to provide a composition for alcohol decomposition which comprises a mineral ion mixture having an alcoholysis effect as an active ingredient.
본 발명에서 해결하고자 하는 다른 기술적 과제는 상기 알콜분해용 조성물을 포함하는 숙취해소용, 간기능 보호용 또는 알콜성 간질환 치료 또는 예방을 위한 조성물을 제공하기 위한 것이다.Another object of the present invention is to provide a composition for the treatment or prevention of hangover, liver function, or alcoholic liver disease comprising the composition for alcoholysis.
또한, 본 발명에서 해결하고자 하는 다른 기술적 과제는 상기 알콜분해용 조성물을 개체에 투여하여 알콜성 간질환을 예방, 개선 또는 치료하는 방법을 제공하기 위한 것이다.Another object of the present invention is to provide a method for preventing, ameliorating or treating alcoholic liver disease by administering the composition for alcoholysis to an individual.
본 발명에서 해결하고자 하는 다른 기술적 과제는 미네랄 이온 혼합물을 유효성분으로 포함하는 피부상처 치유 및 피부재생용 조성물을 제공하기 위한 것이다.Another object of the present invention is to provide a composition for skin wound healing and skin regeneration comprising a mineral ion mixture as an active ingredient.
또한, 본 발명에서 해결하고자 하는 다른 기술적 과제는 상기 피부상처 치유 및 피부재생용 조성물을 개체에 투여하여 피부상처 예방, 개선 또는 치료하고 피부를 재생하는 방법을 제공하기 위한 것이다.Another object of the present invention is to provide a method for preventing skin wounds, improving or treating skin wounds and regenerating skin by administering compositions for skin wound healing and skin regeneration to individuals.
본 발명에서 해결하고자 하는 다른 기술적 과제는 항천식 효과를 가지는 미네랄 이온 혼합물을 유효성분으로 포함하는 항천식용 조성물을 제공하기 위한 것이다.Another object of the present invention is to provide an anti-asthmatic composition comprising a mineral ion mixture having an anti-asthmatic effect as an active ingredient.
또한, 본 발명에서 해결하고자 하는 다른 기술적 과제는 상기 항천식용 조성물을 개체에 투여하여 천식을 예방, 개선 또는 치료하는 방법을 제공하기 위한 것이다.Another object of the present invention is to provide a method for preventing, ameliorating or treating asthma by administering the composition for anti-asthma.
상기한 기술적 과제를 해결하기 위하여, 본 발명에서는 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물을 유효성분으로 포함하는 항암용 조성물을 제공한다.In order to solve the above-mentioned technical problems, the present invention provides a method for producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable, There is provided an anticancer composition comprising, as an active ingredient, a mineral ion mixture including Vermiculite and Muscovite.
상기한 다른 기술적 과제를 해결하기 위하여, 본 발명에서는 상기 항암용 조성물을 개체에 투여하여 암을 예방, 개선 또는 치료하는 방법을 제공한다.In order to solve the above-mentioned other technical problems, the present invention provides a method for preventing, ameliorating or treating cancer by administering the anticancer composition to a subject.
상기한 다른 기술적 과제를 해결하기 위하여, 본 발명에서는 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물을 유효성분으로 포함하는 항균용 조성물을 제공한다.In order to solve the above-mentioned other technical problems, the present invention provides a method of producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable, , Vermiculite, and Muscovite as an active ingredient. The present invention also provides an antimicrobial composition comprising the mineral ion mixture as an active ingredient.
상기한 다른 기술적 과제를 해결하기 위하여, 본 발명에서는 상기 항균용 조성물을 포함하는 항바이러스제를 제공한다.According to another aspect of the present invention, there is provided an antiviral agent comprising the antibiotic composition.
상기한 다른 기술적 과제를 해결하기 위하여, 본 발명에서는 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물을 유효성분으로 포함하는 알콜분해용 조성물을 제공한다.In order to solve the above-mentioned other technical problems, the present invention provides a method of producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable, , Vermiculite, and Muscovite as an active ingredient. The present invention also provides a composition for alcohol decomposition, which comprises a mineral ion mixture containing Vermiculite, Muscovite, and Vermiculite.
상기한 다른 기술적 과제를 해결하기 위하여, 본 발명에서는 상기 알콜분해용 조성물을 포함하는 숙취해소용, 간기능 보호용 또는 알콜성 간질환 치료 또는 예방을 위한 조성물을 제공한다.In order to solve the above-mentioned other technical problems, the present invention provides a composition for alcohol treatment, prevention of hangover, prevention of liver function or composition for the treatment or prevention of alcoholic liver disease comprising the composition for alcoholysis.
상기한 다른 기술적 과제를 해결하기 위하여, 본 발명에서는 상기 알콜분해용 조성물을 개체에 투여하여 알콜성 간질환을 예방, 개선 또는 치료하는 방법을 제공한다.In order to solve the above-mentioned other technical problems, the present invention provides a method for preventing, ameliorating or treating alcoholic liver disease by administering the composition for alcoholysis to an individual.
상기한 다른 기술적 과제를 해결하기 위하여, 본 발명에서는 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물을 유효성분으로 포함하는 피부상처 치유 및 피부재생용 조성물을 제공한다.In order to solve the above-mentioned other technical problems, the present invention provides a method of producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable, , Vermiculite, and Muscovite as an active ingredient. The present invention also provides a composition for skin wound healing and skin regeneration.
상기한 다른 기술적 과제를 해결하기 위하여, 본 발명에서는 상기 피부상처 치유 및 피부재생용 조성물을 개체에 투여하여 피부상처 예방, 개선 또는 치료하고 피부를 재생하는 방법을 제공한다.In order to solve the above-mentioned technical problems, the present invention provides a method for preventing skin wounds, improving or treating skin wounds and regenerating skin by administering compositions for skin wound healing and skin regeneration to individuals.
상기한 다른 기술적 과제를 해결하기 위하여, 본 발명에서는 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물을 유효성분으로 포함하는 항천식용 조성물을 제공한다.In order to solve the above-mentioned other technical problems, the present invention provides a method of producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable, , Vermiculite, and Muscovite as an active ingredient. The present invention also provides a composition for an anti-asthmatic condition comprising, as an active ingredient, a mineral ion mixture including Vermiculite, Muscovite, Vermiculite and Muscovite.
상기한 다른 기술적 과제를 해결하기 위하여, 본 발명에서는 상기 항천식용 조성물을 개체에 투여하여 천식을 예방, 개선 또는 치료하는 방법을 제공한다.In order to solve the above-mentioned other technical problems, the present invention provides a method for preventing, ameliorating or treating asthma by administering the composition for anti-asthma.
이와 같이, 본 발명의 미네랄 이온 혼합물은 인간 유방암 세포주 MDA-MB-231, 인간 간암 세포주 HepG2, 인간 폐암 세포주 A549, 인간 난소암 세포주 OVCA 429, 인간 혈액암 세포주 HL60, 인간 피부암 세포주 A375, 인간 신장암 세포주 RCC4(-) 및 인간 대장암 세포주 HCT116의 암세포 증식을 억제할 수 있으므로 항암용 조성물로서 유용하게 사용할 수 있으며; 다양한 균들에 대한 항균활성이 우수하고; 알콜분해 효능이 우수하여 단기적으로 숙취해소 효과를 나타낼 수 있으며, 장기적으로 복용할 경우 간기능 개선에 효과가 있으며; 피부자극 및 세포독성이 없고 인체 안정성이 우수하면서도 창상 부위에서 신생조직을 형성시키고 반흔을 감소시켜 피부상처 치유 및 피부재생에 효과적이며; 난백알부민(ovalbumin)으로 유도된 다양한 천식증상을 억제하거나 없애는 역할을 하였다. 즉 BALF와 혈청에서 백혈구와 호중구 및 림프구의 증식을 억제하였으며, 기관지 상피세포의 증식이 억제되고, 세기관지 내에 점액(musos)이 줄어들고 세기관지와 혈관(vessel) 주위에 많은 염증세포(inflammatory cell)의 침윤(infiltration)이 줄어드는 것(dose-dependent manner)을 확인할 수 있었다. 또한, Th2 세포관련 싸이토카인 IL-4의 감소 등을 유도하였다. As described above, the mineral ion mixture of the present invention can be used in combination with human breast cancer cell line MDA-MB-231, human liver cancer cell line HepG2, human lung cancer cell line A549, human ovarian cancer cell line OVCA 429, human blood cancer cell line HL60, human skin cancer cell line A375, Can inhibit cancer cell proliferation of cell line RCC4 (-) and human colon cancer cell line HCT116, and thus can be usefully used as an anticancer composition; Excellent antimicrobial activity against various fungi; It is effective in reducing hangover in the short term due to its excellent alcohol-decomposing effect, and is effective in improving liver function when taken over a long period of time; It is free from skin irritation and cytotoxicity, has excellent human stability, but also forms new tissue at the wound area and reduces scars, and is effective for skin wound healing and skin regeneration; It inhibited or eliminated various asthma symptoms induced by ovalbumin. BALF and serum inhibited leukocyte, neutrophil and lymphocyte proliferation, suppressed the proliferation of bronchial epithelial cells, reduced the amount of musos in the bronchioles, and infiltrated many inflammatory cells around bronchioles and vessels dependent manner of infiltration. In addition, IL-4, a cytokine associated with Th2, was induced.
따라서, 본 발명의 미네랄 이온 혼합물을 포함하는 조성물은 천연물질로서 인체에 안전하여 항암, 항균, 알콜분해, 피부상처 치유 또는 피부재생 및 항천식 효과를 가지므로 약학적, 화장료 및 식품 조성물로 유용하게 이용될 수 있다.Therefore, the composition containing the mineral ion mixture of the present invention is safe as a human body and has anticancer, antibacterial, alcohol decomposition, skin wound healing or skin regeneration and anti-asthmatic effect, so that it is useful as a pharmaceutical, cosmetic and food composition Can be used.
도 1은 Raw264.7 세포에 미네랄 이온 혼합물(퓨리톤)을 농도별로 처리한 후 24시간 동안 배양하여 세포 생존율을 나타낸 그래프이다.FIG. 1 is a graph showing cell viability by culturing Raw264.7 cells for 24 hours in a mineral ion mixture (puritone) treated at different concentrations.
도 2는 Raw264.7 세포에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양한 세포 사진이다. FIG. 2 is a photograph of cells cultured for 24 hours in the Raw264.7 cells treated with puritone by concentration. FIG.
도 3은 Raw264.7 세포에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양하여 세포 생존율을 나타낸 그래프이다FIG. 3 is a graph showing cell viability by culturing Raw264.7 cells for 48 hours after treating puritone by concentration
도 4는 Raw264.7 세포에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양한 세포 사진이다. Fig. 4 is a photograph of cells cultured for 48 hours in the Raw264.7 cells treated with puritone by concentration.
도 5는 인간 유방암 세포주 MDA-MB-231에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다.FIG. 5 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human breast cancer cell line MDA-MB-231 for 24 hours after treatment with puritone by concentration.
도 6은 인간 유방암 세포주 MDA-MB-231에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양한 세포 사진이다. 6 is a photograph of cells cultured for 24 hours in a human breast cancer cell line MDA-MB-231 treated with puritone by concentration.
도 7은 인간 유방암 세포주 MDA-MB-231에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다FIG. 7 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human breast cancer cell line MDA-MB-231 at a concentration of puritone by concentration for 48 hours
도 8은 인간 유방암 세포주 MDA-MB-231에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양한 세포 사진이다. 8 is a photograph of cells cultured for 48 hours in a human breast cancer cell line MDA-MB-231 treated with puritone by concentration.
도 9는 인간 간암 세포주 HepG2에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다. FIG. 9 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human liver cancer cell line HepG2 for 24 hours after treatment with puritone by concentration.
도 10은 인간 간암 세포주 HepG2에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다. FIG. 10 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human liver cancer cell line HepG2 at different concentrations of puritone for 48 hours.
도 11은 인간 폐암 세포주 A549에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다. FIG. 11 is a graph showing the effect of suppressing the proliferation of cancer cells by culturing the human lung cancer cell line A549 for 24 hours after treatment with puritone by concentration.
도 12는 인간 폐암 세포주 A549에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다. FIG. 12 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human lung cancer cell line A549 at a concentration of puritone by concentration for 48 hours.
도 13은 인간 난소암 세포주 OVCA 429에 퓨리톤을 처리한 후 3일 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다.13 is a graph showing the inhibitory effect of cancer cell proliferation by culturing human ovarian cancer cell line OVCA 429 for 3 days after treatment with puritone.
도 14는 인간 난소암 세포주 OVCA 429에 퓨리톤을 농도별로 처리한 후 3일 동안 배양한 세포 사진이다.FIG. 14 is a photograph of a cell cultured for 3 days after treatment with puritone at a concentration of human ovarian cancer cell line OVCA 429. FIG.
도 15는 인간 난소암 세포주 OVCA 429에 100%의 퓨리톤을 처리한 후 3일 동안 배양한 결과이다. Fig. 15 shows the result of culturing the human ovarian cancer cell line OVCA 429 for 3 days after treatment with 100% of puritone.
도 16은 인간 혈액암 세포주 HL60에 퓨리톤을 처리한 후 2일 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다.FIG. 16 is a graph showing the effect of inhibiting cancer cell proliferation by culturing human blood cancer cell line HL60 for 2 days after treatment with puritone.
도 17은 인간 피부암 세포주 A375에 퓨리톤을 처리한 후 2일 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다.FIG. 17 is a graph showing the effect of inhibiting cancer cell proliferation by culturing human skin cancer cell line A375 for 2 days after treatment with puritone.
도 18은 인간 피부암 세포주 A375에 퓨리톤을 농도별로 처리한 후 2일 동안 배양한 세포 사진이다. Fig. 18 is a photograph of a cell cultured for 2 days after treatment with puritone at a concentration of human skin cancer cell line A375.
도 19는 인간 신장암 세포주 RCC4(-)에 퓨리톤을 처리한 후 2일 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다.19 is a graph showing the effect of inhibiting cancer cell proliferation by culturing human renal cancer cell line RCC4 (-) for 2 days after treatment with puritone.
도 20은 인간 신장암 세포주 RCC4(-)에 퓨리톤을 농도별로 처리한 후 2일 동안 배양한 세포 사진이다.FIG. 20 is a photograph of a cell cultured for two days after treatment of the human renal cell carcinoma cell line RCC4 (-) with puritone by concentration.
도 21은 인간 대장암 세포주 HCT116에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다. FIG. 21 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 24 hours after treatment with puritone by concentration.
도 22는 인간 대장암 세포주 HCT116에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다. FIG. 22 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 48 hours after treatment with puritone by concentration. FIG.
도 23은 대장균(Escherichia coli)에 대한 퓨리톤의 항균 활성을 나타낸 것이다.Fig. 23 is a graph lt; RTI ID = 0.0 > E. coli . < / RTI >
도 24는 스타필로코커스 아우레스(Staphylococcus aureus)에 대한 퓨리톤의 항균 활성을 나타낸 것이다.Figure 24 shows the antimicrobial activity of puritone against Staphylococcus aureus .
도 25는 슈도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 퓨리톤의 항균 활성을 나타낸 것이다.25 is a graph showing the results of Pseudomonas < RTI ID = 0.0 > 0.0 > aeruginosa . < / RTI >
도 26은 살모넬라 티피무리움(Salmonella typhimurium)에 대한 퓨리톤의 항균 활성을 나타낸 것이다.Figure 26 shows the antimicrobial activity of puritone against Salmonella typhimurium .
도 27은 캔디다 알비칸스(Candida albicans)에 대한 퓨리톤의 항균 활성을 나타낸 것이다.Figure 27 shows the antimicrobial activity of puritone against Candida albicans .
도 28은 퓨리톤에 의한 아세트알데히드 함량 감소효과를 나타낸 그래프이다. 28 is a graph showing an effect of decreasing acetaldehyde content by purite.
도 29는 퓨리톤에 의한 알데히드 탈수소효소 활성 비색 분석결과를 나타낸 그래프이다. FIG. 29 is a graph showing the result of color analysis of activity of aldehyde dehydrogenase by puritone. FIG.
도 30은 퓨리톤의 동물 실험을 통한 피부상처 치유효과로서 절개 면적 감소를 육안으로 관찰한 사진이다. FIG. 30 is a photograph of a cutaneous area reduction observed visually as a skin wound healing effect through an animal experiment of puritone. FIG.
도 31은 퓨리톤의 동물 실험을 통한 피부상처 치유효과로서 절개 면적 감소를 실제 크기를 측정하여 나타낸 그래프이다.FIG. 31 is a graph showing the cut-off area reduction by measuring the actual size as a skin wound healing effect through an animal experiment of purite.
도 32는 퓨리톤의 BALF의 백혈구(WBC) 분석 결과를 나타낸 그래프이다.32 is a graph showing the results of white blood cell (WBC) analysis of puritan BALF.
도 33은 퓨리톤의 BALF의 호중구(neutrophil) 분석 결과를 나타낸 그래프이다. 33 is a graph showing neutrophil analysis results of BALF of puritone.
도 34는 퓨리톤의 BALF의 림프구(lymphocyte) 분석 결과를 나타낸 그래프이다. 34 is a graph showing the results of lymphocyte analysis of BALF of puritone.
도 35는 퓨리톤의 BALF의 IgE 분석 결과를 나타낸 그래프이다.35 is a graph showing the results of IgE analysis of puritan BALF.
도 36은 퓨리톤에 의한 폐조직의 변화를 H&E 염색을 이용하여 관찰한 것이다.FIG. 36 shows changes in lung tissue due to puritone observed using H & E staining.
도 37은 퓨리톤에 의한 폐조직의 변화를 PAS 염색을 이용하여 관찰한 것이다.FIG. 37 shows changes in pulmonary tissue caused by puritone using PAS staining.
도 38은 퓨리톤에 의한 IL-4의 발현 정도를 관찰하여 나타낸 결과이다. FIG. 38 shows the results of observing the degree of expression of IL-4 by puritone.
본 발명의 조성물은 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물을 유효성분으로 포함하는 것을 특징으로 한다.The compositions of the present invention may be used in combination with biotite, kaolinite, montmorillonite, serpentine, mica, clinochlore, vermiculite and And a mineral ion mixture comprising Muscovite as an active ingredient.
바람직하게, 본 발명에서 상기 미네랄 이온 혼합물은 브루사이트(Brucite), 일라이트(Illite), 리메스톤(Limestone), 제올라이트(Zeolite), 올소클레이스(Orthoclase) 또는 올소클레이스 펠드스파(Orthoclase feldspar), 베마이트(boehmite), 네펠린(Nepheline), 팔리코르스카이트(Palygorskite) 또는 애터펄자이트(Attapulgite), 마그네사이트(Magnesite), 스페릴라이트(Sperrylite), 크렌네라이트(Krennerite), 페트자이트(Petzite), 기브사이트(Gibbsite), 앨러페인(Allophane), 플로고파이트(Phlogopite), 레피도라이트(Lepidolite), 실바나이트(Sylvanite), 글로코나이트(Glauconite), 돌로마이트(Dolomite), 토르말린(Tourmaline), 카날라이트(Carnallite), 안드라다이트(Andradite) 및 휴마이트(Humite)를 추가로 포함하는 것을 특징으로 한다.Preferably, in the present invention, the mineral ion mixture is selected from the group consisting of Brucite, Illite, Limestone, Zeolite, Orthoclase or Orthoclase feldspar, Nepheline, Palygorskite or Attapulgite, Magnesite, Sperrylite, Krennerite, Petzieite, and the like. But are not limited to, Petzite, Gibbsite, Allophane, Phlogopite, Lepidolite, Sylvanite, Glauconite, Dolomite, (Tourmaline), Carnallite, Andradite, and Humite. ≪ Desc / Clms Page number 2 >
본 발명의 하나의 구현예에 따르면, 상기 미네랄 이온 혼합물을 유효성분으로 포함하는 항암용 조성물을 제공한다.According to one embodiment of the present invention, there is provided an anticancer composition comprising the mineral ion mixture as an active ingredient.
본 발명에서는 상기 항암용 조성물을 개체에 투여하여 암을 예방, 개선 또는 치료하는 방법을 제공한다.The present invention provides a method for preventing, ameliorating or treating cancer by administering the composition for anti-cancer to the individual.
본 발명의 하나의 구현예에 따르면, 상기 미네랄 이온 혼합물을 유효성분으로 포함하는 항균용 조성물을 제공한다.According to one embodiment of the present invention, there is provided an antimicrobial composition comprising the mineral ion mixture as an active ingredient.
본 발명에서는 상기 항균용 조성물을 포함하는 항바이러스제를 제공한다.The present invention provides an antiviral agent comprising the above antimicrobial composition.
본 발명의 하나의 구현예에 따르면, 상기 미네랄 이온 혼합물을 유효성분으로 포함하는 알콜분해용 조성물을 제공한다.According to one embodiment of the present invention, there is provided a composition for alcoholysis comprising the mineral ion mixture as an active ingredient.
본 발명에서는 상기 알콜분해용 조성물을 포함하는 숙취해소용, 간기능 보호용 또는 알콜성 간질환 치료 또는 예방을 위한 조성물을 제공한다.The present invention provides a composition for the treatment or prevention of hangover, liver function, or alcoholic liver disease comprising the composition for alcoholysis.
본 발명에서는 상기 알콜분해용 조성물을 개체에 투여하여 알콜성 간질환을 예방, 개선 또는 치료하는 방법을 제공한다.The present invention provides a method for preventing, ameliorating or treating alcoholic liver disease by administering the composition for alcoholysis as described above.
본 발명의 하나의 구현예에 따르면, 상기 미네랄 이온 혼합물을 유효성분으로 포함하는 피부상처 치유 및 피부재생용 조성물을 제공한다.According to one embodiment of the present invention, there is provided a composition for skin wound healing and skin regeneration comprising the mineral ion mixture as an active ingredient.
본 발명에서는 상기 피부상처 치유 및 피부재생용 조성물을 개체에 투여하여 피부상처를 예방, 개선 또는 치료하고 피부를 재생하는 방법을 제공한다.The present invention provides a method for preventing, improving or treating skin wounds and regenerating skin by administering the skin wound healing and skin regeneration composition to an individual.
본 발명의 하나의 구현예에 따르면, 상기 미네랄 이온 혼합물을 유효성분으로 포함하는 항천식용 조성물을 제공한다.According to one embodiment of the present invention, there is provided an anti-asthmatic composition comprising the mineral ion mixture as an active ingredient.
본 발명에서는 상기항천식용 조성물을 개체에 투여하여 천식을 예방, 개선 또는 치료하고 피부를 재생하는 방법을 제공한다.The present invention provides a method for preventing, ameliorating or treating asthma by regulating the composition for anti-asthma and for regenerating skin.
본 발명의 하나의 구현예에 따르면, 상기 미네랄 이온 혼합물은 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite), 무스코바이트(Muscovite)를 주성분으로 포함하며, 여기에 브루사이트(Brucite), 일라이트(Illite), 리메스톤(Limestone), 제올라이트(Zeolite), 올소클레이스(Orthoclase) 또는 올소클레이스 펠드스파(Orthoclase feldspar), 베마이트(boehmite), 네펠린(Nepheline), 팔리코르스카이트(Palygorskite) 또는 애터펄자이트(Attapulgite), 마그네사이트(Magnesite), 스페릴라이트(Sperrylite), 크렌네라이트(Krennerite), 페트자이트(Petzite), 기브사이트(Gibbsite), 앨러페인(Allophane), 플로고파이트(Phlogopite), 레피도라이트(Lepidolite), 실바나이트(Sylvanite), 글로코나이트(Glauconite), 돌로마이트(Dolomite), 토르말린(Tourmaline), 카날라이트(Carnallite), 안드라다이트(Andradite) 및 휴마이트(Humite)를 추가로 포함하는 것을 특징으로 하며, 본 발명에서는 상기 미네랄 이온 혼합물을 "퓨리톤"이라 칭한다.According to one embodiment of the present invention, the mineral ion mixture is selected from the group consisting of Biotite, Kaolinite, Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite and Muscovite as main components and also contains Brucite, Illite, Limestone, Zeolite, For example, Orthoclase or Orthoclase feldspar, boehmite, Nepheline, Palygorskite or Attapulgite, Magnesite, Such as Sperrylite, Krennerite, Petzite, Gibbsite, Allophane, Phlogopite, Lepidolite, Sylvanite, Glauconite, dolomite (Dolo mite, Tourmaline, Carnallite, Andradite and Humite. In the present invention, the mineral ion mixture is referred to as "purite" .
본 발명의 하나의 구현예에 따르면, 상기 미네랄 이온 혼합물은 카올리나이트 15 내지 25 중량%, 바이오타이트 12 내지 23 중량%, 몬트모릴로나이트 15 내지 25 중량%, 서펜틴 10 내지 13 중량%, 마이카 7 내지 9 중량%, 버미쿨라이트 3 내지 5 중량%, 무스코바이트 2 내지 4 중량%, 클리노클로레 2 내지 5 중량%, 브루사이트 1 내지 3 중량%, 일라이트 1 내지 3 중량%, 리메스톤 1 내지 3 중량%, 제올라이트 0.5 내지 1.5 중량%, 올소클레이스 또는 올소클레이스 펠드스파 0.5 내지 1.5 중량%, 베마이트 0.8 내지 1.0 중량%, 네펠린 0.7 내지 0.9 중량%, 팔리코르스카이트 또는 애터펄자이트 0.7 내지 0.9 중량%, 마그네사이트 0.6 내지 0.8 중량%, 스페릴라이트 0.5 내지 0.7 중량%, 크렌네라이트 0.5 내지 0.7 중량%, 페트자이트 0.4 내지 0.6 중량%, 기브사이트 0.3 내지 0.5 중량%, 앨러페인 0.3 내지 0.5 중량%, 플로고파이트 0.3 내지 0.5 중량%, 레피도라이트 0.2 내지 0.4 중량%, 실바나이트 0.2 내지 0.4 중량%, 글로코나이트 0.2 내지 0.4 중량%, 돌로마이트 0.2 내지 0.4 중량%, 토르말린 0.1 내지 0.3 중량%, 카날라이트 0.1 내지 0.3 중량%, 안드라다이트 0.1 내지 0.3 중량% 및 휴마이트 0.05 내지 0.15 중량%를 포함하는 것을 특징으로 한다.According to one embodiment of the invention, the mineral ion mixture comprises 15 to 25% by weight of kaolinite, 12 to 23% by weight of biotite, 15 to 25% by weight of montmorillonite, 10 to 13% by weight of serpentine, From 3 to 5% by weight of vermiculite, from 2 to 4% by weight of moscobite, from 2 to 5% by weight of clinocole, from 1 to 3% by weight of brucite, from 1 to 3% by weight of ilite, From 1 to 3% by weight of stones, from 0.5 to 1.5% by weight of zeolites, from 0.5 to 1.5% by weight of oligoclays or oloclayspull spores, from 0.8 to 1.0% by weight of boehmite, from 0.7 to 0.9% by weight of nephelins, 0.7 to 0.9% by weight of atropulgite, 0.6 to 0.8% by weight of magnesium, 0.5 to 0.7% by weight of spearylite, 0.5 to 0.7% by weight of crenellite, 0.4 to 0.6% by weight of petzite, 0.3 to 0.5% %, Allophane 0.3 to 0.5 0.3 to 0.5% by weight of furoginite, 0.2 to 0.4% by weight of lepidolite, 0.2 to 0.4% by weight of silvanite, 0.2 to 0.4% by weight of gluconite, 0.2 to 0.4% by weight of dolomite, 0.1 to 0.3% by weight of tourmaline , 0.1 to 0.3% by weight of canalite, 0.1 to 0.3% by weight of andradite, and 0.05 to 0.15% by weight of humite.
상기 퓨리톤은 20여년전부터 광물의학을 토대로 미국과 한국에서 연구개발된 100% 광물성 천연물질로서 질병치료와 피부건강 및 건강의 밸런스를 유지시키는 제품이다. US FDA로부터 성분분석, 독성분석, 영양분석을 통과해서 인체내(눈, 간, 피부) 모든 부분에 안전성을 인정받았으며, 일반의약품(NDC)으로 승인을 받은 바 있다. 현재 출시한 제품은 5가지의 일반 의약품이 있다. 퓨리톤 안약(Puriton Eye Relief Drop), 얼굴치료, 피부치료, 화상 절상 등 응급처치, 여성 청결치료제 등이다. Puritone is a natural, 100% mineral substance that has been researched and developed in the United States and Korea based on mineral medicine for more than 20 years. It has been approved by the US Food and Drug Administration (FDA) for its safety in all parts of the human body (eye, liver, skin) and its approval as a generic medicinal product (NDC) through its component analysis, toxicity analysis and nutritional analysis. Currently, there are 5 generic drugs. Puriton Eye Relief Drop, facial treatment, skin treatment, first-aid treatment such as burn-up, and women's clean treatment.
퓨리톤 안약(Puriton Eye Drop)은 눈건조증에 대해 높은 치료효능을 보일 뿐만 아니라 불치에 가까운 눈질환인 백내장, 녹내장, 비문증 등의 질환치료에 이르기까지 효능을 나타낸다고 알려졌다. 또한, 퓨리톤 여성 청결치료제(puriton Intimate Disinfection Spray)는 대부분 여성의 깊은 고민으로 자리하고 있는 질염 및 방광염과 일반적 치질에 이르기까지 그 질환의 균을 완벽하게 잡아줌으로써 극대의 치료효능을 가진 신개념 의약품이라 할 수 있다. 액상형태로서 시판되는 것을 구입하여 사용하거나 직접 제조하여 사용할 수 있다. 예를 들어, 퓨리톤은 천연광물로 점토계 원료인 고령토, 벤토나이트, 제올라이트, 탄산칼슘, 운모류 등의 광물을 이용하여 제조될 수 있는데, 이들 광물은 분쇄전 900℃ 이상의 고온소성을 거쳐 원료내에 함유된 유해 불순물 및 중금속 등을 제거하는 공정을 거친다. 소성공정을 마친 원료를 분쇄공정을 통해 원하는 미세한 나노입자의 광물로 가공처리를 하게 된다. 상기 분쇄는 건식 또는 습식 또는 이들을 순차적으로 혼합한 방식으로 이루어질 수 있다. 건식공정에서는 정밀한 미세입자의 생산성은 낮으며 단계별로 미세한 입자를 얻을 수 있으나 대량적인 생산에 한계가 있고 정밀성이 떨어진다. 반면 습식공정은 준비된 광물을 볼밀에 준비된 광물을 투입하여 적당량의 물을 투입하여 고속의 회전을 가하여 미분말을 얻을 수 있는 아주 미세하고 정밀한 입자를 대량적으로 생산할 수 있으나 제조비용이 건식에 비해 높은 단점이 있다. 일반적으로 퓨리톤 액상 제조에 투입되는 광물의 입자크기는 나노입자에 해당되는 5000 mesh(2㎛ 이하)이상의 아주 미세한 분말을 사용한다.Puriton Eye Drop is known to have high therapeutic efficacy against dry eye syndrome, and is effective in treating diseases like cataracts, glaucoma, and insomnia, which are close to incurable diseases. In addition, Puriton Intimate Disinfection Spray is a new concept medicine with maximal therapeutic efficacy by completely capturing the bacteria of the disease from vaginitis and cystitis which are mostly women's deep troubles and general hemorrhoids. can do. A commercially available liquid form may be purchased or used directly. For example, purite is a natural mineral, which can be produced by using minerals such as kaolinite, bentonite, zeolite, calcium carbonate, and mica, which are clay materials. These minerals are calcined at a high temperature The harmful impurities and heavy metals are removed. After the calcination process, the raw material is subjected to a grinding process to process the desired fine nano-particle minerals. The pulverization may be carried out in a dry or wet process or a sequential mixing process. In the dry process, the productivity of fine fine particles is low, and fine particles can be obtained in stages, but there is a limit in mass production and precision is poor. On the other hand, the wet process can produce very fine and precise particles that can obtain fine powder by applying a suitable amount of water to the ball mill, . In general, the particle size of the minerals used for the preparation of the purite liquid phase is very fine powder of 5000 mesh (2 μm or less) corresponding to the nanoparticles.
퓨리톤의 원료는 식품 및 의약품의 용도로서 수많은 종류의 콜로이드성 미네랄이 함유된 몬모릴로나이트(Montmorillonites) 또는 벤토나이트(Bentonite) 등을 주요 구성물로 하는 안정된 점토광물을 주요성분 원료로 사용한다. 점토광물의 주원소는 Si, Al, Na, K, Ti이며 미량원소는 많은 원소 가운데 Fe, Ca, S, Mg, Ce, La, Zr, P 등이며 바이오세라믹 분말은 Fe2O3, TiO2, Na2O, SiO2, P2O5, CeO2, K2O, MgO 등이다. 제품의 특성은 몬모릴로나이트(또는 벤토나이트)인 점토광물을 미세한 입자크기로 분쇄한 후 콜로이드 상태로 정제처리 한 수많은 Trace minerals(미량원소)이 함유된 복합물질이다. 그리고 혈액세포보다 입자크기가 훨씬 작은 천연상태(Colloidal Trace Minerals)의 미네랄이다. 종합하면 점토광물로서 의학적 광물학(Medical Mineralogy)에서 인정된 점토광물이 퓨리톤의 주원료이다.The raw materials of puritone are mainly used as raw materials for food and pharmaceuticals, and stabilized clay minerals containing montmorillonites or bentonite, which contain many kinds of colloidal minerals. The major elements of clay minerals are Si, Al, Na, K, and Ti, and trace elements are Fe, Ca, S, Mg, Ce, La, Zr, and P. Bioceramic powders are Fe 2 O 3 , TiO 2 , Na 2 O, SiO 2 , P 2 O 5 , CeO 2 , K 2 O, MgO, and the like. The product is a composite material containing a lot of trace minerals that are refined in a colloidal state after crushing clay minerals, which are montmorillonite (or bentonite), to a fine particle size. And a colloidal trace minerals minerals that are much smaller in particle size than blood cells. In summary, clay minerals recognized in Medical Mineralogy as clay minerals are the main source of purite.
습식분쇄된 나노입자의 미분말 광물질을 고온 고압 공정장치에 적당량의 광물분말과 증류수를 투입하여 밀폐된 개방형 혼합기에 투입하여 수행한다. 100-300℃ 이상의 열을 가하여 투입된 광물과 물이 고온에서 반응하여 인체에 필수적인 이온화된 미네랄을 용출시키는 공정이며 적정 가열시간을 부여하여 인체에 필요한 다량의 광물성 미네랄을 얻게 된다. 미네랄 용출공정을 거친 후 숙성공정인 광물의 침전과정을 거친다. 그 과정의 부여시간은 액상내에 이온화된 광물의 입자크기에 영향을 미친다. 대략적으로 숙성공정은 원하는 제품에 따라 24시간에서 일주일 이상의 숙성시간이 필요하다.The pulverized minerals of the wet-pulverized nanoparticles are put into a closed open type mixer by putting an appropriate amount of mineral powder and distilled water into a high-temperature and high-pressure processing apparatus. It is a process of dissolving ionized minerals essential to the human body by reacting at a high temperature with the minerals and water which are added by applying heat of 100-300 ℃ or more. A large amount of mineral minerals are obtained. Minerals are extracted and then subjected to a mineral precipitation process. The duration of the process affects the particle size of the ionized minerals in the liquid phase. Approximately, the aging process requires aging time of 24 hours to a week or more depending on the desired product.
숙성과정이 마무리 되면 콜로이드 액상과 침전된 광물의 미분말을 분리하는 필터링 공정을 거친다. 정밀한 필터링 공정을 통해 분리된 퓨리톤 미네랄 수용액을 제조할 수 있다.When the aging process is completed, a filtering process is performed to separate the colloidal liquid phase and the fine powder of the precipitated minerals. A precise filtering process can be used to produce an aqueous solution of the separated purite minerals.
본 발명의 하나의 구현예에 따르면, 본 발명에서는 상기 미네랄 이온 혼합물을 유효성분으로 포함하는 항암용 조성물을 제공한다.According to one embodiment of the present invention, there is provided an anticancer composition comprising the mineral ion mixture as an active ingredient.
바람직하게, 본 발명에서 미네랄 이온 혼합물을 포함하는 항암용 조성물은 약학적 조성물 또는 식품 조성물일 수 있다.Preferably, the anticancer composition comprising the mineral ion mixture in the present invention may be a pharmaceutical composition or a food composition.
본 발명에서 암은 갑상선암, 위암, 대장암, 폐암, 난소암, 유방암, 직장암, 간암, 전립선암, 췌장암, 담낭암, 혈액암, 피부암, 신장암 또는 담도암을 예로 들 수 있으나, 반드시 이로 한정되는 것은 아니다.In the present invention, the cancer is exemplified by thyroid cancer, stomach cancer, colon cancer, lung cancer, ovarian cancer, breast cancer, rectal cancer, liver cancer, prostate cancer, pancreatic cancer, gallbladder cancer, blood cancer, skin cancer, kidney cancer or bile duct cancer. It is not.
본 발명의 바람직한 구현예에 따르면, 본 발명의 항암용 조성물은 하기 표 1에 나타낸 바와 같이 몬트모릴로나이트 17 중량%, 카올리나이트 23 중량%, 바이오타이트 14중량%, 서펜틴 12 중량%, 마이카 8 중량%, 버미쿨라이트 4 중량%, 무스코바이트 3 중량%, 클리노클로레 3 중량%, 브루사이트 2 중량%, 일라이트 2 중량%, 리메스톤 2 중량%, 제올라이트 1 중량%, 올소클레이스 또는 올소클레이스 펠드스파 1 중량%, 베마이트 0.9 중량%, 네펠린 0.8 중량%, 팔리코르스카이트 또는 애터펄자이트 0.8 중량%, 마그네사이트 0.7 중량%, 스페릴라이트 0.6 중량%, 크렌네라이트 0.6 중량%, 페트자이트 0.5 중량%, 기브사이트 0.4 중량%, 앨러페인 0.4 중량%, 플로고파이트 0.4 중량%, 레피도라이트 0.3 중량%, 실바나이트 0.3 중량%, 글로코나이트 0.3 중량%, 돌로마이트 0.3 중량%, 토르말린 0.2 중량%, 카날라이트 0.2 중량%, 안드라다이트 0.2 중량% 및 휴마이트 0.1 중량%로 이루어진 미네랄 이온 혼합물을 포함하는 것을 특징으로 한다.According to a preferred embodiment of the present invention, the anticancer composition of the present invention comprises 17 wt% of montmorillonite, 23 wt% of kaolinite, 14 wt% of biotite, 12 wt% of serpentine, By weight of bismuth chloride, 4% by weight of vermiculite, 3% by weight of muskobite, 3% by weight of clinocore, 2% by weight of brucite, 2% by weight of dilite, 2% by weight of limestone, 1% by weight of oleic acid, 0.5% by weight of boehmite, 0.8% by weight of nephelin, 0.8% by weight of paliquochekate or atropulgite, 0.7% by weight of magnetite, 0.6% by weight of spearylite, 0.6 wt% of light, 0.5 wt% of petzite, 0.4 wt% of gibbsite, 0.4 wt% of allophane, 0.4 wt% of floplight, 0.3 wt% of recrystallization, 0.3 wt% of silvanite, 0.3 wt% , 0.3% by weight of dolomite, 0.2% by weight of tourmaline %, 0.2% by weight of canalite, 0.2% by weight of andalite and 0.1% by weight of humite.
성분ingredient 함량(%)content(%)
몬트모릴로나이트((Na,Ca)0.3(Al,Mg)2Si4O10(OH)2n(H2O)) ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 1717
카올리나이트(A12Si2O5(OH)4)Kaolinite (A1 2 Si 2 O 5 ( OH) 4) 2323
바이오타이트(KFe3(AlSi3O10)(OH)2)Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 1414
서펜틴(Mg,Fe)3Si2O5(OH)4) Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 1212
마이카(AB2- 3(X,Si)4O10(O,F,OH)2)Mica (AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 88
버미쿨라이트(Mg,Fe,Al)3(Al,Si)4O10(OH)2·4H2O) (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 44
무스코바이트(KA12(AlSi3O10)(F,OH)2) Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 33
클리노클로레(Mg,Fe,Al)6(Si,Al)4O10(OH)8) (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 33
브루사이트(Mg(OH)2) Brucite (Mg (OH) 2 ) 22
일라이트(KAl1 . 3Fe0 . 4Mg0 . 2Si3 . 4Al0 . 6O10(OH)2)Illite (KAl 1. 3 Fe 0. 4 Mg 0. 2 Si 3. 4 Al 0. 6 O 10 (OH) 2) 22
리메스톤(CaCO3) Limestone (CaCO 3 ) 22
제올라이트(NaAlSi2O6H2O)Zeolite (NaAlSi 2 O 6 H 2 O) 1One
올소클레이스 또는 올소클레이스 펠드스파(KA1Si3O8) Clay's ortho or ortho-Clay's Spa Seefeld (KA1Si 3 O 8) 1One
베마이트(y-ALO(OH)) The boehmite (y-ALO (OH)) 0.90.9
네펠린(Na,K)AlSiO4)Nephellin (Na, K) AlSiO 4 ) 0.80.8
팔리코르스카이트 또는 애터펄자이트((Mg,Al)2Si4O10(OH)4(H2O)) (Mg, Al) 2 Si 4 O 10 (OH) 4 (H 2 O)), 0.80.8
마그네사이트(MgCO3) Magnesite (MgCO 3) 0.70.7
스페릴라이트(PtAs2) Sphereyl (PtAs 2 ) 0.60.6
크렌네라이트(Au3AgTe8) Crenelite (Au 3 AgTe 8 ) 0.60.6
페트자이트(Ag3AuTe2) Petzite (Ag 3 AuTe 2 ) 0.50.5
기브사이트(Al(OH)3) Gibbsite (Al (OH) 3 ) 0.40.4
앨러페인(Al2O3(SiO2)1 .3- 2(2.5-3)H2O) AL pane (Al 2 O 3 (SiO 2 ) 1 .3- 2 (2.5-3) H 2 O) 0.40.4
플로고파이트((KMg3(AlSi3O10)(OH)2) (KMg 3 (AlSi 3 O 10 ) (OH) 2 ) 0.40.4
레피도라이트(K(Li,Al,Rb)2(Al,Si)4O10(F,OH)2) (Li, Al, Rb) 2 (Al, Si) 4 O 10 (F, OH) 2 ) 0.30.3
실바나이트(SiAgAuTe4) Silvanite (SiAgAuTe 4 ) 0.30.3
글로코나이트((Fe3+,Al,Mg)2(Si,Al)4O10(OH)2) ((Fe 3+ , Al, Mg) 2 (Si, Al) 4 O 10 (OH) 2 ) 0.30.3
돌로마이트(CaMg(CO3)2) Dolomite (CaMg (CO 3) 2) 0.30.3
토르말린(Al,Fe,Li,Mg,Mn)3(Al,Cr,Fe,V)6(BO3)3(Si,Al,B)6O18(OH,F)4)Tourmaline (Al, Fe, Li, Mg , Mn) 3 (Al, Cr, Fe, V) 6 (BO 3) 3 (Si, Al, B) 6 O 18 (OH, F) 4) 0.20.2
카날라이트((KClMgCl2·6(H2O)) Canal light ((KClMgCl 2 · 6 (H 2 O)) 0.20.2
안드라다이트(Ca3Fe2(SiO4)3) Andradite (Ca 3 Fe 2 (SiO 4 ) 3 ) 0.20.2
휴마이트(Mg7(SiO4)3(F,OH)2)Humite (Mg 7 (SiO 4 ) 3 (F, OH) 2 ) 0.10.1
총gun 100100
본 발명의 항암용 조성물은 조성물의 총 중량을 기준으로 하여 미네랄 이온 혼합물이 0.005 내지 50 중량%, 보다 바람직하게는 0.01 내지 30 중량%, 가장 바람직하게는 0.1 내지 10 중량%로 포함할 수 있다. 이 때 미네랄 이온 혼합물의 함량이 0.005 중량% 미만일 경우 본 발명의 목적효과인 암세포 증식 억제효과를 수득할 수 없으며, 50 중량%를 초과할 경우 함량의 증가에 따라 효과가 비례적이지 않아 비효율적일 수 있으며 제형상의 안정성이 확보되지 않는 문제점이 있다.본 발명의 미네랄 이온 혼합물을 함유하는 항암용 조성물은 암세포주의 증식 억제능을 가지며, 천연 물질로서 인체에 안전하다. The anticancer composition of the present invention may contain 0.005 to 50 wt%, more preferably 0.01 to 30 wt%, and most preferably 0.1 to 10 wt% of the mineral ion mixture based on the total weight of the composition. When the content of the mineral ion mixture is less than 0.005 wt%, the cancer cell proliferation inhibitory effect of the present invention can not be obtained. When the content of the mineral ion mixture is more than 50 wt%, the effect is not proportional to the increase of the content, And the stability of the shape is not ensured. The anticancer composition containing the mineral ion mixture of the present invention has the ability to inhibit proliferation of cancer cells and is safe for human body as a natural substance.
본 발명의 구체적인 실시양태에 따르면, 미네랄 이온 혼합물은 인간 유방암 세포주 MDA-MB-231, 인간 간암 세포주 HepG2, 인간 폐암 세포주 A549, 인간 난소암 세포주 OVCA 429, 인간 혈액암 세포주 HL60, 인간 피부암 세포주 A375, 인간 신장암 세포주 RCC4(-) 및 인간 대장암 세포주 HCT116에 대한 증식 억제효과를 나타내는 것을 확인할 수 있다. According to a specific embodiment of the present invention, the mineral ion mixture is selected from human breast cancer cell line MDA-MB-231, human liver cancer cell line HepG2, human lung cancer cell line A549, human ovarian cancer cell line OVCA 429, human blood cancer cell line HL60, human skin cancer cell line A375, (-) and the human colon cancer cell line HCT116, respectively.
본 발명에서는 상기 항암용 조성물을 개체에 투여하여 암을 예방, 개선 또는 치료하는 방법을 제공한다.The present invention provides a method for preventing, ameliorating or treating cancer by administering the composition for anti-cancer to the individual.
본 발명의 하나의 구현예에 따르면, 본 발명에서는 상기 미네랄 이온 혼합물을 유효성분으로 포함하는 항균용 조성물을 제공한다.According to one embodiment of the present invention, there is provided an antimicrobial composition comprising the mineral ion mixture as an active ingredient.
바람직하게, 본 발명에서 미네랄 이온 혼합물을 포함하는 항균용 조성물은 약학적 조성물 또는 화장료 조성물일 수 있다.Preferably, the antimicrobial composition comprising the mineral ion mixture in the present invention may be a pharmaceutical composition or a cosmetic composition.
본 발명의 하나의 구현예에 따르면, 본 발명에서는 상기 항균용 조성물을 포함하는 항바이러스제를 제공한다.According to one embodiment of the present invention, the present invention provides an antiviral agent comprising the above antimicrobial composition.
본 발명에서 사용되는 용어 "항균"은 균에 저항하는 능력을 의미하며, 세균이나 곰팡이, 효모 등과 같은 미생물의 작용으로부터 방어하기 위해 이루어지는 모든 기작을 의미한다. 이러한 항균 효과는 미생물로 인한 부패를 방지하는 방부효과로 이어진다.As used herein, the term "antimicrobial" refers to the ability to resist bacteria and refers to all mechanisms that are performed to defend against the action of microorganisms such as bacteria, fungi, yeast, and the like. These antimicrobial effects lead to preservative effects that prevent microbial spoilage.
본 발명의 바람직한 구현예에 따르면, 본 발명의 항균용 조성물은 하기 표 2에 나타낸 바와 같이 바이오타이트 20 중량%, 카올리나이트 17 중량%, 몬트모릴로나이트 16 중량%, 서펜틴 12 중량%, 마이카 8 중량%, 클리노클로레 4 중량%, 버미쿨라이트 4 중량%, 무스코바이트 3 중량%, 브루사이트 2 중량%, 일라이트 2 중량%, 리메스톤 2 중량%, 제올라이트 1 중량%, 올소클레이스 또는 올소클레이스 펠드스파 1 중량%, 베마이트 0.9 중량%, 네펠린 0.8 중량%, 팔리코르스카이트 또는 애터펄자이트 0.8 중량%, 마그네사이트 0.7 중량%, 스페릴라이트 0.6 중량%, 크렌네라이트 0.6 중량%, 페트자이트 0.5 중량%, 기브사이트 0.4 중량%, 앨러페인 0.4 중량%, 플로고파이트 0.4 중량%, 레피도라이트 0.3 중량%, 실바나이트 0.3 중량%, 글로코나이트 0.3 중량%, 돌로마이트 0.3 중량%, 토르말린 0.2 중량%, 카날라이트 0.2 중량%, 안드라다이트 0.2 중량% 및 휴마이트 0.1 중량%로 이루어진 미네랄 이온 혼합물을 포함하는 것을 특징으로 한다.According to a preferred embodiment of the present invention, the antimicrobial composition of the present invention comprises 20 wt% of biotite, 17 wt% of kaolinite, 16 wt% of montmorillonite, 12 wt% of serpentine, 4 weight% of clinocole, 4 weight% of vermiculite, 3 weight% of moscobite, 2 weight% of brucite, 2 weight% of ilite, 2 weight% of limestone, 1 weight of zeolite, 1% by weight of oleic acid, 0.5% by weight of boehmite, 0.8% by weight of nephelin, 0.8% by weight of paliquochekate or atropulgite, 0.7% by weight of magnetite, 0.6% by weight of spearylite, 0.6 wt% of light, 0.5 wt% of petzite, 0.4 wt% of gibbsite, 0.4 wt% of allophane, 0.4 wt% of floplight, 0.3 wt% of recrystallization, 0.3 wt% of silvanite, 0.3 wt% 0.3% by weight of dolomite, 0.2% by weight of tourmaline %, Characterized in that it comprises a mixture of mineral ions Canal Added 0.2% by weight, Andhra die agent 0.2% by weight and 0.1% by weight of boehmite holiday.
성분ingredient 함량(%)content(%)
바이오타이트(KFe3(AlSi3O10)(OH)2)Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 2020
카올리나이트(A12Si2O5(OH)4)Kaolinite (A1 2 Si 2 O 5 ( OH) 4) 1717
몬트모릴로나이트((Na,Ca)0.3(Al,Mg)2Si4O10(OH)2n(H2O)) ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 1616
서펜틴(Mg,Fe)3Si2O5(OH)4) Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 1212
마이카(AB2- 3(X,Si)4O10(O,F,OH)2)Mica (AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 88
클리노클로레(Mg,Fe,Al)6(Si,Al)4O10(OH)8) (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 44
버미쿨라이트(Mg,Fe,Al)3(Al,Si)4O10(OH)2·4H2O) (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 44
무스코바이트(KA12(AlSi3O10)(F,OH)2) Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 33
브루사이트(Mg(OH)2) Brucite (Mg (OH) 2 ) 22
리메스톤(CaCO3) Limestone (CaCO 3 ) 22
제올라이트(NaAlSi2O6H2O)Zeolite (NaAlSi 2 O 6 H 2 O) 1One
일라이트(KAl1 . 3Fe0 . 4Mg0 . 2Si3 . 4Al0 . 6O10(OH)2)Illite (KAl 1. 3 Fe 0. 4 Mg 0. 2 Si 3. 4 Al 0. 6 O 10 (OH) 2) 22
올소클레이스 또는 올소클레이스 펠드스파(KA1Si3O8) Clay's ortho or ortho-Clay's Spa Seefeld (KA1Si 3 O 8) 1One
베마이트(y-ALO(OH)) The boehmite (y-ALO (OH)) 0.90.9
네펠린(Na,K)AlSiO4)Nephellin (Na, K) AlSiO 4 ) 0.80.8
팔리코르스카이트 또는 애터펄자이트((Mg,Al)2Si4O10(OH)4(H2O)) (Mg, Al) 2 Si 4 O 10 (OH) 4 (H 2 O)), 0.80.8
마그네사이트(MgCO3) Magnesite (MgCO 3) 0.70.7
스페릴라이트(PtAs2) Sphereyl (PtAs 2 ) 0.60.6
크렌네라이트(Au3AgTe8) Crenelite (Au 3 AgTe 8 ) 0.60.6
페트자이트(Ag3AuTe2) Petzite (Ag 3 AuTe 2 ) 0.50.5
기브사이트(Al(OH)3) Gibbsite (Al (OH) 3 ) 0.40.4
앨러페인(Al2O3(SiO2)1 .3- 2(2.5-3)H2O) AL pane (Al 2 O 3 (SiO 2 ) 1 .3- 2 (2.5-3) H 2 O) 0.40.4
플로고파이트((KMg3(AlSi3O10)(OH)2) (KMg 3 (AlSi 3 O 10 ) (OH) 2 ) 0.40.4
레피도라이트(K(Li,Al,Rb)2(Al,Si)4O10(F,OH)2) (Li, Al, Rb) 2 (Al, Si) 4 O 10 (F, OH) 2 ) 0.30.3
실바나이트(SiAgAuTe4) Silvanite (SiAgAuTe 4 ) 0.30.3
글로코나이트((Fe3+,Al,Mg)2(Si,Al)4O10(OH)2) ((Fe 3+ , Al, Mg) 2 (Si, Al) 4 O 10 (OH) 2 ) 0.30.3
돌로마이트(CaMg(CO3)2) Dolomite (CaMg (CO 3) 2) 0.30.3
토르말린(Al,Fe,Li,Mg,Mn)3(Al,Cr,Fe,V)6(BO3)3(Si,Al,B)6O18(OH,F)4)Tourmaline (Al, Fe, Li, Mg , Mn) 3 (Al, Cr, Fe, V) 6 (BO 3) 3 (Si, Al, B) 6 O 18 (OH, F) 4) 0.20.2
카날라이트((KClMgCl2·6(H2O)) Canal light ((KClMgCl 2 · 6 (H 2 O)) 0.20.2
안드라다이트(Ca3Fe2(SiO4)3) Andradite (Ca 3 Fe 2 (SiO 4 ) 3 ) 0.20.2
휴마이트(Mg7(SiO4)3(F,OH)2)Humite (Mg 7 (SiO 4 ) 3 (F, OH) 2 ) 0.10.1
총 gun 100100
본 발명의 항균용 조성물은 조성물의 총 중량을 기준으로 하여 미네랄 이온 혼합물이 0.005 내지 50 중량%, 보다 바람직하게는 0.01 내지 30 중량%, 가장 바람직하게는 0.1 내지 10 중량%로 포함할 수 있다. 이 때 미네랄 이온 혼합물의 함량이 0.005 중량% 미만일 경우 본 발명의 목적효과인 항균효과를 수득할 수 없으며, 50 중량%를 초과할 경우 함량의 증가에 따라 효과가 비례적이지 않아 비효율적일 수 있으며 제형상의 안정성이 확보되지 않는 문제점이 있다.The antimicrobial composition of the present invention may contain 0.005 to 50 wt%, more preferably 0.01 to 30 wt%, and most preferably 0.1 to 10 wt% of the mineral ion mixture based on the total weight of the composition. If the content of the mineral ion mixture is less than 0.005% by weight, the antimicrobial effect of the present invention can not be obtained. If the content of the mineral ion mixture exceeds 50% by weight, the effect may not be proportional to the content, There is a problem that the stability of the shape is not ensured.
본 발명의 하나의 구현예에 따르면, 본 발명에서는 상기 미네랄 이온 혼합물을 유효성분으로 포함하는 알콜분해용 조성물을 제공한다.According to one embodiment of the present invention, there is provided a composition for alcoholysis comprising the mineral ion mixture as an active ingredient.
본 발명의 하나의 구현예에 다르면, 본 발명에서는 상기 알콜분해용 조성물을 포함하는 숙취해소용, 간기능 보호용 또는 알콜성 간질환 치료 또는 예방을 위한 조성물을 제공하기 위한 것이다.According to one embodiment of the present invention, the present invention provides a composition for alcohol treatment, prevention of liver function, or a composition for the treatment or prevention of alcoholic liver disease comprising the composition for alcoholysis.
바람직하게, 본 발명에서 미네랄 이온 혼합물을 포함하는 알콜분해용 조성물은 약학적 조성물 또는 식품 조성물일 수 있다.Preferably, the composition for alcoholysis comprising a mineral ion mixture in the present invention may be a pharmaceutical composition or a food composition.
본 발명에서 알콜성 간질환은 알콜성 지방간, 알콜성 간염 또는 알콜성 간경변증을 예로 들 수 있으나, 반드시 이로 한정되는 것은 아니다.In the present invention, alcoholic liver diseases include, but are not necessarily limited to, alcoholic fatty liver disease, alcoholic hepatitis, or alcoholic cirrhosis.
본 발명의 바람직한 구현예에 따르면, 본 발명의 항균용 조성물은 하기 표 3에 나타낸 바와 같이 몬트모릴로나이트 24 중량%, 카올리나이트 16 중량%, 바이오타이트 15 중량%, 서펜틴 11 중량%, 마이카 8 중량%, 버미쿨라이트 4 중량%, 무스코바이트 3 중량%, 클리노클로레 3 중량%, 브루사이트 2 중량%, 일라이트 2 중량%, 리메스톤 2 중량%, 제올라이트 1 중량%, 올소클레이스 또는 올소클레이스 펠드스파 1 중량%, 베마이트 0.9 중량%, 네펠린 0.8 중량%, 팔리코르스카이트 또는 애터펄자이트 0.8 중량%, 마그네사이트 0.7 중량%, 스페릴라이트 0.6 중량%, 크렌네라이트 0.6 중량%, 페트자이트 0.5 중량%, 기브사이트 0.4 중량%, 앨러페인 0.4 중량%, 플로고파이트 0.4 중량%, 레피도라이트 0.3 중량%, 실바나이트 0.3 중량%, 글로코나이트 0.3 중량%, 돌로마이트 0.3 중량%, 토르말린 0.2 중량%, 카날라이트 0.2 중량%, 안드라다이트 0.2 중량% 및 휴마이트 0.1 중량%로 이루어진 미네랄 이온 혼합물을 포함하는 것을 특징으로 한다.According to a preferred embodiment of the present invention, the antimicrobial composition of the present invention comprises 24% by weight of montmorillonite, 16% by weight of kaolinite, 15% by weight of biotite, 11% by weight of serpentine, By weight of bismuth chloride, 4% by weight of vermiculite, 3% by weight of muskobite, 3% by weight of clinocore, 2% by weight of brucite, 2% by weight of dilite, 2% by weight of limestone, 1% by weight of oleic acid, 0.5% by weight of boehmite, 0.8% by weight of nephelin, 0.8% by weight of paliquochekate or atropulgite, 0.7% by weight of magnetite, 0.6% by weight of spearylite, 0.6 wt% of light, 0.5 wt% of petzite, 0.4 wt% of gibbsite, 0.4 wt% of allophane, 0.4 wt% of floplight, 0.3 wt% of recrystallization, 0.3 wt% of silvanite, 0.3 wt% 0.3% by weight of dolomite, 0.2% by weight of tourmaline %, Characterized in that it comprises a mixture of mineral ions Canal Added 0.2% by weight, Andhra die agent 0.2% by weight and 0.1% by weight of boehmite holiday.
성분ingredient 함량(%)content(%)
몬트모릴로나이트((Na,Ca)0.3(Al,Mg)2Si4O10(OH)2n(H2O)) ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 2424
카올리나이트(A12Si2O5(OH)4)Kaolinite (A1 2 Si 2 O 5 ( OH) 4) 1616
바이오타이트(KFe3(AlSi3O10)(OH)2)Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 1515
서펜틴(Mg,Fe)3Si2O5(OH)4) Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 1111
마이카(AB2- 3(X,Si)4O10(O,F,OH)2)Mica (AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 88
버미쿨라이트(Mg,Fe,Al)3(Al,Si)4O10(OH)2·4H2O) (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 44
무스코바이트(KA12(AlSi3O10)(F,OH)2) Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 33
클리노클로레(Mg,Fe,Al)6(Si,Al)4O10(OH)8) (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 33
브루사이트(Mg(OH)2) Brucite (Mg (OH) 2 ) 22
일라이트(KAl1 . 3Fe0 . 4Mg0 . 2Si3 . 4Al0 . 6O10(OH)2)Illite (KAl 1. 3 Fe 0. 4 Mg 0. 2 Si 3. 4 Al 0. 6 O 10 (OH) 2) 22
리메스톤(CaCO3) Limestone (CaCO 3 ) 22
제올라이트(NaAlSi2O6H2O)Zeolite (NaAlSi 2 O 6 H 2 O) 1One
올소클레이스 또는 올소클레이스 펠드스파(KA1Si3O8) Clay's ortho or ortho-Clay's Spa Seefeld (KA1Si 3 O 8) 1One
베마이트(y-ALO(OH)) The boehmite (y-ALO (OH)) 0.90.9
네펠린(Na,K)AlSiO4)Nephellin (Na, K) AlSiO 4 ) 0.80.8
팔리코르스카이트 또는 애터펄자이트((Mg,Al)2Si4O10(OH)4(H2O)) (Mg, Al) 2 Si 4 O 10 (OH) 4 (H 2 O)), 0.80.8
마그네사이트(MgCO3) Magnesite (MgCO 3) 0.70.7
스페릴라이트(PtAs2) Sphereyl (PtAs 2 ) 0.60.6
크렌네라이트(Au3AgTe8) Crenelite (Au 3 AgTe 8 ) 0.60.6
페트자이트(Ag3AuTe2) Petzite (Ag 3 AuTe 2 ) 0.50.5
기브사이트(Al(OH)3) Gibbsite (Al (OH) 3 ) 0.40.4
앨러페인(Al2O3(SiO2)1 .3- 2(2.5-3)H2O) AL pane (Al 2 O 3 (SiO 2 ) 1 .3- 2 (2.5-3) H 2 O) 0.40.4
플로고파이트((KMg3(AlSi3O10)(OH)2) (KMg 3 (AlSi 3 O 10 ) (OH) 2 ) 0.40.4
레피도라이트(K(Li,Al,Rb)2(Al,Si)4O10(F,OH)2) (Li, Al, Rb) 2 (Al, Si) 4 O 10 (F, OH) 2 ) 0.30.3
실바나이트(SiAgAuTe4) Silvanite (SiAgAuTe 4 ) 0.30.3
글로코나이트((Fe3+,Al,Mg)2(Si,Al)4O10(OH)2) ((Fe 3+ , Al, Mg) 2 (Si, Al) 4 O 10 (OH) 2 ) 0.30.3
돌로마이트(CaMg(CO3)2) Dolomite (CaMg (CO 3) 2) 0.30.3
토르말린(Al,Fe,Li,Mg,Mn)3(Al,Cr,Fe,V)6(BO3)3(Si,Al,B)6O18(OH,F)4)Tourmaline (Al, Fe, Li, Mg , Mn) 3 (Al, Cr, Fe, V) 6 (BO 3) 3 (Si, Al, B) 6 O 18 (OH, F) 4) 0.20.2
카날라이트((KClMgCl2·6(H2O)) Canal light ((KClMgCl 2 · 6 (H 2 O)) 0.20.2
안드라다이트(Ca3Fe2(SiO4)3) Andradite (Ca 3 Fe 2 (SiO 4 ) 3 ) 0.20.2
휴마이트(Mg7(SiO4)3(F,OH)2)Humite (Mg 7 (SiO 4 ) 3 (F, OH) 2 ) 0.10.1
총gun 100100
본 발명의 알콜분해용 조성물은 조성물의 총 중량을 기준으로 하여 미네랄 이온 혼합물이 0.005 내지 50 중량%, 보다 바람직하게는 0.01 내지 30 중량%, 가장 바람직하게는 0.1 내지 10 중량%로 포함할 수 있다. 이 때 미네랄 이온 혼합물의 함량이 0.005 중량% 미만일 경우 본 발명의 목적효과인 알콜분해 효과를 수득할 수 없으며, 50 중량%를 초과할 경우 함량의 증가에 따라 효과가 비례적이지 않아 비효율적일 수 있으며 제형상의 안정성이 확보되지 않는 문제점이 있다.The composition for alcoholysis of the present invention may contain 0.005 to 50 wt%, more preferably 0.01 to 30 wt%, and most preferably 0.1 to 10 wt% of a mineral ion mixture based on the total weight of the composition . If the content of the mineral ion mixture is less than 0.005% by weight, the alcohol decomposition effect of the present invention can not be obtained. If the content of the mineral ion mixture is more than 50% by weight, the effect may not be proportional to the content, There is a problem that the stability of the shape is not ensured.
본 발명의 구체적인 실시양태에 따르면, 미네랄 이온 혼합물은 알콜분해 효능이 우수하여 단기적으로 숙취해소 효과를 나타낼 수 있으며, 장기적으로 복용할 경우 간기능 개선에 효과가 있을 것으로 기대된다.According to the concrete embodiment of the present invention, the mineral ion mixture is excellent in the alcohol decomposing effect and can exhibit the hangover resolution effect in the short term, and it is expected that the long-term administration will be effective for improving the liver function.
본 발명에서는 상기 알콜분해용 조성물을 개체에 투여하여 알콜성 간질환을 예방, 개선 또는 치료하는 방법을 제공한다.The present invention provides a method for preventing, ameliorating or treating alcoholic liver disease by administering the composition for alcoholysis as described above.
본 발명의 하나의 구현예에 따르면, 본 발명에서는 상기 미네랄 이온 혼합물을 유효성분으로 포함하는 피부상처 치유 또는 피부재생 촉진용 조성물을 제공한다.According to one embodiment of the present invention, there is provided a composition for promoting skin wound healing or skin regeneration comprising the mineral ion mixture as an active ingredient.
바람직하게, 본 발명에서 미네랄 이온 혼합물을 포함하는 피부상처 치유 또는 피부재생 촉진용 조성물은 약학적 조성물 또는 화장료 조성물일 수 있다.Preferably, the skin wound healing or skin regeneration promoting composition comprising a mineral ion mixture in the present invention may be a pharmaceutical composition or a cosmetic composition.
본 발명에서 사용된 "상처"란 조직 구조의 연속성 또는 완전성의 물리적인 파열을 의미하며, "피부상처 치유"란 조직 완전성의 복원을 의미한다. 이는 조직 완전성의 부분적 또는 완전 복원을 의미할 수 있는 것이며, 따라서 상처 치료란 피부상처 치유 과정에 관여하는 하나 이상의 단계 또는 과정의 촉진, 개선, 진행, 가속 또는 진전을 의미한다. 또한, 상처는, 예컨대 타박상 또는 내부 궤양화와 같이 피부의 외부 구조적 완전성이 유지되는 임의의 내부 상처이거나 외부 상처, 특히 피부상처일 수 있으며, 따라서 조직은 내부 또는 외부의 신체 조직일 수 있다. 일례로, 조직은 피부(예컨대, 인간 피부)이며, 상처는 진피 또는 표피 상처와 같은 피부상처일 수 있다.As used herein, "wound" means a physical rupture of continuity or completeness of tissue structure, and "skin wound healing" means restoration of tissue integrity. This may mean a partial or complete restoration of tissue integrity, and thus wound treatment refers to the promotion, improvement, progression, acceleration or progress of one or more steps or processes involved in the skin wound healing process. In addition, the wound may be any internal wound or external wound, particularly a skin wound, where the external structural integrity of the skin is maintained, such as, for example, bruising or internal ulceration, and thus the tissue may be internal or external body tissue. In one example, the tissue is skin (e.g., human skin) and the wound may be a skin wound, such as a dermal or epidermal wound.
본 발명에서 사용된 "피부재생"은 손상에 대한 조직의 회복 과정으로, 주화성 (chemotaxis), 세포의 분화 및 복제 (differentiation and replication), 기질 단백질 (matrix protein)의 합성, 혈관의 신생 및 창상의 재구성 등을 포함하는 복잡한 생물학적 과정이다. 피부재생 과정의 초기에 생성되어 이후의 과정을 조절하는 대표적인 물질 중 하나로 성장인자를 들 수 있는데, 이는 피부재생 과정 전반에 걸쳐 강력한 영향을 미치면서도 세포의 성장, 분화 및 대사 등을 조절한다.As used herein, "skin regeneration" is a tissue regeneration process for damage, which includes chemotaxis, differentiation and replication of cells, synthesis of matrix proteins, And the rest of the biological process. One of the representative substances that regulate the subsequent process, which is generated in the early stage of the skin regeneration process, includes growth factors, which regulate the growth, differentiation and metabolism of the cells while strongly affecting the skin regeneration process.
본 발명의 피부상처 치유 또는 피부재생용 조성물이 적용될 수 있는 상처의 종류로는, 이에 제한되지는 않으나, 베인 상처 및 열상, 외과적 절개 또는 상처, 천자, 찰과상(graze), 긁힌 상처, 압박 상처, 찰과상(abrasion), 마찰 상처(예: 기저귀 발진, 마찰 수포), 욕창 궤양(예: 욕창 또는 와창), 열 작용에 의한 상처(직접, 또는 전도, 대류 또는 복사선을 통한 냉원 및 열원 및 전기 공급원으로부터의 화상), 화학적 상처(예: 산 또는 알칼리 화상) 또는 개방 또는 무손상 종기, 피부 발진, 흠집 및 여드름을 비롯한 병원성 감염(예: 바이러스, 박테리아 또는 진균 감염), 궤양, 만성적인 상처(당뇨병-관련 상처, 예컨대 하퇴 및 족부 궤양, 정맥성 다리 궤양 및 욕창 포함)를 포함할 수 있다.The types of wounds to which the skin wound healing or skin regeneration composition of the present invention can be applied include, but are not limited to, veneer wounds and lacerations, surgical incisions or wounds, punctures, grazes, scratched wounds, (Eg, pressure sores), pressure sores (eg diaper rashes, frictional blisters), pressure ulcers (eg pressure sores or windows), wounds caused by heat (direct or indirect sources of heat, Bacterial or fungal infections), ulcers, chronic wounds (including, but not limited to, burns), chemical wounds (such as acid or alkaline burns) or open or intact boils, skin rashes, scratches and acne -Related injuries such as lower leg and foot ulcers, venous leg ulcers, and pressure ulcers).
본 발명의 바람직한 구현예에 따르면, 본 발명의 피부상처 치유 또는 피부재생 촉진용 조성물은 하기 표 4에 나타낸 바와 같이 몬트모릴로나이트 24 중량%, 카올리나이트 16 중량%, 바이오타이트 15 중량%, 서펜틴 11 중량%, 마이카 8 중량%, 버미쿨라이트 4 중량%, 무스코바이트 3 중량%, 클리노클로레 3 중량%, 브루사이트 2 중량%, 일라이트 2 중량%, 리메스톤 2 중량%, 제올라이트 1 중량%, 올소클레이스 또는 올소클레이스 펠드스파 1 중량%, 베마이트 0.9 중량%, 네펠린 0.8 중량%, 팔리코르스카이트 또는 애터펄자이트 0.8 중량%, 마그네사이트 0.7 중량%, 스페릴라이트 0.6 중량%, 크렌네라이트 0.6 중량%, 페트자이트 0.5 중량%, 기브사이트 0.4 중량%, 앨러페인 0.4 중량%, 플로고파이트 0.4 중량%, 레피도라이트 0.3 중량%, 실바나이트 0.3 중량%, 글로코나이트 0.3 중량%, 돌로마이트 0.3 중량%, 토르말린 0.2 중량%, 카날라이트 0.2 중량%, 안드라다이트 0.2 중량% 및 휴마이트 0.1 중량%로 이루어진 미네랄 이온 혼합물을 포함하는 것을 특징으로 한다.According to a preferred embodiment of the present invention, the skin wound healing or skin regeneration promoting composition of the present invention comprises 24% by weight of montmorillonite, 16% by weight of kaolinite, 15% by weight of biotite, 11 weight%, mica 8 weight%, vermiculite 4 weight%, moscobite 3 weight%, clinocole 3 weight%, brucite 2 weight%, ilite 2 weight%, limestone 2 weight%, zeolite 1% by weight of silica gel, 1% by weight of oligo-clay or oloclayspherd spar, 0.9% by weight of boehmite, 0.8% by weight of nephelin, 0.8% by weight of paliquochetite or atropulgite, 0.7% 0.6% by weight of crenellite, 0.5% by weight of petzite, 0.4% by weight of gibbsite, 0.4% by weight of allophane, 0.4% by weight of floplight, 0.3% by weight of recrystallized silica, 0.3% 0.3% by weight of gluconite, Agent 0.3% by weight, 0.2% by weight of tourmaline, Canal Added 0.2% by weight, Andhra die bit is characterized in that it comprises a mineral ion mixture consisting of 0.2 wt% and 0.1 wt.% Of boehmite holiday.
성분ingredient 함량(%)content(%)
몬트모릴로나이트((Na,Ca)0.3(Al,Mg)2Si4O10(OH)2n(H2O)) ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 2424
카올리나이트(A12Si2O5(OH)4)Kaolinite (A1 2 Si 2 O 5 ( OH) 4) 1616
바이오타이트(KFe3(AlSi3O10)(OH)2)Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 1515
서펜틴(Mg,Fe)3Si2O5(OH)4) Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 1111
마이카(AB2- 3(X,Si)4O10(O,F,OH)2)Mica (AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 88
버미쿨라이트(Mg,Fe,Al)3(Al,Si)4O10(OH)2·4H2O) (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 44
무스코바이트(KA12(AlSi3O10)(F,OH)2) Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 33
클리노클로레(Mg,Fe,Al)6(Si,Al)4O10(OH)8) (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 33
브루사이트(Mg(OH)2) Brucite (Mg (OH) 2 ) 22
일라이트(KAl1 . 3Fe0 . 4Mg0 . 2Si3 . 4Al0 . 6O10(OH)2)Illite (KAl 1. 3 Fe 0. 4 Mg 0. 2 Si 3. 4 Al 0. 6 O 10 (OH) 2) 22
리메스톤(CaCO3) Limestone (CaCO 3 ) 22
제올라이트(NaAlSi2O6H2O)Zeolite (NaAlSi 2 O 6 H 2 O) 1One
올소클레이스 또는 올소클레이스 펠드스파(KA1Si3O8) Clay's ortho or ortho-Clay's Spa Seefeld (KA1Si 3 O 8) 1One
베마이트(y-ALO(OH)) The boehmite (y-ALO (OH)) 0.90.9
네펠린(Na,K)AlSiO4)Nephellin (Na, K) AlSiO 4 ) 0.80.8
팔리코르스카이트 또는 애터펄자이트((Mg,Al)2Si4O10(OH)4(H2O)) (Mg, Al) 2 Si 4 O 10 (OH) 4 (H 2 O)), 0.80.8
마그네사이트(MgCO3) Magnesite (MgCO 3) 0.70.7
스페릴라이트(PtAs2) Sphereyl (PtAs 2 ) 0.60.6
크렌네라이트(Au3AgTe8) Crenelite (Au 3 AgTe 8 ) 0.60.6
페트자이트(Ag3AuTe2) Petzite (Ag 3 AuTe 2 ) 0.50.5
기브사이트(Al(OH)3) Gibbsite (Al (OH) 3 ) 0.40.4
앨러페인(Al2O3(SiO2)1 .3- 2(2.5-3)H2O) AL pane (Al 2 O 3 (SiO 2 ) 1 .3- 2 (2.5-3) H 2 O) 0.40.4
플로고파이트((KMg3(AlSi3O10)(OH)2) (KMg 3 (AlSi 3 O 10 ) (OH) 2 ) 0.40.4
레피도라이트(K(Li,Al,Rb)2(Al,Si)4O10(F,OH)2) (Li, Al, Rb) 2 (Al, Si) 4 O 10 (F, OH) 2 ) 0.30.3
실바나이트(SiAgAuTe4) Silvanite (SiAgAuTe 4 ) 0.30.3
글로코나이트((Fe3+,Al,Mg)2(Si,Al)4O10(OH)2) ((Fe 3+ , Al, Mg) 2 (Si, Al) 4 O 10 (OH) 2 ) 0.30.3
돌로마이트(CaMg(CO3)2) Dolomite (CaMg (CO 3) 2) 0.30.3
토르말린(Al,Fe,Li,Mg,Mn)3(Al,Cr,Fe,V)6(BO3)3(Si,Al,B)6O18(OH,F)4)Tourmaline (Al, Fe, Li, Mg , Mn) 3 (Al, Cr, Fe, V) 6 (BO 3) 3 (Si, Al, B) 6 O 18 (OH, F) 4) 0.20.2
카날라이트((KClMgCl2·6(H2O)) Canal light ((KClMgCl 2 · 6 (H 2 O)) 0.20.2
안드라다이트(Ca3Fe2(SiO4)3) Andradite (Ca 3 Fe 2 (SiO 4 ) 3 ) 0.20.2
휴마이트(Mg7(SiO4)3(F,OH)2)Humite (Mg 7 (SiO 4 ) 3 (F, OH) 2 ) 0.10.1
총gun 100100
본 발명의 피부상처 치유 또는 피부재생 촉진용 조성물은 조성물의 총 중량을 기준으로 하여 미네랄 이온 혼합물이 0.005 내지 50 중량%, 보다 바람직하게는 0.01 내지 30 중량%, 가장 바람직하게는 0.1 내지 10 중량%로 포함할 수 있다. 이 때 미네랄 이온 혼합물의 함량이 0.005 중량% 미만일 경우 본 발명의 목적효과인 피부상처 치유 및 피부재생 촉진효과를 수득할 수 없으며, 50 중량%를 초과할 경우 함량의 증가에 따라 효과가 비례적이지 않아 비효율적일 수 있으며 제형상의 안정성이 확보되지 않는 문제점이 있다.The skin wound healing or skin regeneration promoting composition of the present invention may contain 0.005 to 50 wt.%, More preferably 0.01 to 30 wt.%, Most preferably 0.1 to 10 wt.% Of a mineral ion mixture based on the total weight of the composition. As shown in FIG. If the content of the mineral ion mixture is less than 0.005% by weight, the effect of promoting skin wound healing and skin regeneration, which is the object of the present invention, can not be obtained. If the content exceeds 50% by weight, the effect is proportionate There is a problem that the stability of the shape can not be secured.
본 발명의 구체적인 실시양태에 따르면, 미네랄 이온 혼합물은 피부자극 및 세포독성이 없고 인체 안정성이 우수하면서도 창상 부위에서 신생조직을 형성시키고 반흔을 감소시켜 피부상처 치유 및 피부재생용 화장료 또는 약학적 조성물에 유효성분으로 안전하게 이용될 수 있다.According to a specific embodiment of the present invention, the mineral ion mixture is free from skin irritation and cytotoxicity and has excellent human stability, but also forms new tissue at the wound area and reduces scars to provide cosmetic or pharmaceutical compositions for skin wound healing and skin regeneration It can be safely used as an active ingredient.
본 발명에서는 상기 피부상처 치유 및 피부재생용 조성물을 개체에 투여하여 피부상처 예방, 개선 또는 치료하고 피부를 재생하는 방법을 제공한다. The present invention provides a method of preventing skin wounds, improving or treating skin wounds and regenerating skin by administering compositions for skin wound healing and skin regeneration to individuals.
본 발명의 하나의 구현예에 따르면, 본 발명에서는 상기 미네랄 이온 혼합물을 유효성분으로 포함하는 천식의 예방 또는 치료용 조성물을 제공한다.According to one embodiment of the present invention, there is provided a composition for preventing or treating asthma comprising the mineral ion mixture as an active ingredient.
바람직하게, 본 발명에서 미네랄 이온 혼합물을 포함하는 천식의 예방 또는 치료용 조성물은 약학적 조성물 또는 식품 조성물일 수 있다.Preferably, the composition for preventing or treating asthma comprising a mineral ion mixture in the present invention may be a pharmaceutical composition or a food composition.
본 발명에서 용어, "천식"은 폐 속에 있는 기관지가 아주 예민해진 상태로, 때때로 기관지가 좁아져서 숨이 차고 가랑가랑하는 숨소리가 들리면서 기침을 심하게 하는 증상을 나타내는 질환으로, 기관지의 알레르기 염증반응 때문에 발생하는 알레르기 질환이다. 천식의 대표적인 증상은 호흡곤란, 기침, 천명(쌕쌕거리는 거친 숨소리) 등이며, 좁아진 기관지를 짧은 시간 내에 완화시키는 증상 완화제(기관지 확장제) 또는 기관지의 알레르기 염증을 억제하여 천식발작을 예방하는 질병 조절제(항염증제, 류코트리엔 조절제) 등이 대표적인 치료제로 사용된다. 본 발명에서 상기 천식은 기관지성 천식, 알러지성 천식, 아토피형 천식, 비아토피형 천식, 운동유발 천식, 아스피린 천식, 심인성 천식 또는 폐포성 천식일 수 있으나, 이에 제한되지 않는다. In the present invention, the term "asthma" refers to a disease in which the bronchus in the lung is very sensitive, sometimes the bronchus narrows, and the breathing, It is caused by allergic diseases. The most common symptoms of asthma include dyspnea, cough, wheezing (wheezy breathing), a symptom reliever (bronchodilator) that alleviates the narrowed bronchus in a short time, or a disease modifier that prevents asthma attacks by inhibiting bronchial allergic inflammation Anti-inflammatory agents, and leukotriene modulators). In the present invention, the asthma may be, but not limited to, bronchial asthma, allergic asthma, atopic asthma, non-atopic asthma, exercise induced asthma, aspirin asthma, cardiogenic asthma or alveolar asthma.
본 발명의 바람직한 구현예에 따르면, 본 발명의 천식의 예방 또는 치료용 조성물은 하기 표 5에 나타낸 바와 같이 카올리나이트 19 중량%, 바이오타이트 18 중량%, 몬트모릴로나이트 17 중량%, 서펜틴 12 중량%, 마이카 8 중량%, 버미쿨라이트 4 중량%, 무스코바이트 3 중량%, 클리노클로레 3 중량%, 브루사이트 2 중량%, 일라이트 2 중량%, 리메스톤 2 중량%, 제올라이트 1 중량%, 올소클레이스 또는 올소클레이스 펠드스파 1 중량%, 베마이트 0.9 중량%, 네펠린 0.8 중량%, 팔리코르스카이트 또는 애터펄자이트 0.8 중량%, 마그네사이트 0.7 중량%, 스페릴라이트 0.6 중량%, 크렌네라이트 0.6 중량%, 페트자이트 0.5 중량%, 기브사이트 0.4 중량%, 앨러페인 0.4 중량%, 플로고파이트 0.4 중량%, 레피도라이트 0.3 중량%, 실바나이트 0.3 중량%, 글로코나이트 0.3 중량%, 돌로마이트 0.3 중량%, 토르말린 0.2 중량%, 카날라이트 0.2 중량%, 안드라다이트 0.2 중량% 및 휴마이트 0.1 중량%로 이루어진 미네랄 이온 혼합물을 포함하는 것을 특징으로 한다.According to a preferred embodiment of the present invention, the composition for preventing or treating asthma according to the present invention comprises 19% by weight of kaolinite, 18% by weight of biotite, 17% by weight of montmorillonite, 12% % Mica, 4% by weight of vermiculite, 3% by weight of moscobite, 3% by weight of clinocore, 2% by weight of brucite, 2% by weight of ilite, 2% by weight of limestone and 1% by weight of zeolite 1% by weight, oloclase or oloclayspherd spar, 0.9% by weight boehmite, 0.8% by weight nephelin, 0.8% by weight of palycorhkate or atropulgite, 0.7% by weight of magnesium, 0.6% by weight of spearylite 0.6% by weight of crenellite, 0.5% by weight of petzite, 0.4% by weight of gibbsite, 0.4% by weight of allophane, 0.4% by weight of floplight, 0.3% by weight of recrystallized silica, 0.3% 0.3% by weight of nitrite, 0.3% by weight of dolomite, , 0.2% by weight of tourmaline, 0.2% by weight of canalite, 0.2% by weight of Andrade and 0.1% by weight of humite.
성분ingredient 함량(%)content(%)
카올리나이트(A12Si2O5(OH)4)Kaolinite (A1 2 Si 2 O 5 ( OH) 4) 1919
바이오타이트(KFe3(AlSi3O10)(OH)2)Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 1818
몬트모릴로나이트((Na,Ca)0.3(Al,Mg)2Si4O10(OH)2n(H2O)) ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 1717
서펜틴(Mg,Fe)3Si2O5(OH)4) Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 1212
마이카(AB2- 3(X,Si)4O10(O,F,OH)2)Mica (AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 88
버미쿨라이트(Mg,Fe,Al)3(Al,Si)4O10(OH)2·4H2O) (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 44
무스코바이트(KA12(AlSi3O10)(F,OH)2) Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 33
클리노클로레(Mg,Fe,Al)6(Si,Al)4O10(OH)8) (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 33
브루사이트(Mg(OH)2) Brucite (Mg (OH) 2 ) 22
일라이트(KAl1 . 3Fe0 . 4Mg0 . 2Si3 . 4Al0 . 6O10(OH)2)Illite (KAl 1. 3 Fe 0. 4 Mg 0. 2 Si 3. 4 Al 0. 6 O 10 (OH) 2) 22
리메스톤(CaCO3) Limestone (CaCO 3 ) 22
제올라이트(NaAlSi2O6H2O)Zeolite (NaAlSi 2 O 6 H 2 O) 1One
올소클레이스 또는 올소클레이스 펠드스파(KA1Si3O8) Clay's ortho or ortho-Clay's Spa Seefeld (KA1Si 3 O 8) 1One
베마이트(y-ALO(OH)) The boehmite (y-ALO (OH)) 0.90.9
네펠린(Na,K)AlSiO4)Nephellin (Na, K) AlSiO 4 ) 0.80.8
팔리코르스카이트 또는 애터펄자이트((Mg,Al)2Si4O10(OH)4(H2O)) (Mg, Al) 2 Si 4 O 10 (OH) 4 (H 2 O)), 0.80.8
마그네사이트(MgCO3) Magnesite (MgCO 3) 0.70.7
스페릴라이트(PtAs2) Sphereyl (PtAs 2 ) 0.60.6
크렌네라이트(Au3AgTe8) Crenelite (Au 3 AgTe 8 ) 0.60.6
페트자이트(Ag3AuTe2) Petzite (Ag 3 AuTe 2 ) 0.50.5
기브사이트(Al(OH)3) Gibbsite (Al (OH) 3 ) 0.40.4
앨러페인(Al2O3(SiO2)1 .3- 2(2.5-3)H2O) AL pane (Al 2 O 3 (SiO 2 ) 1 .3- 2 (2.5-3) H 2 O) 0.40.4
플로고파이트((KMg3(AlSi3O10)(OH)2) (KMg 3 (AlSi 3 O 10 ) (OH) 2 ) 0.40.4
레피도라이트(K(Li,Al,Rb)2(Al,Si)4O10(F,OH)2) (Li, Al, Rb) 2 (Al, Si) 4 O 10 (F, OH) 2 ) 0.30.3
실바나이트(SiAgAuTe4) Silvanite (SiAgAuTe 4 ) 0.30.3
글로코나이트((Fe3+,Al,Mg)2(Si,Al)4O10(OH)2) ((Fe 3+ , Al, Mg) 2 (Si, Al) 4 O 10 (OH) 2 ) 0.30.3
돌로마이트(CaMg(CO3)2) Dolomite (CaMg (CO 3) 2) 0.30.3
토르말린(Al,Fe,Li,Mg,Mn)3(Al,Cr,Fe,V)6(BO3)3(Si,Al,B)6O18(OH,F)4)Tourmaline (Al, Fe, Li, Mg , Mn) 3 (Al, Cr, Fe, V) 6 (BO 3) 3 (Si, Al, B) 6 O 18 (OH, F) 4) 0.20.2
카날라이트((KClMgCl2·6(H2O)) Canal light ((KClMgCl 2 · 6 (H 2 O)) 0.20.2
안드라다이트(Ca3Fe2(SiO4)3) Andradite (Ca 3 Fe 2 (SiO 4 ) 3 ) 0.20.2
휴마이트(Mg7(SiO4)3(F,OH)2)Humite (Mg 7 (SiO 4 ) 3 (F, OH) 2 ) 0.10.1
총gun 100100
본 발명의 천식의 예방 또는 치료용 조성물에는 미네랄 이온 혼합물이 조성물의 총 중량을 기준으로 하여 0.005 내지 50 중량%, 보다 바람직하게는 0.01 내지 30 중량%, 가장 바람직하게는 0.1 내지 10 중량%로 포함할 수 있다. 이 때 미네랄 이온 혼합물의 함량이 0.005 중량% 미만일 경우 본 발명의 목적효과인 항천식 효과를 수득할 수 없으며, 50 중량%를 초과할 경우 함량의 증가에 따라 효과가 비례적이지 않아 비효율적일 수 있으며 제형상의 안정성이 확보되지 않는 문제점이 있다.The composition for preventing or treating asthma according to the present invention contains 0.005 to 50% by weight, more preferably 0.01 to 30% by weight, most preferably 0.1 to 10% by weight, based on the total weight of the composition, of a mineral ion mixture can do. If the content of the mineral ion mixture is less than 0.005% by weight, the anti-asthmatic effect of the present invention can not be obtained. If the content of the mineral ion mixture is more than 50% by weight, the effect may not be proportional to the content, There is a problem that the stability of the shape is not ensured.
본 발명의 구체적인 실시양태에 따르면, 미네랄 이온 혼합물은 기관지 또는 혈관 주위의 염증세포 수를 감소시키거나 기관 지상피의 배상세포의 점액분비를 감소시킬 수 있음이 본 발명에 의해 확인되었다. 천식환자들에게서 기관지 폐포 세척술을 수행하여 기도 염증을 확인한 결과, 기관지 폐포 세척액에는 림프구, 비만세포, 호산구 및 활성화된 대식세포 등이 증가해 있음이 확인되었다. 이에, 천식이 기도 염증 질환이라고 일반화되고, 여러 염증 세포들이 대부분 활성화되어 각종 매개물질들을 분비하여 천식을 유발하는 것으로 알려져 있어, 염증세포의 감소는 천식의 치료와 관련이 있는 것으로 알려져 있다(Haley KJ, et al., Am J Respir Crit Care Med, 1998;158:565-72). 한편, 천식은 기도의 협착 및 기관지에 염증성 세포의 침윤과 더불어 고블렛(goblet) 세포가 형성되어 점액을 분비하며 콜라젠의 침착이 두드러지게 나타나므로, 기관지의 점액 분비량의 증가 또한 천식 증상의 일종으로 알려져 있다.According to a specific embodiment of the present invention, it has been confirmed by the present invention that the mineral ion mixture can reduce the number of inflammatory cells around the bronchi or the blood vessels or reduce the mucus secretion of the bronchial goblet cells. Bronchoalveolar lavage was performed in patients with asthma, and airway inflammation was confirmed. As a result, lymphocytes, mast cells, eosinophils and activated macrophages were increased in bronchoalveolar lavage fluid. Therefore, it is known that asthma is generalized as airway inflammation disease, and most inflammatory cells are activated and secrete various mediators to induce asthma, and reduction of inflammatory cells is known to be related to the treatment of asthma (Haley KJ , et al., Am J Respir Crit Care Med, 1998; 158: 565-72). On the other hand, asthma is a kind of asthmatic symptom, because airway stenosis and infiltration of inflammatory cells into the bronchi, goblet cells are formed, secretion of mucus is prominent, and collagen deposition is prominent. It is known.
본 발명의 일 실시예로서, H&E(Hematoxylin & Eosin) 염색을 통해 폐조직 내 염증을 관찰하고, PAS(periodic acid Schiff) 염색을 통해 기관지 내 점액분비량을 관찰한 결과, i) 천식유발군의 기관지 및 혈관 주위에 광범위한 염증세포의 침윤이 관찰된 반면, 퓨리톤 투여군 모두에서, 기관지 및 혈관 주위의 염증세포의 침윤이 감소됨을 확인하였고, ii) 천식유발군에서는 기관지상피의 배상세포에서 점액분비의 증가가 관찰된 반면, 퓨리톤 투여군 모두에서 기관지상피의 배상세포의 점액분비가 현저하게 감소됨을 확인하였다. 이러한 결과 또한 상기 퓨리톤이 천식의 치료에 유효함을 잘 보여주는 것이다.As an example of the present invention, inflammation in lung tissues was observed through H & E (Hematoxylin & Eosin) staining, and mucous secretion amount was examined through PAS (periodic acid Schiff) staining. As a result, i) And infiltration of inflammatory cells around the blood vessels was observed. On the other hand, infiltration of inflammatory cells around the bronchi and blood vessels was reduced in both of the puritan group, and ii) in the asthmatic group, the mucin secretion , Whereas mucin secretion of bronchial epithelial goblet cells was markedly decreased in both groups. These results also show that the puritone is effective for the treatment of asthma.
본 발명에서는 상기 항천식용 조성물을 개체에 투여하여 천식을 예방, 개선 또는 치료하는 방법을 제공한다.The present invention provides a method for preventing, ameliorating or treating asthma by administering the composition for anti-asthma to the individual.
본 발명에 있어서, 상기 "유효성분"이란 단독으로 목적하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미한다. In the present invention, the above-mentioned "active ingredient" means a component that exhibits the desired activity alone or can exhibit activity together with a carrier which is itself inactive.
본 발명의 하나의 실시양태에 따르면, 미네랄 이온 혼합물을 유효성분으로 포함하는 약학적 조성물을 제공한다.According to one embodiment of the present invention, there is provided a pharmaceutical composition comprising a mineral ion mixture as an active ingredient.
상기 약학적 조성물은 정제, 환제, 산제, 과립제, 캡슐제, 현탁제, 내용액제, 유제, 시럽제, 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결 건조제 및 좌제로 이루어진 군으로부터 선택되는 어느 하나의 제형을 가질 수 있으며, 경구 또는 비경구의 여러 가지 제형일 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 경구투여를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutical composition may be any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, sterilized aqueous solutions, nonaqueous solvents, suspensions, emulsions, And may be oral or parenteral formulations of various forms. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used. Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent. Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
본 발명의 조성물은 약학적으로 유효한 양으로 투여할 수 있다. 본 발명에서 용어 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 개체 종류 및 중증도, 연령, 성별, 질병의 종류, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와 순차적 또는 동시에 투여될 수 있다. 그리고 단일 또는 다중 투여될 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 당업자에 의해 용이하게 결정될 수 있다. 본 발명에서 용어 "투여"는 어떠한 적절한 방법으로 개체에게 본 발명의 약학적 조성물을 도입하는 것을 의미하며, 투여 경로는 목적 조직에 도달할 수 있는 한 경구 또는 비경구의 다양한 경로를 통하여 투여될 수 있다. 그러나 본 발명의 목적상, 특정 환자에 대한 구체적인 치료적 유효량은 달성하고자 하는 반응의 종류와 정도, 경우에 따라 다른 제제가 사용되는지의 여부를 비롯한 구체적 조성물, 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 구체적 조성물과 함께 사용되거나 동시 사용되는 약물을 비롯한 다양한 인자와 의약 분야에 잘 알려진 유사 인자에 따라 다르게 적용하는 것이 바람직하다. The composition of the present invention may be administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount " as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will vary depending on the species and severity, age, sex, , The activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention may be administered as an individual therapeutic agent or in combination with another therapeutic agent, and may be administered sequentially or simultaneously with a conventional therapeutic agent. And can be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art. The term "administering" in the present invention means introducing the pharmaceutical composition of the present invention into a subject by any suitable method, and the administration route can be administered through various routes of oral or parenteral administration as long as it can reach the target tissues . For purposes of the present invention, however, the specific therapeutically effective amount for a particular patient will depend upon the nature and extent of the reaction to be achieved, the particular composition, including whether or not other agents are used, the age, weight, Sex and diet of the patient, the time of administration, the route of administration and the rate of administration of the composition, the duration of the treatment, the drugs used or concurrently used with the specific composition, and similar factors well known in the medical arts.
따라서, 본 발명의 조성물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물 형태, 투여경로 및 기간에 따라 다르며, 적합한 총 1일 사용량은 올바른 의학적 판단범위 내에서 처치의에 의해 결정될 수 있으나, 일반적으로 0.001 내지 1000 mg/kg의 양, 바람직하게는 0.05 내지 200 mg/kg, 보다 바람직하게는 0.1 내지 100 mg/kg의 양을 일일 1회 내지 수회로 나누어 투여할 수 있다. 상기 조성물은 목적으로 하는 개체이면 특별히 한정되지 않고, 어떠한 개체이든 적용가능하다. 예를 들면, 원숭이, 개, 고양이, 토끼, 모르모트, 랫트, 마우스, 소, 양, 돼지, 염소 등과 같은 비인간동물, 인간, 조류 및 어류 등 어느 개체에나 적용할 수 있으며, 투여의 방식은 당업계의 통상적인 방법이라면 제한없이 포함한다. 예를 들어, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다.Accordingly, the preferred dosage of the composition of the present invention will depend on the condition and the weight of the patient, the severity of the disease, the type of drug, the route of administration and the period of time, and the appropriate total daily dose can be determined by treatment However, it is generally administered in an amount of 0.001 to 1000 mg / kg, preferably 0.05 to 200 mg / kg, more preferably 0.1 to 100 mg / kg, once or several times a day. The composition is not particularly limited as long as it is a target object, and any object can be applied. For example, it can be applied to any non-human animal such as a monkey, a dog, a cat, a rabbit, a guinea pig, a rat, a mouse, a cattle, a sheep, a pig, Including but not limited to, For example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
본 발명의 하나의 실시양태에 따르면, 퓨리톤을 유효성분으로 포함하는 화장료 조성물을 제공한다.According to one embodiment of the present invention, there is provided a cosmetic composition comprising a puritone as an active ingredient.
본 발명의 하나의 실시양태에 따른 화장료 조성물에는 유효성분으로서의 퓨리톤 이외에 화장품 조성물에 통상적으로 첨가되는 성분, 예컨대 항산화제, 안정화제, 가용화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 및 담체를 추가로 첨가할 수 있다. The cosmetic composition according to one embodiment of the present invention may contain, in addition to the friton as an active ingredient, conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, May be further added.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 영양 크림, 수렴 화장수, 유연 화장수, 로션, 에센스, 영양젤 또는 마사지 크림의 제형으로 제조될 수 있다.The cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be prepared as a nutritional cream, a convergent lotion, a soft lotion, a lotion, an essence, a nutritional gel or a massage cream.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트 검, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, use is made of an animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide .
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, tosse, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. In the case of a spray, in particular, chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 가용화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 검등이 이용될 수 있다.In the case where the formulation of the present invention is a suspension, a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Castellulose, aluminum metahydroxide, bentonite, agar or tracert, etc. may be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is an interfacial active agent-containing cleansing, the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
본 발명의 하나의 실시양태에 따르면, 미네랄 이온 혼합물을 유효성분으로 포함하는 식품 조성물을 제공한다.According to one embodiment of the present invention, there is provided a food composition comprising a mineral ion mixture as an active ingredient.
본 발명의 조성물을 식품에 포함하여 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 건강식품 및 건강기능식품 또는 건강기능식품 성분과 함께 사용할 수 있고, 통상적인 방법에 따라 적절하게 사용할 수 있다. 유효성분의 혼합량은 사용 목적에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조 시에 본 발명의 조성물은 원료에 대하여 바람직하게는 15 중량부 이하, 보다 바람직하게는 10 중량부 이하의 양으로 첨가할 수 있다. 그러나, 건강 조절 및 위생을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있으며, 안정성 면에서 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용할 수 있다.When the composition of the present invention is used as a food, the composition may be added as it is or may be used in combination with other health food, health functional food or health functional food component, and may be appropriately used according to a conventional method. The amount of the active ingredient to be mixed can be appropriately determined depending on the purpose of use. Generally, the composition of the present invention may be added in an amount of preferably not more than 15 parts by weight, more preferably not more than 10 parts by weight, based on the raw material, in the production of food or beverage. However, in the case of long-term intake intended for health control and hygiene, the amount may be less than the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount in the above range.
본 발명의 조성물을 포함할 수 있는 식품의 종류에는 특별한 제한은 없으며, 구체적인 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있고, 통상적인 의미에서의 식품을 모두 포함할 수 있으며, 동물을 위한 사료로 이용되는 식품을 포함할 수 있다. 또한, 본 발명의 식품 조성물이 음료의 형태로 사용될 경우에는 통상의 음료와 같이 여러 가지 감미제, 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 수크로스와 같은 디사카라이드, 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 및 자일리톨, 소르비톨, 에리트리톨과 같은 당알콜일 수 있다. 상기 천연 탄수화물의 비율은 이에 제한되지는 않으나, 본 발명의 조성물 100 ㎖ 당 바람직하게는 약 0.01 내지 0.04 g, 보다 바람직하게는 0.02 내지 0.03 g일 수 있다. 상기 감미제는 타우마틴, 스테비아 추출물과 같은 천연 감미제 및 사카린, 아스파르탐과 같은 합성 감미제일 수 있다. 상기 외에 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.The composition of the present invention is not particularly limited, and examples thereof include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramie noodle, other noodles, gum, ice cream , Various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and may include all foods in the conventional sense, and foods used as feed for animals. In addition, when the food composition of the present invention is used in the form of a drink, it may contain various sweetening agents, flavoring agents, or natural carbohydrates as additional components such as ordinary beverages. The natural carbohydrates may be polysaccharides such as disaccharides such as monosaccharides such as glucose and fructose, maltose, sucrose, dextrin, cyclodextrins, and sugar alcohols such as xylitol, sorbitol and erythritol. The ratio of the natural carbohydrate is not limited thereto, but may be about 0.01 to 0.04 g, and more preferably 0.02 to 0.03 g per 100 ml of the composition of the present invention. The sweeteners may be natural sweeteners such as tau martin and stevia extract, and synthetic sweeteners such as saccharin and aspartame. In addition to the above, the food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
한편, 본 발명의 퓨리톤은 천연물질로서 인체에 무해하며, 독성 및 부작용이 거의 없으므로 장기간 사용시에도 안심하고 사용할 수 있으며, 특히 상기한 바와 같은 약학적, 화장료 및 식품 조성물에 안전하게 적용할 수 있다.On the other hand, the puritone of the present invention is a natural substance which is harmless to the human body, has little toxicity and side effects, and can be safely used for a long time, and can be safely applied to pharmaceuticals, cosmetics and food compositions as described above.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다. Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.
<< 실시예Example 1>  1> 미네랄 이온 혼합물의Of mineral ion mixture 세포독성 측정 Cytotoxicity measurement
미네랄 이온 혼합물(퓨리톤)이 RAW264.7 세포에서의 세포생존률에 미치는 영향을 확인하기 위하여 하기와 같은 방법으로 실험하였다(Lee, S.U., Choi, Y.H., Kim, Y.S., Min, Y.K., Rhee, M., Kim, S.H., 2010. Anti-resorptive sa,urolactam exhibits in vitro anti-inflammatory activity via ERK-NF-kappaB signaling pathway. International immunopharmacology 10, 298-303.)In order to confirm the effect of mineral ion mixture (puritone) on cell survival rate in RAW264.7 cells, the following experiment was conducted (Lee, SU, Choi, YH, Kim, YS, Min, YK, Rhee, ., Kim, SH, 2010. Anti-resorptive sa, urolactam exhibits in vitro anti-inflammatory activity via ERK-NF-kappaB signaling pathway. International immunopharmacology 10, 298-303.
생쥐의 대식세포인 Raw264.7 세포(TIB-71, ATCC)를 소태아혈청(Fetal Bovine Serum)을 10% 및 페니실린 1%를 첨가한 DMEM 배지(Dulbecco's Modified Eagle Medium, Gibco)에 1x104/㎖의 농도로 현탁하여 200 ㎕씩 96 웰 플레이트에 접종하여 12시간동안 부착하였다. 퓨리톤을 농도별(0, 1, 2, 5, 10, 50, 100, 150 ㎕/200 ㎕ (0 - 75%))로 처리한 후, 24시간 및 48시간 동안 배양하였다. Of macrophages in mice Raw264.7 cells (TIB-71, ATCC) of fetal bovine serum (Fetal Bovine Serum) and 10% penicillin and 1% in DMEM culture medium (Dulbecco's Modified Eagle Medium, Gibco ) was added to 1x10 4 / ㎖ , And 200 [mu] L of the solution was inoculated in a 96-well plate and adhered for 12 hours. Puritone was treated with concentration (0, 1, 2, 5, 10, 50, 100, 150 ㎕ / 200 ㎕ (0 - 75%)) and cultured for 24 hours and 48 hours.
이후 10㎕의 MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphinyltetrazolium bromide) 용액 (저장 농도: 5 mg/㎖)을 첨가하고 3시간 동안 추가반응을 유도하였다. 반응 종료 및 포마잔 결정을 용해하기 위하여, 각 웰에 100 ㎕의 MTT 정지 용액 (0.01M HCl 내 10% 소듐 도데실 설페이트)을 추가적으로 첨가하였다. 세포 생존율은 MTT가 포마잔으로 환원된 양을 570 nm에서 흡광도를 분광광도계(Molecular Device, CA, USA)를 이용하여 측정하여 얻어진 OD 값을 통해 산출하였다.Then, 10 μl of MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphinyltetrazolium bromide) solution (storage concentration: 5 mg / ml) was added and further reaction was induced for 3 hours. To terminate the reaction and dissolve the formazan crystals, 100 [mu] l MTT stop solution (10% sodium dodecyl sulfate in 0.01 M HCl) was additionally added to each well. The cell viability was calculated from the OD value obtained by measuring the absorbance at 570 nm using a spectrophotometer (Molecular Device, CA, USA) in which the amount of MTT reduced to formazan was measured.
도 1은 Raw264.7 세포에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양하여 세포 생존율을 나타낸 그래프이고, 도 2는 Raw264.7 세포에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양한 세포 사진이다. 여기에서 보듯이, 세포 배양 24시간 동안 0.5 내지 25%로 세포 증식이 나타났으며, RAW264.7 세포 내에서 세포 생존율의 감소를 거의 나타내지 않아 세포독성이 없음을 확인하였다.FIG. 1 is a graph showing the cell survival rate by culturing Raw264.7 cells in a concentration-dependent manner for 24 hours. FIG. 2 is a graph showing the cell survival rate of Raw264.7 cells treated with puritone It is a photograph. As shown here, cell proliferation was observed at 0.5 to 25% for 24 hours in the cell culture, and there was little decrease in cell survival rate in RAW264.7 cells, and it was confirmed that there was no cytotoxicity.
도 3은 Raw264.7 세포에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양하여 세포 생존율을 나타낸 그래프이고, 도 4는 Raw264.7 세포에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양한 세포 사진이다. 여기에서 보듯이, 세포 배양 48시간 동안 0.5 내지 25%로 세포 증식이 나타났으며, RAW264.7 세포 내에서 세포 생존율의 감소를 거의 나타내지 않아 세포독성이 없음을 확인하였다.FIG. 3 is a graph showing cell viability by culturing Raw264.7 cells in a concentration-dependent manner at a concentration of puritone for 48 hours. FIG. 4 is a graph showing the cell viability of Raw264.7 cells after 48 hours of treatment with puritone It is a photograph. As shown here, cell proliferation was observed at 0.5 to 25% for 48 hours in the cell culture, and there was little decrease in cell survival rate in RAW264.7 cells, confirming no cytotoxicity.
<< 실시예Example 2>  2> 퓨리톤의Puritone 항암활성 측정 Measurement of antitumor activity
(1) (One) 퓨리톤의Puritone 유방암 세포주  Breast cancer cell line MDAMDA -MB--MB- 231에 대한 증식 억제효과231 &lt; / RTI &gt; 측정 Measure
하기 표 6과 같은 성분으로 이루어진 미네랄 이온 혼합물(퓨리톤)이 유방암 세포주 MDA-MB-231에서의 암세포 증식 억제효과를 확인하기 위하여 하기와 같은 방법으로 실험하였다.In order to confirm the cancer cell proliferation inhibitory effect of the mineral ion mixture (puritone) composed of the components shown in Table 6 below in the breast cancer cell line MDA-MB-231, the following experiment was conducted.
성분ingredient 함량(%)content(%)
몬트모릴로나이트((Na,Ca)0.3(Al,Mg)2Si4O10(OH)2n(H2O)) ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 1717
카올리나이트(A12Si2O5(OH)4)Kaolinite (A1 2 Si 2 O 5 ( OH) 4) 2323
바이오타이트(KFe3(AlSi3O10)(OH)2)Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 1414
서펜틴(Mg,Fe)3Si2O5(OH)4) Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 1212
마이카(AB2- 3(X,Si)4O10(O,F,OH)2)Mica (AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 88
버미쿨라이트(Mg,Fe,Al)3(Al,Si)4O10(OH)2·4H2O) (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 44
무스코바이트(KA12(AlSi3O10)(F,OH)2) Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 33
클리노클로레(Mg,Fe,Al)6(Si,Al)4O10(OH)8) (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 33
브루사이트(Mg(OH)2) Brucite (Mg (OH) 2 ) 22
일라이트(KAl1 . 3Fe0 . 4Mg0 . 2Si3 . 4Al0 . 6O10(OH)2)Illite (KAl 1. 3 Fe 0. 4 Mg 0. 2 Si 3. 4 Al 0. 6 O 10 (OH) 2) 22
리메스톤(CaCO3) Limestone (CaCO 3 ) 22
제올라이트(NaAlSi2O6H2O)Zeolite (NaAlSi 2 O 6 H 2 O) 1One
올소클레이스 또는 올소클레이스 펠드스파(KA1Si3O8) Clay's ortho or ortho-Clay's Spa Seefeld (KA1Si 3 O 8) 1One
베마이트(y-ALO(OH)) The boehmite (y-ALO (OH)) 0.90.9
네펠린(Na,K)AlSiO4)Nephellin (Na, K) AlSiO 4 ) 0.80.8
팔리코르스카이트 또는 애터펄자이트((Mg,Al)2Si4O10(OH)4(H2O)) (Mg, Al) 2 Si 4 O 10 (OH) 4 (H 2 O)), 0.80.8
마그네사이트(MgCO3) Magnesite (MgCO 3) 0.70.7
스페릴라이트(PtAs2) Sphereyl (PtAs 2 ) 0.60.6
크렌네라이트(Au3AgTe8) Crenelite (Au 3 AgTe 8 ) 0.60.6
페트자이트(Ag3AuTe2) Petzite (Ag 3 AuTe 2 ) 0.50.5
기브사이트(Al(OH)3) Gibbsite (Al (OH) 3 ) 0.40.4
앨러페인(Al2O3(SiO2)1 .3- 2(2.5-3)H2O) AL pane (Al 2 O 3 (SiO 2 ) 1 .3- 2 (2.5-3) H 2 O) 0.40.4
플로고파이트((KMg3(AlSi3O10)(OH)2) (KMg 3 (AlSi 3 O 10 ) (OH) 2 ) 0.40.4
레피도라이트(K(Li,Al,Rb)2(Al,Si)4O10(F,OH)2) (Li, Al, Rb) 2 (Al, Si) 4 O 10 (F, OH) 2 ) 0.30.3
실바나이트(SiAgAuTe4) Silvanite (SiAgAuTe 4 ) 0.30.3
글로코나이트((Fe3+,Al,Mg)2(Si,Al)4O10(OH)2) ((Fe 3+ , Al, Mg) 2 (Si, Al) 4 O 10 (OH) 2 ) 0.30.3
돌로마이트(CaMg(CO3)2) Dolomite (CaMg (CO 3) 2) 0.30.3
토르말린(Al,Fe,Li,Mg,Mn)3(Al,Cr,Fe,V)6(BO3)3(Si,Al,B)6O18(OH,F)4)Tourmaline (Al, Fe, Li, Mg , Mn) 3 (Al, Cr, Fe, V) 6 (BO 3) 3 (Si, Al, B) 6 O 18 (OH, F) 4) 0.20.2
카날라이트((KClMgCl2·6(H2O)) Canal light ((KClMgCl 2 · 6 (H 2 O)) 0.20.2
안드라다이트(Ca3Fe2(SiO4)3) Andradite (Ca 3 Fe 2 (SiO 4 ) 3 ) 0.20.2
휴마이트(Mg7(SiO4)3(F,OH)2)Humite (Mg 7 (SiO 4 ) 3 (F, OH) 2 ) 0.10.1
총gun 100100
인간 유방암 세포주 MDA-MB-231를 소태아혈청(Fetal Bovine Serum)을 10% 및 페니실린 1%를 첨가한 DMEM 배지(Dulbecco's Modified Eagle Medium, Gibco)에 1x104/㎖의 농도로 현탁하여 200 ㎕씩 96 웰 플레이트에 접종하여 12시간동안 부착하였다. 퓨리톤을 농도별(0, 1, 2, 5, 10, 50, 100 ㎕/200 ㎕ (0 - 55%))로 처리한 후, 24시간 및 48시간 동안 배양하였다. The human breast cancer cell line MDA-MB-231 was suspended in DMEM medium (Dulbecco's Modified Eagle Medium, Gibco) supplemented with 10% fetal bovine serum and 1% penicillin at a concentration of 1 x 10 4 / Inoculated on a 96-well plate and allowed to attach for 12 hours. Puritone was treated with concentrations (0, 1, 2, 5, 10, 50, 100 μl / 200 μl (0 - 55%)) and cultured for 24 and 48 hours.
이후 10㎕의 MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphinyltetrazolium bromide) 용액 (저장 농도: 5 mg/㎖)을 첨가하고 3시간 동안 추가반응을 유도하였다. 반응 종료 및 포마잔 결정을 용해하기 위하여, 각 웰에 100 ㎕의 MTT 정지 용액 (0.01M HCl 내 10% 소듐 도데실 설페이트)을 추가적으로 첨가하였다. 세포 생존율은 MTT가 포마잔으로 환원된 양을 570 nm에서 흡광도를 분광광도계(Molecular Device, CA, USA)를 이용하여 측정하여 얻어진 OD 값을 통해 산출하였다.Then, 10 μl of MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphinyltetrazolium bromide) solution (storage concentration: 5 mg / ml) was added and further reaction was induced for 3 hours. To terminate the reaction and dissolve the formazan crystals, 100 [mu] l MTT stop solution (10% sodium dodecyl sulfate in 0.01 M HCl) was additionally added to each well. The cell viability was calculated from the OD value obtained by measuring the absorbance at 570 nm using a spectrophotometer (Molecular Device, CA, USA) in which the amount of MTT reduced to formazan was measured.
도 5는 인간 유방암 세포주 MDA-MB-231에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이고, 도 6은 인간 유방암 세포주 MDA-MB-231에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양한 세포 사진이다. 여기에서 보듯이, 세포 배양 24시간 동안 25 내지 50%로 암세포 증식 억제효과를 나타냄을 알 수 있었다.FIG. 5 is a graph showing the effect of inhibiting the proliferation of cancer cells by culturing the human breast cancer cell line MDA-MB-231 for 24 hours after treatment with puritone by concentration; FIG. 6 is a graph showing the effect And then cultured for 24 hours. As shown here, it was found that the cell growth inhibition effect was 25 to 50% for 24 hours.
도 7은 인간 유방암 세포주 MDA-MB-231에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이고, 도 8은 인간 유방암 세포주 MDA-MB-231에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양한 세포 사진이다. 여기에서 보듯이, 세포 배양 동안 25 내지 50%로 암세포 증식 억제효과를 나타냄을 알 수 있었다.FIG. 7 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human breast cancer cell line MDA-MB-231 at a concentration of puritone by concentration for 48 hours, and FIG. 8 is a graph showing the effect of suppressing the proliferation of human breast cancer cell line MDA- And then cultured for 48 hours. As shown here, it was found that the cell growth inhibitory effect was 25 to 50% during cell culture.
(2) (2) 퓨리톤의Puritone 간암 세포주  Liver cancer cell line HepG2에On HepG2 대한 증식 억제효과 측정 Measurement of inhibitory effect on proliferation
퓨리톤이 간암 세포주 HepG2에서의 암세포 증식 억제효과를 확인하기 위하여 하기와 같은 방법으로 실험하였다.Puritone was tested by the following method in order to confirm the inhibitory effect of cancer cell growth on liver cancer cell line HepG2.
인간 간암 세포주 HepG2를 소태아혈청(Fetal Bovine Serum)을 10% 및 페니실린 1%를 첨가한 DMEM 배지(Dulbecco's Modified Eagle Medium, Gibco)에 1x104/㎖의 농도로 현탁하여 200 ㎕씩 96 웰 플레이트에 접종하여 12시간동안 부착하였다. 퓨리톤을 농도별(0, 1, 2, 5, 10, 50, 100, 150 ㎕/200 ㎕ (0 - 75%))로 처리한 후, 24시간 및 48시간 동안 배양하였다. Human liver cancer cell line HepG2 was suspended in DMEM medium (Dulbecco's Modified Eagle Medium, Gibco) supplemented with 10% fetal bovine serum and 1% penicillin at a concentration of 1 x 10 4 / ml, And inoculated for 12 hours. Puritone was treated with concentration (0, 1, 2, 5, 10, 50, 100, 150 ㎕ / 200 ㎕ (0 - 75%)) and cultured for 24 hours and 48 hours.
이후 10㎕의 MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphinyltetrazolium bromide) 용액 (저장 농도: 5 mg/㎖)을 첨가하고 3시간 동안 추가반응을 유도하였다. 반응 종료 및 포마잔 결정을 용해하기 위하여, 각 웰에 100 ㎕의 MTT 정지 용액 (0.01M HCl 내 10% 소듐 도데실 설페이트)을 추가적으로 첨가하였다. 세포 생존율은 MTT가 포마잔으로 환원된 양을 570 nm에서 흡광도를 분광광도계(Molecular Device, CA, USA)를 이용하여 측정하여 얻어진 OD 값을 통해 산출하였다.Then, 10 μl of MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphinyltetrazolium bromide) solution (storage concentration: 5 mg / ml) was added and further reaction was induced for 3 hours. To terminate the reaction and dissolve the formazan crystals, 100 [mu] l MTT stop solution (10% sodium dodecyl sulfate in 0.01 M HCl) was additionally added to each well. The cell viability was calculated from the OD value obtained by measuring the absorbance at 570 nm using a spectrophotometer (Molecular Device, CA, USA) in which the amount of MTT reduced to formazan was measured.
도 9는 인간 간암 세포주 HepG2에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다. 여기에서 보듯이, 세포 배양 24시간 동안 50 내지 70%로 암세포 증식 억제효과를 나타냄을 알 수 있었다.FIG. 9 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human liver cancer cell line HepG2 for 24 hours after treatment with puritone by concentration. As shown here, it was found that the cell growth inhibition effect was 50 to 70% for 24 hours.
도 10은 인간 간암 세포주 HepG2에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다. 여기에서 보듯이, 세포 배양 48시간 동안 50 내지 75%로 암세포 증식 억제효과를 나타냄을 알 수 있었다.FIG. 10 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human liver cancer cell line HepG2 at different concentrations of puritone for 48 hours. As shown here, it was found that the cell growth inhibition effect was 50 to 75% for 48 hours.
(3) (3) 퓨리톤의Puritone 폐암 세포주  Lung cancer cell line A549에 대한 증식 억제효과Proliferation inhibition effect on A549 측정 Measure
퓨리톤이 폐암 세포주 A549에서의 암세포 증식 억제효과를 확인하기 위하여 하기와 같은 방법으로 실험하였다.Puritone was tested by the following method to confirm the inhibitory effect of cancer cell line A549 on cancer cell proliferation.
인간 폐암 세포주 A549를 소태아혈청(Fetal Bovine Serum)을 10% 및 페니실린 1%를 첨가한 RPMI 1640 배지에 1x104/㎖의 농도로 현탁하여 200 ㎕씩 96 웰 플레이트에 접종하여 12시간동안 부착하였다. 퓨리톤을 농도별(0, 1, 2, 5, 10, 50, 100, 150 ㎕/200 ㎕ (0 - 75%))로 처리한 후, 24시간 및 48시간 동안 배양하였다. Human lung cancer cell line A549 was suspended in RPMI 1640 medium supplemented with 10% fetal bovine serum (Fetal Bovine Serum) and 1% penicillin at a concentration of 1x10 4 / ml, and 200 μl of each was inoculated in a 96-well plate and adhered for 12 hours . Puritone was treated with concentration (0, 1, 2, 5, 10, 50, 100, 150 ㎕ / 200 ㎕ (0 - 75%)) and cultured for 24 hours and 48 hours.
이후 10㎕의 MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphinyltetrazolium bromide) 용액 (저장 농도: 5 mg/㎖)을 첨가하고 3시간 동안 추가반응을 유도하였다. 반응 종료 및 포마잔 결정을 용해하기 위하여, 각 웰에 100 ㎕의 MTT 정지 용액 (0.01M HCl 내 10% 소듐 도데실 설페이트)을 추가적으로 첨가하였다. 세포 생존율은 MTT가 포마잔으로 환원된 양을 570 nm에서 흡광도를 분광광도계(Molecular Device, CA, USA)를 이용하여 측정하여 얻어진 OD 값을 통해 산출하였다.Then, 10 μl of MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphinyltetrazolium bromide) solution (storage concentration: 5 mg / ml) was added and further reaction was induced for 3 hours. To terminate the reaction and dissolve the formazan crystals, 100 [mu] l MTT stop solution (10% sodium dodecyl sulfate in 0.01 M HCl) was additionally added to each well. The cell viability was calculated from the OD value obtained by measuring the absorbance at 570 nm using a spectrophotometer (Molecular Device, CA, USA) in which the amount of MTT reduced to formazan was measured.
도 11은 인간 폐암 세포주 A549에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다. 여기에서 보듯이, 세포 배양 24시간 동안 50 내지 70%로 암세포 증식 억제효과를 나타냄을 알 수 있었다.FIG. 11 is a graph showing the effect of suppressing the proliferation of cancer cells by culturing the human lung cancer cell line A549 for 24 hours after treatment with puritone by concentration. As shown here, it was found that the cell growth inhibition effect was 50 to 70% for 24 hours.
도 12는 인간 폐암 세포주 A549에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다. 여기에서 보듯이, 세포 배양 48시간 동안 50 내지 75%로 암세포 증식 억제효과를 나타냄을 알 수 있었다.FIG. 12 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human lung cancer cell line A549 at a concentration of puritone by concentration for 48 hours. As shown here, it was found that the cell growth inhibition effect was 50 to 75% for 48 hours.
(4) (4) 퓨리톤의Puritone 난소암 세포주  Ovarian cancer cell line OVCAOVCA 429에 대한 증식 억제효과429 &lt; / RTI &gt; 측정 Measure
퓨리톤이 난소암 세포주(Ovary cancer cell) OVCA 249에서의 암세포 증식 억제효과를 하기와 같은 방법으로 실험하였다.Puritone inhibited cancer cell proliferation in ovarian cancer cell OVCA 249 by the following method.
계대 배양 24 시간 후, 96-웰 플레이트 내의 세포를 퓨리톤 및 H2O로 처리한 다음 pH12로 조절하여 1 일 동안 처리하였다. 세포 생존력은 CellTiter-Glo 발광 세포 생존력 분석법 (Promega Corporation, Madison, WI, USA)을 사용하여 측정하였다. 96-웰 플레이트를 약 30분 동안 실온으로 간단히 평형시켰다. CellTiter-Glo　시약 (100 μl)을 각 웰에 넣었다. 이어서, Tecan Infinite F200 마이크로 플레이트 판독기를 사용하여 배지 및 시약을 오비탈 쉐이커(orbital shaker)에서 2분 동안 혼합하고 실온에서 10 분 동안 방치하여 발광을 기록하였다. 발광 최종 값은 상대 백분율로 나타내었다.After 24 hours of passage, cells in 96-well plates were treated with puritone and H2O and then adjusted to pH 12 for 1 day. Cell viability was measured using CellTiter-Glo luminescence cell viability assay (Promega Corporation, Madison, WI, USA). The 96-well plate was briefly equilibrated to room temperature for about 30 minutes. CellTiter-Glo reagent (100 [mu] l) was added to each well. The medium and reagents were then mixed in an orbital shaker for 2 minutes using a Tecan Infinite F200 microplate reader and allowed to stand at room temperature for 10 minutes to record the luminescence. The final luminosity was expressed as a relative percentage.
도 13은 인간 난소암 세포주 OVCA 429에 퓨리톤을 처리한 후 3일 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이고, 도 14는 인간 난소암 세포주 OVCA 429에 퓨리톤을 농도별로 처리한 후 3일 동안 배양한 세포 사진이다. 여기에서 보듯이, 70%의 농도로 처리된 퓨리톤은 99 % OVCA429 세포 성장 억제효능을 나타내었다.FIG. 13 is a graph showing inhibitory effect on cancer cell proliferation by culturing human ovarian cancer cell line OVCA 429 for 3 days after treatment with puritone, FIG. 14 is a graph showing the effect of puritone treatment on human ovarian cancer cell line OVCA 429 Cell culture. As shown here, the puritone treated at a concentration of 70% showed 99% inhibition of OVCA429 cell growth.
도 15는 인간 난소암 세포주 OVCA 429에 100%의 퓨리톤을 처리한 후 3일 동안 배양한 결과이다. 여기에서 보듯이, 퓨리톤은 99 % OVCA429 세포 성장 억제효능을 나타내었다.Fig. 15 shows the result of culturing the human ovarian cancer cell line OVCA 429 for 3 days after treatment with 100% of puritone. As shown here, the puritone showed 99% inhibition of OVCA429 cell growth.
(5) (5) 퓨리톤의Puritone 혈액암 세포주  Blood cancer cell line HL60에 대한 증식 억제효과Proliferation inhibitory effect on HL60 측정 Measure
퓨리톤이 혈액암 세포주 (Promyelocytic Leukemia) HL60에서의 암세포 증식 억제효과를 상기 실시예 5와 같은 방법으로 실험하였다.Puritone inhibited cancer cell proliferation in Promyelocytic Leukemia HL60 in the same manner as in Example 5 above.
도 16은 인간 혈액암 세포주 HL60에 퓨리톤을 처리한 후 2일 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이이다. 여기에서 보듯이, 50 % 퓨리톤 처리시 HL60 세포 성장 억제가 70 %로 나타났으며, 70% 퓨리톤 처리시 99% 의 HL60 세포 성장 억제효과를 나타내었다. 16 is a graph showing the inhibitory effect of cancer cell proliferation by culturing human blood cancer cell line HL60 for 2 days after treatment with puritone. As shown here, HL60 cell growth inhibition was 70% at 50% puritone treatment and 99% HL60 cell growth inhibition at 70% puritone treatment.
(6) (6) 퓨리톤의Puritone 피부암 세포주  Skin cancer cell line A375에 대한 증식 억제효과Proliferation inhibition effect on A375 측정 Measure
퓨리톤이 피부암 세포주 (Melanoma Cell) A375에서의 암세포 증식 억제효과를 상기실시예 5와 같은 방법으로 실험하였다.Puritone inhibited cancer cell proliferation in melanoma cell A375 in the same manner as in Example 5 above.
도 17은 인간 피부암 세포주 A375에 퓨리톤을 처리한 후 2일 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이고, 도 19는 인간 피부암 세포주 A375에 퓨리톤을 농도별로 처리한 후 2일 동안 배양한 세포 사진이다. 여기에서 보듯이, 50 % 퓨리톤 처리시 A375 세포 성장 억제가 20 %로 나타났으며, 70% 퓨리톤 처리시 99% 의 HL60 세포 성장 억제효과를 나타내었다. FIG. 17 is a graph showing the inhibitory effect of cancer cell proliferation inhibition by culturing human skin cancer cell line A375 for 2 days after treatment with puritone. FIG. 19 is a graph showing the effect of puritone treatment on human skin cancer cell line A375 It is a photograph. As shown here, A375 cell growth inhibition was 20% at 50% puritone treatment and 99% HL60 cell growth inhibition at 70% puritone treatment.
(7) (7) 퓨리톤의Puritone 신장암 세포주  Kidney cancer cell line RCC4(-)에On RCC4 (-) 대한 증식 억제효과 측정 Measurement of inhibitory effect on proliferation
퓨리톤이 신장암 세포주(Ranal cancer cell) RCC4(-)에서의 암세포 증식 억제효과를 상기와 같은 방법으로 실험하였다.Puritone inhibited the cancer cell proliferation inhibition in the renal cancer cell RCC4 (-) as described above.
도 19는 인간 신장암 세포주 RCC4(-)에 퓨리톤을 처리한 후 2일 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이고, 도 20은 인간 신장암 세포주 RCC4(-)에 퓨리톤을 농도별로 처리한 후 2일 동안 배양한 세포 사진이다. 여기에서 보듯이, 70 % 퓨리톤 처리시 RCC4(-) 세포 성장 억제가 99 %로 나타났다. FIG. 19 is a graph showing the cancer cell proliferation inhibitory effect by culturing the human renal cell carcinoma cell line RCC4 (-) for 2 days after treatment with puritone. FIG. 20 is a graph showing the effect of treating the human renal cancer cell line RCC4 And then cultured for 2 days. As shown here, the inhibition of RCC4 (-) cell growth by 70% puritone treatment was 99%.
(8) (8) 퓨리톤의Puritone 대장암 세포주  Colon cancer cell line HCT116에On HCT116 대한 증식 억제효과 측정 Measurement of inhibitory effect on proliferation
퓨리톤이 대장암 세포주(colorectal cancer cell line) HCT116에서의 암세포 증식 억제효과를 상기와 같은 방법으로 실험하였다.Puritone inhibited cancer cell proliferation in colorectal cancer cell line HCT116 in the same manner as described above.
도 21은 인간 대장암 세포주 HCT116에 퓨리톤을 농도별로 처리한 후 24시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다. 여기에서 보듯이, 세포 배양 24시간 동안 50 내지 90%로 암세포 증식 억제효과를 나타냄을 알 수 있었다.FIG. 21 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 24 hours after treatment with puritone by concentration. As shown here, the inhibitory effect on cancer cell proliferation was shown to be 50 to 90% for 24 hours of cell culture.
도 22는 인간 대장암 세포주 HCT116에 퓨리톤을 농도별로 처리한 후 48시간 동안 배양하여 암세포 증식 억제효과를 나타낸 그래프이다. 여기에서 보듯이, 세포 배양 48시간 동안 50 내지 60%로 암세포 증식 억제효과를 나타냄을 알 수 있었다.FIG. 22 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 48 hours after treatment with puritone by concentration. FIG. As shown here, it was found that the cell growth inhibition effect was 50 to 60% for 48 hours.
<< 실시예Example 3>  3> 퓨리톤의Puritone 항균활성 측정 Antimicrobial activity measurement
(1) (One) 살바이러스Live virus (( VirucidalVirucidal ) 효능 측정) Efficacy measurement
하기 표 7과 같은 조성을 가지는 미네랄 이온 혼합물의 지카 바이러스(Zika virus) 및 인플루엔자 A (H5N1) 바이러스에 대한 퓨리톤의 in vitro 살바이러스 효능을 측정하였다.In vitro virucidal efficacy of puritone against the Zika virus and influenza A (H5N1) viruses of the mineral ion mixture having the composition shown in Table 7 below was measured.
성분ingredient 함량(%)content(%)
바이오타이트(KFe3(AlSi3O10)(OH)2)Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 2020
카올리나이트(A12Si2O5(OH)4)Kaolinite (A1 2 Si 2 O 5 ( OH) 4) 1717
몬트모릴로나이트((Na,Ca)0.3(Al,Mg)2Si4O10(OH)2n(H2O)) ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 1616
서펜틴(Mg,Fe)3Si2O5(OH)4) Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 1212
마이카(AB2- 3(X,Si)4O10(O,F,OH)2)Mica (AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 88
클리노클로레(Mg,Fe,Al)6(Si,Al)4O10(OH)8) (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 44
버미쿨라이트(Mg,Fe,Al)3(Al,Si)4O10(OH)2·4H2O) (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 44
무스코바이트(KA12(AlSi3O10)(F,OH)2) Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 33
브루사이트(Mg(OH)2) Brucite (Mg (OH) 2 ) 22
리메스톤(CaCO3) Limestone (CaCO 3 ) 22
제올라이트(NaAlSi2O6H2O)Zeolite (NaAlSi 2 O 6 H 2 O) 1One
일라이트(KAl1 . 3Fe0 . 4Mg0 . 2Si3 . 4Al0 . 6O10(OH)2)Illite (KAl 1. 3 Fe 0. 4 Mg 0. 2 Si 3. 4 Al 0. 6 O 10 (OH) 2) 22
올소클레이스 또는 올소클레이스 펠드스파(KA1Si3O8) Clay's ortho or ortho-Clay's Spa Seefeld (KA1Si 3 O 8) 1One
베마이트(y-ALO(OH)) The boehmite (y-ALO (OH)) 0.90.9
네펠린(Na,K)AlSiO4)Nephellin (Na, K) AlSiO 4 ) 0.80.8
팔리코르스카이트 또는 애터펄자이트((Mg,Al)2Si4O10(OH)4(H2O)) (Mg, Al) 2 Si 4 O 10 (OH) 4 (H 2 O)), 0.80.8
마그네사이트(MgCO3) Magnesite (MgCO 3) 0.70.7
스페릴라이트(PtAs2) Sphereyl (PtAs 2 ) 0.60.6
크렌네라이트(Au3AgTe8) Crenelite (Au 3 AgTe 8 ) 0.60.6
페트자이트(Ag3AuTe2) Petzite (Ag 3 AuTe 2 ) 0.50.5
기브사이트(Al(OH)3) Gibbsite (Al (OH) 3 ) 0.40.4
앨러페인(Al2O3(SiO2)1 .3- 2(2.5-3)H2O) AL pane (Al 2 O 3 (SiO 2 ) 1 .3- 2 (2.5-3) H 2 O) 0.40.4
플로고파이트((KMg3(AlSi3O10)(OH)2) (KMg 3 (AlSi 3 O 10 ) (OH) 2 ) 0.40.4
레피도라이트(K(Li,Al,Rb)2(Al,Si)4O10(F,OH)2) (Li, Al, Rb) 2 (Al, Si) 4 O 10 (F, OH) 2 ) 0.30.3
실바나이트(SiAgAuTe4) Silvanite (SiAgAuTe 4 ) 0.30.3
글로코나이트((Fe3+,Al,Mg)2(Si,Al)4O10(OH)2) ((Fe 3+ , Al, Mg) 2 (Si, Al) 4 O 10 (OH) 2 ) 0.30.3
돌로마이트(CaMg(CO3)2) Dolomite (CaMg (CO 3) 2) 0.30.3
토르말린(Al,Fe,Li,Mg,Mn)3(Al,Cr,Fe,V)6(BO3)3(Si,Al,B)6O18(OH,F)4)Tourmaline (Al, Fe, Li, Mg , Mn) 3 (Al, Cr, Fe, V) 6 (BO 3) 3 (Si, Al, B) 6 O 18 (OH, F) 4) 0.20.2
카날라이트((KClMgCl2·6(H2O)) Canal light ((KClMgCl 2 · 6 (H 2 O)) 0.20.2
안드라다이트(Ca3Fe2(SiO4)3) Andradite (Ca 3 Fe 2 (SiO 4 ) 3 ) 0.20.2
휴마이트(Mg7(SiO4)3(F,OH)2)Humite (Mg 7 (SiO 4 ) 3 (F, OH) 2 ) 0.10.1
총 gun 100100
구체적으로, 퓨리톤 액체를 물에서 50%로 희석시켰다. 각 시료 희석액 1 mL를 각 시점마다 3 회씩 튜브에 첨가하고 각 바이러스를 시험하였다. 음성 대조군 (물) 및 양성 대조군 (70 % 에탄올)이 각각의 복제물에 포함되었다. 한 세트의 독성 대조군 튜브를 바이러스 첨가없이 동일한 방식으로 준비하였다. 바이러스를 각 시점 (4 시간 및 18 시간) 동안 튜브에 첨가하였다. 지카 바이러스(Zika virus) 원료 10 μl와 인플루엔자 A (H5N1) 바이러스 원료 100 μl를 각각의 튜브에 첨가하고 완전히 혼합했다. H5N1 균주의 역가가 낮아서 테스트에 필요한 부피가 증가하였다. 따라서, 바이러스가 첨가된 후 테스트된 약물의 최고 농도는 90 % 였지만 Zika는 99 %였다. 튜브를 실온에서 4 시간 또는 18 시간 동안 배양하였다. 배양 후, 시료를 1/10 희석하여 세포 배양 배지에 첨가하고 연속 로그 희석을 수행하였다. 희석된 시료를 인플루엔자용 MDCK 세포 80-90 % 및 Zika용 Vero 76 세포를 갖는 96-웰 플레이트 각각 4개 웰에 첨가하였다. 독성 대조군을 상기에서 기술한 것과 동일한 방식으로 희석하고 플레이팅하였다. 감염되지 않은 대조구의 절반에 세포 내 화합물의 항바이러스 활성 (중화 조절)을 모니터링하기 위해 바이러스 (30 CCID50 / 웰)를 첨가하였다. 플레이트를 37 ± 2 ℃에서 5 % CO2에서 배양하였다. 배양은 H5N1에 대해서는 3 일째에 Zika 바이러스에 대해서는 6 일째에 세포 변성 효과 (CPE)의 존재 또는 부재에 대해 점수를 매겼다. Reed-Muench 방법을 사용하여 시료의 종점 역가 (50 % 세포 배양 감염 용량, CCID50)를 결정하였고, 음수 (물) 대조군과 비교하여 화합물의 로그 감소 값 (LRV)을 계산하였다.Specifically, the puritone liquid was diluted to 50% in water. 1 mL of each sample dilution was added to the tube three times at each time point and each virus was tested. A negative control (water) and a positive control (70% ethanol) were included in each replicate. One set of toxic control tubes was prepared in the same manner without the addition of virus. Virus was added to the tube at each time point (4 hours and 18 hours). 10 μl of Zika virus stock and 100 μl of influenza A (H5N1) viral stock were added to each tube and mixed thoroughly. The activity of the H5N1 strain was low and the volume required for the test was increased. Thus, the highest concentration of tested drug after virus addition was 90%, but Zika was 99%. The tubes were incubated at room temperature for 4 hours or 18 hours. After incubation, the samples were diluted 1/10, added to the cell culture medium, and serial log dilution was performed. Diluted samples were added to 4 wells of each of 96- well plates with 80-90% MDCK cells for influenza and Vero 76 cells for Zika. The toxic controls were diluted and plated in the same manner as described above. Virus (30 CCID50 / well) was added to monitor the antiviral activity (neutralization regulation) of intracellular compounds in half of the uninfected control. The plates were incubated at 5% CO 2 at 37 ± 2 ℃. Cultures were scored for the presence or absence of cytopathic effect (CPE) on day 3 for H5N1 and on day 6 for Zika virus. The endpoint titer of the sample (50% cell culture infectious dose, CCID50) was determined using the Reed-Muench method and the log reduction value (LRV) of the compound compared to the negative (water) control was calculated.
하기 표 8 및 표 9에는 각각 지카 바이러스 및 인플루엔자 A에 대한 퓨리톤의 살바이러스 활성을 나타내었다. Tables 8 and 9 below show the virucidal activity of puritone against Zicca virus and influenza A, respectively.
Figure PCTKR2018015205-appb-T000001
Figure PCTKR2018015205-appb-T000001
Figure PCTKR2018015205-appb-T000002
Figure PCTKR2018015205-appb-T000002
중화 대조군은 titer assay에서 바이러스가 효과적으로 검출되었음을 보여준다. 독성 대조군은 titer plate가 유효하고 시험판에서 독성이 관찰되지 않았다.The neutralized control group showed that the virus was effectively detected in the titer assay. In the toxic control group, the titer plate was valid and toxicity was not observed on the test plate.
상기 표 8 및 9에서 보듯이, Zika 바이러스의 경우 70 % 에탄올이 완전히 효과적이었으며, 바이러스 처리하지 않은 대조군은 예상대로였습니다. 비희석된 화합물과 50 % 용액은 모두 4 시간 및 18 시간의 접촉 시간에 효과적인 살바이러스 활성을 나타내었다.As shown in Tables 8 and 9, In the case of Zika virus, 70% ethanol was completely effective and the control group without virus treatment was as expected. Both the undiluted compound and the 50% solution exhibited effective viral activity at contact times of 4 hours and 18 hours.
한편, 인플루엔자 A (H5N1) 바이러스의 경우 70 % 에탄올이 완전히 효과적이었으며 바이러스 처리되지 않은 대조군은 예상대로였습니다. 희석되지 않은 화합물은 4 시간 및 18 시간의 접촉 시간에 효과적인 살바이러스 활성을 나타내었으며, 50 % 용액은 18 시간의 접촉시간에 효과적이었으나, 4 시간의 접촉시간에는 덜 효과적이었다.On the other hand, in the case of influenza A (H5N1) virus, 70% ethanol was completely effective and the control group with no virus treatment was as expected. The undiluted compound showed effective viral activity at contact times of 4 and 18 hours, while the 50% solution was effective at contact times of 18 hours, but less effective at contact times of 4 hours.
(2) 각종 균에 대한 항균활성 측정(2) Measurement of antimicrobial activity against various bacteria
항균 효능을 가지고 있다고 보고된 성분을 대상으로 대장균(Escherichia coli), 스타필로코커스 아우레스(Staphylococcus aureus), 슈도모나스 아에루기노사(Pseudomonas aeruginosa), 캔디다 알비칸스(Candida albicans) 및 살모넬라 티피무리움(Salmonella typhimurium)에 대한 항균 효과를 측정하였다. 각 미생물을 1,000,000 CFU/ml로 성장시킨 후 각 시료와 정제수에 첨가하였다. 24시간 및 7일 후 플레이트내 미생물 수를 개수하였다. 그 결과를 하기 표 10 및 도 23 내지 도 27에 나타내었다.E. coli targeting component reported to have antibacterial efficacy (Escherichia coli), Staphylococcus brother, Les (Staphylococcus aureus), Pseudomonas rugi Ah Labor (Pseudomonas aeruginosa), Candida albicans (Candida albicans) and Salmonella typhimurium bunch was measured an antibacterial effect for help (Salmonella typhimurium). Each microorganism was grown to 1,000,000 CFU / ml and added to each sample and purified water. After 24 hours and 7 days, the number of microorganisms in the plate was recovered. The results are shown in Table 10 and FIG. 23 to FIG.
Figure PCTKR2018015205-appb-T000003
Figure PCTKR2018015205-appb-T000003
도 23은 대장균(Escherichia coli)에 대한 퓨리톤의 항균 활성을 나타낸 것이다.Fig. 23 is a graph lt; RTI ID = 0.0 &gt; E. coli . &lt; / RTI &gt;
도 24는 스타필로코커스 아우레스(Staphylococcus aureus)에 대한 퓨리톤의 항균 활성을 나타낸 것이다.Figure 24 shows the antimicrobial activity of puritone against Staphylococcus aureus .
도 25는 슈도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 퓨리톤의 항균 활성을 나타낸 것이다.25 is a graph showing the results of Pseudomonas &lt; RTI ID = 0.0 &gt; 0.0 &gt; aeruginosa . &lt; / RTI &gt;
도 26은 살모넬라 티피무리움(Salmonella typhimurium)에 대한 퓨리톤의 항균 활성을 나타낸 것이다.Figure 26 shows the antimicrobial activity of puritone against Salmonella typhimurium .
도 27은 캔디다 알비칸스(Candida albicans)에 대한 퓨리톤의 항균 활성을 나타낸 것이다.Figure 27 shows the antimicrobial activity of puritone against Candida albicans .
상기 표 10 및 도 23 내지 도 27에서 보듯이, 정제수에서는 24시간 후 박테리아가 남아 있거나 성장한 것을 알 수 있다. 반면, 퓨리톤 시료는 24시간 후 존재하지 않았으며, 7일 후에도 박테리아가 재성장하지 않음을 확인할 수 있었다.As shown in Table 10 and FIG. 23 to FIG. 27, it can be seen that the bacteria remained or grew after 24 hours in the purified water. On the other hand, the purite sample was not present after 24 hours, and it was confirmed that the bacteria did not regrow after 7 days.
<< 실시예Example 4>  4> 퓨리톤의Puritone 알콜분해능Alcohol resolution ability 평가 evaluation
하기 표 11과 같은 조성을 가지는 미네랄 이온 혼합물(퓨리톤)의 in vivo 실험으로 아세트알데히드 분석과 알데히드 탈수소효소 활성 비색 분석(Aldehyde Dehydrogenase Activity Colorimetric Assay) 실험을 진행하였다. Was carried out to a mineral having a composition as shown in Table 11, the ion mixture (Fourier ton) of in vivo experiments acetaldehyde analysis and aldehyde dehydrogenase activity by colorimetric assay (Aldehyde Dehydrogenase Activity Colorimetric Assay) test.
성분ingredient 함량(%)content(%)
몬트모릴로나이트((Na,Ca)0.3(Al,Mg)2Si4O10(OH)2n(H2O)) ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 2424
카올리나이트(A12Si2O5(OH)4)Kaolinite (A1 2 Si 2 O 5 ( OH) 4) 1616
바이오타이트(KFe3(AlSi3O10)(OH)2)Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 1515
서펜틴(Mg,Fe)3Si2O5(OH)4) Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 1111
마이카(AB2- 3(X,Si)4O10(O,F,OH)2)Mica (AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 88
버미쿨라이트(Mg,Fe,Al)3(Al,Si)4O10(OH)2·4H2O) (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 44
무스코바이트(KA12(AlSi3O10)(F,OH)2) Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 33
클리노클로레(Mg,Fe,Al)6(Si,Al)4O10(OH)8) (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 33
브루사이트(Mg(OH)2) Brucite (Mg (OH) 2 ) 22
일라이트(KAl1 . 3Fe0 . 4Mg0 . 2Si3 . 4Al0 . 6O10(OH)2)Illite (KAl 1. 3 Fe 0. 4 Mg 0. 2 Si 3. 4 Al 0. 6 O 10 (OH) 2) 22
리메스톤(CaCO3) Limestone (CaCO 3 ) 22
제올라이트(NaAlSi2O6H2O)Zeolite (NaAlSi 2 O 6 H 2 O) 1One
올소클레이스 또는 올소클레이스 펠드스파(KA1Si3O8) Clay's ortho or ortho-Clay's Spa Seefeld (KA1Si 3 O 8) 1One
베마이트(y-ALO(OH)) The boehmite (y-ALO (OH)) 0.90.9
네펠린(Na,K)AlSiO4)Nephellin (Na, K) AlSiO 4 ) 0.80.8
팔리코르스카이트 또는 애터펄자이트((Mg,Al)2Si4O10(OH)4(H2O)) (Mg, Al) 2 Si 4 O 10 (OH) 4 (H 2 O)), 0.80.8
마그네사이트(MgCO3) Magnesite (MgCO 3) 0.70.7
스페릴라이트(PtAs2) Sphereyl (PtAs 2 ) 0.60.6
크렌네라이트(Au3AgTe8) Crenelite (Au 3 AgTe 8 ) 0.60.6
페트자이트(Ag3AuTe2) Petzite (Ag 3 AuTe 2 ) 0.50.5
기브사이트(Al(OH)3) Gibbsite (Al (OH) 3 ) 0.40.4
앨러페인(Al2O3(SiO2)1 .3- 2(2.5-3)H2O) AL pane (Al 2 O 3 (SiO 2 ) 1 .3- 2 (2.5-3) H 2 O) 0.40.4
플로고파이트((KMg3(AlSi3O10)(OH)2) (KMg 3 (AlSi 3 O 10 ) (OH) 2 ) 0.40.4
레피도라이트(K(Li,Al,Rb)2(Al,Si)4O10(F,OH)2) (Li, Al, Rb) 2 (Al, Si) 4 O 10 (F, OH) 2 ) 0.30.3
실바나이트(SiAgAuTe4) Silvanite (SiAgAuTe 4 ) 0.30.3
글로코나이트((Fe3+,Al,Mg)2(Si,Al)4O10(OH)2) ((Fe 3+ , Al, Mg) 2 (Si, Al) 4 O 10 (OH) 2 ) 0.30.3
돌로마이트(CaMg(CO3)2) Dolomite (CaMg (CO 3) 2) 0.30.3
토르말린(Al,Fe,Li,Mg,Mn)3(Al,Cr,Fe,V)6(BO3)3(Si,Al,B)6O18(OH,F)4)Tourmaline (Al, Fe, Li, Mg , Mn) 3 (Al, Cr, Fe, V) 6 (BO 3) 3 (Si, Al, B) 6 O 18 (OH, F) 4) 0.20.2
카날라이트((KClMgCl2·6(H2O)) Canal light ((KClMgCl 2 · 6 (H 2 O)) 0.20.2
안드라다이트(Ca3Fe2(SiO4)3) Andradite (Ca 3 Fe 2 (SiO 4 ) 3 ) 0.20.2
휴마이트(Mg7(SiO4)3(F,OH)2)Humite (Mg 7 (SiO 4 ) 3 (F, OH) 2 ) 0.10.1
총gun 100100
구체적으로, 6주령의 ICR 마우스(24마리)를 입수하여 5일간 순화시킨 후 4개의 군 (n=6)으로 분리하였다. 2개의 군에 각각 퓨리톤 400 ㎕ 및 800 ㎕를 부검 1 시간 전에 경구투여하였다.Specifically, 6-week-old ICR mice (24 rats) were obtained and purified for 5 days and then separated into four groups (n = 6). 400 μl and 800 μl of puritone were orally administered to the two groups one hour before autopsy.
이후 부검 30 분 전에 99.9% 에틸 알콜을 50% 알콜로 희석하여 경구투여하였다. 알콜 투여 30 분이 지난 시간을 0 시간으로 하여 0시간, 1시간, 3시간, 5시간, 7시간에 혈액을 채취하였다.After 30 minutes of autopsy, 99.9% ethyl alcohol was diluted with 50% alcohol and administered orally. Blood was collected at 0 hour, 1 hour, 3 hours, 5 hours, and 7 hours at 0 hour after 30 minutes of alcohol administration.
(1) 아세트알데히드 분석 (1) Acetaldehyde analysis
하기 방법에 따라 Acetaldehyde Assay kit [BioAssay Systmes, Cat. No. EACT-100]을 사용하여 아세트알데히드 함량을 분석하였다.Acetaldehyde Assay kit [BioAssay Systmes, Cat. No. EACT-100] was used to analyze the acetaldehyde content.
96웰 플레이트에 Standard와 sample을 각 웰에 20 ㎕씩 넣은 다음 Working Reagent를 각 웰에 80 ㎕씩 넣고 실온에서 30분간 반응시켰다. 이후 562nm에서 흡광도를 측정하고 아세트알데히드 함량을 분석하였다. 대조군으로 수돗물을 사용하였다.Standard and sample were added to each well of a 96-well plate in an amount of 20 μl, and then 80 μl of Working Reagent was added to each well, followed by reaction at room temperature for 30 minutes. The absorbance was then measured at 562 nm and the content of acetaldehyde was analyzed. As a control, tap water was used.
도 28은 퓨리톤에 의한 아세트알데히드 함량 감소효과를 나타낸 그래프이다. 여기에서 보듯이, 알콜 투여 후 0 시간부터 3 시간 동안은 퓨리톤에 의한 알콜 분해로 인해 아세트알데히드 함량이 높았으나, 3시간 이후 아세트알데히드 함량이 빠르게 감소하는 것을 확인할 수 있었다.28 is a graph showing an effect of decreasing acetaldehyde content by purite. As shown here, acetaldehyde content was high due to alcohol degradation by puritone from 0 hours to 3 hours after alcohol administration, but acetaldehyde content rapidly decreased after 3 hours.
(2) 알데히드 탈수소효소 활성 비색 분석((2) Aldehyde dehydrogenase activity colorimetric analysis AldehydeAldehyde DehydrogenaseDehydrogenase Activity Colorimetric Assay) Activity Colorimetric Assay)
하기 방법에 따라 Acetaldehyde Assay kit [BioAssay Systmes, Cat. No. EACT-100]을 사용하여 알데히드 탈수소효소 활성 비색 분석을 실시하였다.Acetaldehyde Assay kit [BioAssay Systmes, Cat. No. EACT-100] was used to analyze the activity colorimetry of aldehyde dehydrogenase.
96웰 플레이트에 ALDH 분석 완충액으로 희석한 standard 및 sample 50 ㎕씩 각 웰에 넣었다. 이어서, Reaction Mixture을 50 ㎕씩 각 웰에 넣은 다음 실온에서 20 내지 60분간 반응시켰다. 이후 450nm에서 흡광도를 측정하고 알데히드 탈수소효소 함량을 분석하였다. 대조군으로 수돗물을 사용하였다To a 96 well plate were added 50 [mu] l of standard and sample diluted with ALDH assay buffer into each well. Then, 50 μl of Reaction Mixture was added to each well, followed by reaction at room temperature for 20 to 60 minutes. The absorbance was then measured at 450 nm and the aldehyde dehydrogenase content was analyzed. Tap water was used as a control group
도 29는 퓨리톤에 의한 알데히드 탈수소효소 활성 비색 분석결과를 나타낸 그래프이다. 여기에서 보듯이, 퓨리톤에 의해 알콜 투여 3시간 이후에는 ALDH가 증가하며 숙취원인 물질인 아세트알데히드를 감소시키는 것을 확인할 수 있었다.FIG. 29 is a graph showing the result of color analysis of activity of aldehyde dehydrogenase by puritone. FIG. As shown here, after 3 hours of alcohol administration by puritone, ALDH increased and acetaldehyde, a causative agent of hangover, was decreased.
<< 실시예Example 5>  5> 퓨리톤의Puritone 창상 유도 동물모델에서 육안으로  From the wounded animal model to the naked eye 피부상처Skin wounds 치유효과 관찰 Healing effect observation
하기 표 12와 같은 조성을 가지는 미네랄 이온 혼합물(퓨리톤)의 피부상처 치유효과를 관찰하였다.The skin wound healing effect of a mineral ion mixture (puritone) having the composition shown in Table 12 below was observed.
성분ingredient 함량(%)content(%)
몬트모릴로나이트((Na,Ca)0.3(Al,Mg)2Si4O10(OH)2n(H2O)) ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 2424
카올리나이트(A12Si2O5(OH)4)Kaolinite (A1 2 Si 2 O 5 ( OH) 4) 1616
바이오타이트(KFe3(AlSi3O10)(OH)2)Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 1515
서펜틴(Mg,Fe)3Si2O5(OH)4) Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 1111
마이카(AB2- 3(X,Si)4O10(O,F,OH)2)Mica (AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 88
버미쿨라이트(Mg,Fe,Al)3(Al,Si)4O10(OH)2·4H2O) (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 44
무스코바이트(KA12(AlSi3O10)(F,OH)2) Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 33
클리노클로레(Mg,Fe,Al)6(Si,Al)4O10(OH)8) (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 33
브루사이트(Mg(OH)2) Brucite (Mg (OH) 2 ) 22
일라이트(KAl1 . 3Fe0 . 4Mg0 . 2Si3 . 4Al0 . 6O10(OH)2)Illite (KAl 1. 3 Fe 0. 4 Mg 0. 2 Si 3. 4 Al 0. 6 O 10 (OH) 2) 22
리메스톤(CaCO3) Limestone (CaCO 3 ) 22
제올라이트(NaAlSi2O6H2O)Zeolite (NaAlSi 2 O 6 H 2 O) 1One
올소클레이스 또는 올소클레이스 펠드스파(KA1Si3O8) Clay's ortho or ortho-Clay's Spa Seefeld (KA1Si 3 O 8) 1One
베마이트(y-ALO(OH)) The boehmite (y-ALO (OH)) 0.90.9
네펠린(Na,K)AlSiO4)Nephellin (Na, K) AlSiO 4 ) 0.80.8
팔리코르스카이트 또는 애터펄자이트((Mg,Al)2Si4O10(OH)4(H2O)) (Mg, Al) 2 Si 4 O 10 (OH) 4 (H 2 O)), 0.80.8
마그네사이트(MgCO3) Magnesite (MgCO 3) 0.70.7
스페릴라이트(PtAs2) Sphereyl (PtAs 2 ) 0.60.6
크렌네라이트(Au3AgTe8) Crenelite (Au 3 AgTe 8 ) 0.60.6
페트자이트(Ag3AuTe2) Petzite (Ag 3 AuTe 2 ) 0.50.5
기브사이트(Al(OH)3) Gibbsite (Al (OH) 3 ) 0.40.4
앨러페인(Al2O3(SiO2)1 .3- 2(2.5-3)H2O) AL pane (Al 2 O 3 (SiO 2 ) 1 .3- 2 (2.5-3) H 2 O) 0.40.4
플로고파이트((KMg3(AlSi3O10)(OH)2) (KMg 3 (AlSi 3 O 10 ) (OH) 2 ) 0.40.4
레피도라이트(K(Li,Al,Rb)2(Al,Si)4O10(F,OH)2) (Li, Al, Rb) 2 (Al, Si) 4 O 10 (F, OH) 2 ) 0.30.3
실바나이트(SiAgAuTe4) Silvanite (SiAgAuTe 4 ) 0.30.3
글로코나이트((Fe3+,Al,Mg)2(Si,Al)4O10(OH)2) ((Fe 3+ , Al, Mg) 2 (Si, Al) 4 O 10 (OH) 2 ) 0.30.3
돌로마이트(CaMg(CO3)2) Dolomite (CaMg (CO 3) 2) 0.30.3
토르말린(Al,Fe,Li,Mg,Mn)3(Al,Cr,Fe,V)6(BO3)3(Si,Al,B)6O18(OH,F)4)Tourmaline (Al, Fe, Li, Mg , Mn) 3 (Al, Cr, Fe, V) 6 (BO 3) 3 (Si, Al, B) 6 O 18 (OH, F) 4) 0.20.2
카날라이트((KClMgCl2·6(H2O)) Canal light ((KClMgCl 2 · 6 (H 2 O)) 0.20.2
안드라다이트(Ca3Fe2(SiO4)3) Andradite (Ca 3 Fe 2 (SiO 4 ) 3 ) 0.20.2
휴마이트(Mg7(SiO4)3(F,OH)2)Humite (Mg 7 (SiO 4 ) 3 (F, OH) 2 ) 0.10.1
총gun 100100
체중이 180-220 g인 Wistar 수컷 흰쥐를 사용하여 시험 전에 동물 실험실에서 1 주 이상 보관하였다. 동물들은 음식과 물을 자유롭게 섭취할 수 있도록 하였다.생쥐에 선형 절개창을 다음과 같이 만들었다. 구체적으로, 동물들은 펜토바비탈나트륨(sodium pentobarbital) 4O mg/ke, i.p.)을 사용하여 마취시킨 다음 각 동물의 뒷면의 오른쪽을 전기 클리퍼로 면도하고 피부는 알코올 면봉을 사용하여 닦아주었다. 이어서, 척추 중심선에서 1.5cm 떨어진 곳에서 피부의 전체 두께를 통해 외과용 블레이드로 길이 12mm의 선형의 척추인접 절개(paravertebral incision)을 만들었다. 상처를 낸 동물을 무작위로 3개의 군으로 나누었다(n = 4). 절개 유발 대조군(wound control), 퓨리톤 투여군(study) 및 양성대조군인 Band-Aid 군으로 군당 4마리씩 분리하였다.Wistar male rats weighing 180-220 g were kept in the laboratory for more than 1 week before the test. The animals were allowed free access to food and water. A linear incision was made in mice as follows. Specifically, the animals were anesthetized using sodium pentobarbital 40 mg / ke, i.p.), and the right side of each animal was shaved with an electric clipper, and the skin was wiped with an alcohol swab. Subsequently, a linear vertebral incision of 12 mm in length was made with a surgical blade through the entire thickness of the skin 1.5 cm from the spinal center line. The injured animals were randomly divided into three groups (n = 4). The wound control, puritone, and Band-Aid groups were divided into four groups.
퓨리톤 투여군 및 양성대조군의 각 동물의 절개 부위에 각각 퓨리톤 및 Band-Aid Brand First Aid Hurt Free Antiseptic Liquid를 생쥐 총 중량 당 100 mg/kg의 양으로 15일 동안 매일 3~4회 분무 도포하였다.Puritone and Band-Aid Brand First Aid Hurt Free Antiseptic Liquid were sprayed 3-4 times daily for 15 days in an amount of 100 mg / kg per mouse total weight, respectively, on the incision sites of the puritone-treated group and the positive control group .
생쥐의 절개치유 진행과정을 관찰하기 위해 절개유발 후 매일 디지털 카메라를 이용하여 각 군별로 일정한 거리에서 절개 부위를 촬영하여 상처의 변화를 육안으로 관찰하였으며, 객관적 지표로 나타내기 위해 절개의 면적을 측정, H&E 염색 또는 M&T 염색을 통해 피부조직의 형태학적 관찰을 수행하였다. In order to observe the progress of the incision healing of the mice, the incision was photographed at a constant distance from each group using a digital camera every day after incision, and the change of the wound was visually observed. The area of the incision was measured , H & E staining, or M & T staining.
본 실험에서 얻은 결과에 대해서는 평균 ± 표준편차(mean ± S.D.)로 나타내었으며, 통계처리는 SPSS (version 21, Chicago, IL, USA)를 이용하여 일원변량분석(One way ANOVA)을 실시한 후 Ducan's multiple range test로 유의성을 검증한다(p < 0.05).Statistical analysis was performed by one-way ANOVA using SPSS (version 21, Chicago, IL, USA) and Ducan's multiple range test (p <0.05).
절개 유도 후 상처부위에는 염증기 단계와 함께 혈관수축 및 혈소판 응고 반응이 일어나고 그 후 교원질의 합성, 신생 혈관의 형성 등에 의한 복잡한 병리학적 과정이 일어나 육아조직이 상처 부위를 채우는 재상피화 후 상처부위가 수축되게 된다. After incision, induction of inflammation, vasoconstriction and platelet clotting reaction, followed by complicated pathological processes such as collagen synthesis and formation of neovascularization, resulted in re-epithelization of the injured tissue, .
도 30은 퓨리톤의 동물 실험을 통한 절개 치유 효과로서 절개 면적 감소를 육안으로 관찰한 사진이다. 도 31은 퓨리톤의 동물 실험을 통한 절개 치유 효과로서 절개 면적 감소를 실제 크기를 측정하여 나타낸 그래프이다.FIG. 30 is a photograph of a cut-off healing effect through an animal experiment of puritone, and a visual reduction of the incision area. FIG. FIG. 31 is a graph showing an actual size of the incision area reduction as an incision healing effect through an animal experiment of puritone. FIG.
도 30 및 도 31에서 보듯이, 상처의 면적은 치료 기간 동안 감소되는 경향을 나타내었으며, 상처 1일째에는 퓨리톤 튜여군이 양성대조군에 비하여 상처 크기가 컸지만 2일째부터 양성대조군에 비하여 현저하게 작아져 상처 6일 내지 11일째 가장 큰 크기 차이로 1mm 정도의 크기 차이가 나는 것을 확인할 수 있었다. 이로부터 퓨리톤은 상처면적을 유의적으로 감소시키는 것을 알 수 있다.As shown in FIGS. 30 and 31, the wound area showed a tendency to decrease during the treatment period. On the first day of injury, the wound size was larger in the puritanthus females than in the positive control group, but from the 2nd day, And it was confirmed that the size difference of about 1 mm was caused by the largest size difference between 6 days and 11 days from the wound. From this, it can be seen that the puritone significantly reduces the wound area.
<< 실시예Example 6>  6> BALBBALB /c 마우스에 대한 / c for mouse 퓨리톤의Puritone 항천식Anti-asthma 효능 평가 Efficacy evaluation
(1) 재료 및 방법(1) Materials and methods
본 시험은 실험동물을 난백 알부민(ovalbumin)으로 천식을 유도한 후 퓨리톤의 항천식 효능을 보기 위하여 실시하였다.This study was conducted to investigate the antitolic effect of puritone after inducing asthma with ovalbumin in experimental animals.
하기 표 13과 같은 조성을 가지는 미네랄 이온 혼합물(퓨리톤)의 항천식 효능을 평가하였다.The anti-asthmatic efficacy of the mineral ion mixture (puritone) having the composition shown in Table 13 below was evaluated.
성분ingredient 함량(%)content(%)
카올리나이트(A12Si2O5(OH)4)Kaolinite (A1 2 Si 2 O 5 ( OH) 4) 1919
바이오타이트(KFe3(AlSi3O10)(OH)2)Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 1818
몬트모릴로나이트((Na,Ca)0.3(Al,Mg)2Si4O10(OH)2n(H2O)) ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 1717
서펜틴(Mg,Fe)3Si2O5(OH)4) Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 1212
마이카(AB2- 3(X,Si)4O10(O,F,OH)2)Mica (AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 88
버미쿨라이트(Mg,Fe,Al)3(Al,Si)4O10(OH)2·4H2O) (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 44
무스코바이트(KA12(AlSi3O10)(F,OH)2) Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 33
클리노클로레(Mg,Fe,Al)6(Si,Al)4O10(OH)8) (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 33
브루사이트(Mg(OH)2) Brucite (Mg (OH) 2 ) 22
일라이트(KAl1 . 3Fe0 . 4Mg0 . 2Si3 . 4Al0 . 6O10(OH)2)Illite (KAl 1. 3 Fe 0. 4 Mg 0. 2 Si 3. 4 Al 0. 6 O 10 (OH) 2) 22
리메스톤(CaCO3) Limestone (CaCO 3 ) 22
제올라이트(NaAlSi2O6H2O)Zeolite (NaAlSi 2 O 6 H 2 O) 1One
올소클레이스 또는 올소클레이스 펠드스파(KA1Si3O8) Clay's ortho or ortho-Clay's Spa Seefeld (KA1Si 3 O 8) 1One
베마이트(y-ALO(OH)) The boehmite (y-ALO (OH)) 0.90.9
네펠린(Na,K)AlSiO4)Nephellin (Na, K) AlSiO 4 ) 0.80.8
팔리코르스카이트 또는 애터펄자이트((Mg,Al)2Si4O10(OH)4(H2O)) (Mg, Al) 2 Si 4 O 10 (OH) 4 (H 2 O)), 0.80.8
마그네사이트(MgCO3) Magnesite (MgCO 3) 0.70.7
스페릴라이트(PtAs2) Sphereyl (PtAs 2 ) 0.60.6
크렌네라이트(Au3AgTe8) Crenelite (Au 3 AgTe 8 ) 0.60.6
페트자이트(Ag3AuTe2) Petzite (Ag 3 AuTe 2 ) 0.50.5
기브사이트(Al(OH)3) Gibbsite (Al (OH) 3 ) 0.40.4
앨러페인(Al2O3(SiO2)1 .3- 2(2.5-3)H2O) AL pane (Al 2 O 3 (SiO 2 ) 1 .3- 2 (2.5-3) H 2 O) 0.40.4
플로고파이트((KMg3(AlSi3O10)(OH)2) (KMg 3 (AlSi 3 O 10 ) (OH) 2 ) 0.40.4
레피도라이트(K(Li,Al,Rb)2(Al,Si)4O10(F,OH)2) (Li, Al, Rb) 2 (Al, Si) 4 O 10 (F, OH) 2 ) 0.30.3
실바나이트(SiAgAuTe4) Silvanite (SiAgAuTe 4 ) 0.30.3
글로코나이트((Fe3+,Al,Mg)2(Si,Al)4O10(OH)2) ((Fe 3+ , Al, Mg) 2 (Si, Al) 4 O 10 (OH) 2 ) 0.30.3
돌로마이트(CaMg(CO3)2) Dolomite (CaMg (CO 3) 2) 0.30.3
토르말린(Al,Fe,Li,Mg,Mn)3(Al,Cr,Fe,V)6(BO3)3(Si,Al,B)6O18(OH,F)4)Tourmaline (Al, Fe, Li, Mg , Mn) 3 (Al, Cr, Fe, V) 6 (BO 3) 3 (Si, Al, B) 6 O 18 (OH, F) 4) 0.20.2
카날라이트((KClMgCl2·6(H2O)) Canal light ((KClMgCl 2 · 6 (H 2 O)) 0.20.2
안드라다이트(Ca3Fe2(SiO4)3) Andradite (Ca 3 Fe 2 (SiO 4 ) 3 ) 0.20.2
휴마이트(Mg7(SiO4)3(F,OH)2)Humite (Mg 7 (SiO 4 ) 3 (F, OH) 2 ) 0.10.1
총gun 100100
(i) 실험동물(i) an experimental animal
실험에 사용된 실험동물은 풍부한 시험 기초 자료가 축적되어 있고 시험결과의 해석 및 평가에 참고할 수 있으며 관련문헌에 근거해서 특정병원체 부재(SPF) 마우스인 BALB/c 마우스를 선택하였다. 동물 수는 시험결과를 해석할 수 있는 최소한의 충분한 수로 산정하여 투여물질에 따라 총 6개의 그룹으로 나누었으며 각 군당 8마리씩 산정하였다. 산정 기준은 부검 시 4마리는 BALF 채취, 4마리는 폐 조직을 얻기 위함이다.The experimental animals used in the experiments have accumulated abundant test data and can be used for the interpretation and evaluation of the test results. Based on the relevant literature, a specific pathogen member (SPF) mouse, BALB / c mouse, was selected. The number of animals was calculated as the minimum number sufficient to interpret the test results and divided into 6 groups according to the substance to be administered, and 8 animals per group were calculated. The criteria for the calculation are 4 BALF samples for autopsy and 4 lungs for lung tissue.
(ii) 실험방법(ii) Experimental method
동물실험일정은 동물 입수 후 시험을 실시하는 동물실 내에서 순화기간을 가지고 매일 1회 이상 관찰하였다. 시험군은 순화기간 중 건강한 것으로 판정한 동물의 체중을 측정하여 순위화하고 각 군의 평균체중이 균일하게 분포하도록 시험군을 무작위 분배하여 군분리하였다. 각 그룹은 대조군, 난백 알부민 야기대조군(OVA), 양성대조군(Dexamethasone, Dex), 퓨리톤 700 ㎕ 및 1400 ㎕으로 총 5그룹으로 설정하였다. 실험은 순화기간 후 2주간 1주 1회 복강주사로 OVA를 감작한다. 3주째부터 5일 동안 오전에 양성대조물질과 퓨리톤을 경구투여하고, 오후에 5 % OVA 용액 흡입을 실시하였다. 투여량은 실험동물 체중(g) 당 28 ㎕를 경구 투여하였다. 5일 동안 투여 후 그 다음날 부검을 실시하였다.The animal test schedule was observed at least once a day with a purifying period in the animal room where animals were tested after they were received. In the test group, the weight of the animals determined to be healthy during the refinement period was measured and ranked, and the test groups were randomly distributed so that the average weight of each group was uniformly distributed. Each group was set up as a total of 5 groups: control group, ovarian albumin-induced control group (OVA), positive control group (Dexamethasone, Dex), 700 μl of purite and 1400 μl. The experiment sensitizes OVA by intraperitoneal injection once a week for 2 weeks after the purifying period. Positive control substances and puritone were orally administered in the morning for 5 days from the third week, and 5% OVA solution was administered in the afternoon. The dose was orally administered to 28 [mu] l per body weight (g) of the experimental animals. After 5 days of administration, autopsy was performed the next day.
(iii) 투여방법(iii) Method of administration
(가) 복강투여: 관련문헌에 근거하여 난백 알부민(OVA) 20 ㎍ + 명반 수화물(alum hydrate) 1 mg + 정상 생리식염수 500 ㎕/head 로 투여하였다. 투여해야 할 동물 마리수를 총 50 마리로 계산하여 OVA 1000 ㎍ + 명반 수화물 50 mg + 정상 생리식염수 25 mL로 환산하여 조제하였다. 주 1회로 2주간 복강주사로 감작시키고 1 mL 주사기를 이용하여 주사하였다. (A) Peritoneal administration: 20 μg of ovalbumin (OVA) + 1 mg of alum hydrate + 500 μg / head of normal saline was administered based on the related literature. The total number of animals to be administered was calculated as 50 ovarii, and converted into OVA 1000 ㎍ + ovine hydrate 50 mg + normal physiological saline 25 mL. 1 week for 2 weeks by intramuscular injection and injected with 1 mL syringe.
(나) 경구투여: 대조군과 야기대조군은 생리식염수를 투여하고 퓨리톤 700 ㎕ 및 1400 ㎕의 양으로 사용하였다. 덱사메타손(Dexamethasone)은 생리식염수에 넣고 소용돌이 교반(vortexing)하여 용해시켜 최종 투여 액량에 맞게 조제하였다. 모든 조제는 투여 당일 조제한다.(B) Oral administration: The control group and the yagi control group were administered physiological saline and used in an amount of 700 μl and 1400 μl of puritone. Dexamethasone was dissolved in physiological saline, vortexed and dissolved to prepare a final dose. All preparations should be prepared on the day of administration.
(다) 흡입(Inhalation): OVA 1 g + 정상 생리식염수 20 mL (5% OVA Solution)로 만들어 소용돌이 교반하여 투여하였다. 분무기(OMRON, NE-U17)를 사용하여 5일 동안 강제 흡입을 실시하고 흡입챔버(inhalation exposure chamber)를 이용하여 전신노출시켰다.(C) Inhalation: 1 g of OVA + 20 mL of normal saline solution (5% OVA Solution) and vortexed with stirring. The animals were forcedly inhaled using a sprayer (OMRON, NE-U17) for 5 days and exposed to radiation using an inhalation exposure chamber.
(2) 실험 분석 방법 (2) Experimental analysis method
(i) 체중변화량: 시험기간 중 주 2회 측정하였다.(i) Weight change: Two times a week during the test period.
(ii) 주간 사료섭취량: 시험기간 중 3일 1회 측정하여 1주일 단위로 평균하였다.(ii) Weekly feed intake: measured once every three days during the test period and averaged weekly.
(iii) BALF 채취: 마취가 된 실험동물을 핀셋으로 조직을 벌려 기관을 확보 후 수술실을 밑으로 넣어주어 느슨히 묶어주고 가위로 기관을 살짝 자른 후 바늘을 제거한 주사기에 PBS 0.2 mL을 넣고 존데에 꽃은 후 주입하였다. 주입 후 다시 PBS를 빨아들이면서 BALF를 채취하였다. 같은 방법으로 0.2 mL 씩 3번 BALF를 채취하였다. 첫 번째 BALF는 1번 튜브로 넣고 두 번째, 세 번째 BALF는 2번 튜브에 넣었다.(iii) Collection of BALF: Anesthetized animals were tweezed with tweezers to secure the organs, and the operation room was placed under the operating room. Loosely tie the organ with the scissors, and then 0.2 mL of PBS was added to the syringe with the needle removed. Flowers were infused afterwards. BALF was collected by injecting PBS again after injection. BALF was sampled three times in 0.2 mL increments. The first BALF was inserted into tube 1, the second, and the third BALF was inserted into tube 2.
(iv) 조직의 보관: 부검 시 1/2은 액체질소에 넣어 급속동결한 후 초저온냉동고 혹은 액체질소통(약 -75˚c)에 보관하여 ELISA용으로 활용하고, 1/2은 10% 포르말린 용액에 보관하여 조직병리용으로 활용하였다.(iv) Storage of tissues: For autopsy, 1/2 should be stored in liquid nitrogen for rapid freezing, then stored in a cryocooler or liquid-liquid freezer (about -75 ° C) for ELISA and 1/2 for 10% formalin Solution for histopathological examination.
(3) 시료분석 및 결과(3) Sample analysis and results
(i) BALF의 혈구분석(i) blood cell analysis of BALF
첫 번째 채취한 BALF는 1번 튜브, 두 번째, 세 번째 채취한 BALF는 2번 튜브에 같이 넣었다. 1번 튜브는 5분간 3000 rpm에서 원심분리 후 상층액을 3번으로 옮긴 후 남은 펠렛과 PBS 20 ㎕를 넣어 섞어주었다. 2번 튜브는 5분간 3000 rpm에서 원심분리 후 상층액을 버리고 펠렛과 PBS 60 ㎕를 넣어 섞어준 후 1번의 20 ㎕와 섞어 총 80 ㎕로 혈구분석기(Hemavet 950FS, Drew Scientific Inc, Korea)를 활용하여 혈구분석을 실시하였다.The first BALF was taken in tube # 1, the second, and the third BALF taken in tube # 2. After centrifugation at 3000 rpm for 5 minutes, the supernatant was transferred to No. 3, and the remaining pellet was mixed with 20 μl of PBS. After centrifugation at 3000 rpm for 5 minutes, the supernatant was discarded and the pellet and PBS (60 μl) were added and mixed. One 20 μl of the mixture was mixed with a total of 80 μl using a hematology analyzer (Hemavet 950FS, Drew Scientific Inc, Korea) And blood cell counts were analyzed.
도 32는 퓨리톤의 BALF의 백혈구(WBC) 분석 결과를 나타낸 그래프이고, 도 33은 퓨리톤의 BALF의 호중구(neutrophil) 분석 결과를 나타낸 그래프이고, 도 34는 퓨리톤의 BALF의 림프구(lymphocyte) 분석 결과를 나타낸 그래프이다. 여기에서, CON은 정상동물군, DEX는 천식치료제인 덱사메타손 처리군, 퓨리톤 700 ㎕는 퓨리톤을 700 ㎕ 처리한 군이며 퓨리톤 1400 ㎕는 퓨리톤을 1400 ㎕ 처리한 군을 의미한다. 이러한 결과는 처리를 완료한 후 부검하여 기관지폐포액(bronchioalveolar fluid, BALF)을 얻어서 백혈구(white blood cell, WBC), 호중구(neutrophil) 및 림프구(lymphocyte)의 양이 감소되는 경향을 확인하는 것으로 검증하였다. 도 32 내지 도 34에서 보듯이, 퓨리톤 처리군의 경우 용량 의존적으로 WBC, 호중구(neutrophil) 및 림프구(lymphocyte)의 양이 감소하였다. 33 is a graph showing the result of neutrophil analysis of puritan BALF, and FIG. 34 is a graph showing the results of lymphocyte analysis of BALF of purite. FIG. 32 is a graph showing the results of white blood cell (WBC) analysis of puritan BALF, FIG. CON is a normal animal group, DEX is a dexamethasone treatment group which is an asthma treatment drug, 700 ㎕ of purite is 700 ㎕ treated with purite, and 1400 of purite is treated with 1400 of purite. This result confirms that the amount of white blood cell (WBC), neutrophil and lymphocyte is reduced by autopsy after bronchioalveolar fluid (BALF) Respectively. As shown in FIGS. 32 to 34, the amounts of WBC, neutrophil and lymphocyte were decreased in the puritone-treated group in a dose-dependent manner.
(ii) BALF의 IgE 분석(ii) IgE analysis of BALF
IgE 분석을 위한 키트 및 장비를 사용하여 실시하였다. Lt; RTI ID = 0.0 &gt; IgE &lt; / RTI &gt; assay.
도 35는 퓨리톤의 BALF의 IgE 분석 결과를 나타낸 그래프로서, 처리를 완료한 후 부검하여 혈장(serum)을 얻어서 면역글로빈(immunoglobulin) E (IgE)를 확인한 결과이다. 면역글로빈은 항체(antibody)로 IgA, IgM, IgE, IgD, IgG의 5가지로 분류되며 기생충 감염과 과민성 면역반응이 발생할 경우 IgE의 양이 급격히 증가한다. 천식은 과민성면역반응 중 하나로 천식의 발생과 치료여부를 검증하는 지표 중 하나가 IgE이다. 여기에서 보듯이, 퓨리톤 처리군의 경우 용량 의존적으로 IgE의 양이 감소하였다.FIG. 35 is a graph showing the results of IgE analysis of Puritone BALF. After completion of the treatment, an autopsy was performed to obtain serum, and immunoglobulin E (IgE) was confirmed. Immunoglobin is an antibody that is classified into five types of IgA, IgM, IgE, IgD and IgG. When parasite infections and irritable immune reactions occur, the amount of IgE increases sharply. Asthma is one of the irritable immune responses, and IgE is one of the indicators to check the occurrence and treatment of asthma. As shown here, the amount of IgE in the puritone treated group was dose-dependently decreased.
(ii) H&E 염색(ii) H & E staining
H&E 염색은 헤마톡실린(Hematoxylin)과 에오신(Eosin) 염색법으로 조직 염색에서 가장 널리 사용되는 염색법이다. 헤마톡실린은 염기성으로 조직에서 인산기가 많이 들어있는 핵을 염색하기 위하여 사용이 된다. 에오신은 산성으로 염기성을 띠는 원자단과 결합하여 색을 내게 되는데 세포질, 세포벽 등의 세포의 바깥구조를 염색한다.H & E staining is the most widely used staining method in tissue staining with hematoxylin and eosin staining. Hematoxylin is used to stain nuclei containing a large amount of phosphoric acid in tissues. Eosine binds with acidic and basic atomic groups to produce color, which stains the outer structure of cells such as cytoplasm and cell walls.
파리핀 제거 및 수화과정으로 자일렌 15분, 80% 알코올 1분, 90% 알코올 1분, 100% 알코올 1분의 과정을 실시하였다. 탈수과정 후 1차 증류수에 5분 동안 수세를 실시한 후 헤마톡실린에 1분 30초 동안 담가 염색하였다. 염색 후 조직이 파랗게 보일 때까지 1차 증류수에 15분간 세척하였다. 청명과정 및 탈수과정으로 95% 알코올 1분, 에오신 6분, 95% 알코올 1분, 95% 알코올 1분, 100% 알코올 1분, 자일렌 6분 동안 한 후에 마운팅(Mounting) 과정으로 조직봉입을 실시하였다. 조직봉입 후 현미경으로 관찰하였다.For the removal of pin flies and the hydration process, 15 minutes of xylene, 1 minute of 80% alcohol, 1 minute of 90% alcohol and 1 minute of 100% alcohol were performed. After the dehydration process, the first distilled water was washed with water for 5 minutes and then immersed in hematoxylin for 1 minute and 30 seconds. After staining, the tissue was washed in primary distilled water for 15 minutes until it appeared blue. For clarification and dehydration, tissue was sealed by mounting process after 1 minute of 95% alcohol, 6 minutes of eosin, 1 minute of 95% alcohol, 1 minute of 95% alcohol, 1 minute of alcohol and xylene of 6 minutes. Respectively. The tissue was sealed and observed with a microscope.
도 36은 퓨리톤에 의한 폐조직의 변화를 H&E 염색을 이용하여 관찰한 것이다. 여기에서 보듯이, a가 정상군이며, b가 천식유도군, c가 덱사메타손 치료군, d가 퓨리톤 700 ㎕ 처리군, e가 퓨리톤 1400 ㎕ 처리군이다. 천식유도군(e)의 경우 세기관지(bronchiol) 상피세포(epithelial cell)의 증식(hyperplasia), 세기관지 내에 점액(musos)이 가득차는 것과 세기관지와 혈관(vessel) 주위에 많은 염증세포(inflammatory cell)가 침윤(infiltration)되는 것을 관찰할 수 있었다. 덱사메타손 치료군(c)과 본 발명의 퓨리틴 처리군(d 및 e)은 기관지 상피세포의 증식이 억제되고, 세기관지 내에 점액(musos)이 줄어들고 세기관지와 혈관(vessel) 주위에 많은 염증세포(inflammatory cell)가 침윤(infiltration)이 줄어드는 것(dose-dependent manner)을 확인할 수 있었다.FIG. 36 shows changes in lung tissue due to puritone observed using H & E staining. As shown here, a is the normal group, b is the asthma induction group, c is the dexamethasone treatment group, d is the treatment group of 700 μl of purite, and e is the treated group of 1400 μ of purite. In the asthma-inducing group (e), bronchiolar epithelial cells (hyperplasia), bronchioles are filled with musos, and many inflammatory cells around bronchioles and vessels And infiltration was observed. The dexamethasone treatment group (c) and the puritane treatment group (d and e) of the present invention inhibit the proliferation of bronchial epithelial cells, reduce the amount of musos in the bronchioles, and stimulate many inflammatory cells around the bronchioles and vessels ) Was able to confirm a dose-dependent manner of infiltration.
(iv) PAS 염색(iv) PAS staining
PAS 염색은 조직 내에는 폴리사카라이드, 뮤코다당류(mucopolysaccharides), 뮤코단백질, 당단백 등이 존재하는데 이들 단백질과 결합된 탄수화물 기가 과요오드산(periodic acid)에 의해 산화되어 알데하이드 기를 생성하고 이것이 시프시약(Schiff's reagent)과 작용하여 붉은 자주색을 띄는 원리이다.In PAS staining, polysaccharides, mucopolysaccharides, mucopolysaccharides and glycoproteins are present in the tissues. The carbohydrate groups bound to these proteins are oxidized by periodic acid to produce aldehyde groups, Schiff's reagent) and is a purple-red principle.
파라핀 제거 및 수화과정으로 자일렌 15분, 80% 알코올 1분, 90% 알코올 1분, 100% 알코올 1분의 과정을 실시하였다. 실시 후 10분 동안 0.5 % 과요오드산 용액에 담가 조직을 산화시켰다. 산화 후 5분 동안 흐르는 수돗물에 수세하고 3분 정도 동안 1차 증류수로 가볍게 수세하였다. 수세 후 10분 동안 시프 시약에 담가 반응시킨 후 5분 동안 흐르는 수돗물에 수세하였다. 수세 후 1분 30초 동안 헤마톡실린으로 염색하고 다시 10분 동안 흐르는 물에 수세하였다. 수세 후 마운팅 과정으로 조직봉입을 실시한 후 현미경으로 관찰하였다.Paraffin removal and hydration were carried out with 15 minutes of xylene, 1 minute of 80% alcohol, 1 minute of 90% alcohol and 1 minute of 100% alcohol. After the operation, the tissues were oxidized by soaking in 0.5% iodine solution for 10 minutes. After the oxidation, tap water flowing for 5 minutes was washed with water and lightly rinsed with primary distilled water for 3 minutes. After washing with water, the reaction solution was immersed in a Sip reagent for 10 minutes and then washed with running tap water for 5 minutes. After washing with water, it was stained with hematoxylin for 1 minute and 30 seconds and then rinsed with water for 10 minutes. After washing with water, the tissue was sealed by a mounting process and observed with a microscope.
도 37은 퓨리톤에 의한 폐조직의 변화를 PAS 염색을 이용하여 관찰한 것이다. 여기에서 보듯이, 천식의 경우(b) 세기관지 내에 점액(musos)이 가득 찬 것을 관찰할 수 있었으며, 덱사메타손 치료군(c)과 본 발명의 퓨리틴 처리군(d 및 e)의 경우 세기관지 내 점액이 줄어듦을 확인할 수 있었다.FIG. 37 shows changes in pulmonary tissue caused by puritone using PAS staining. As can be seen, in the case of asthma (b), it was observed that the musculoskeleton was filled in the bronchus. In the dexamethasone treatment group (c) and the puritin treatment group (d and e) of the present invention, It is possible to confirm the reduction.
(v) ELISA 분석 (v) ELISA analysis
폐 조직에서의 IL-4의 수준을 분석하기 위해, OptEIA 마우스 ELISA를 BD 바이오사이언스(Biosciences)로부터 구입하였다. 모든 분석은 제조업체의 지침에 따라 수행되었다. 모든 폐 샘플은 프로테아제 억제제 칵테일 및 RIPA 완충액 (Thermo Fisher Scientific)으로 제조된 용해 완충액에 의해 제조되었다. 모든 군의 폐 조직 분취 량을 칭량하고 용해 완충액으로 균질화하였다. 원심 분리기를 8200 rpm으로 15 분간 원심분리하고, 상등액을 수거하고 마이크로 플레이트 판독기 (EZ Read 400, Biochrom, Cambourne, UK)를 사용하여 측정하였다.To analyze the level of IL-4 in lung tissue, OptEIA mouse ELISA was purchased from BD Biosciences. All analyzes were performed according to the manufacturer's instructions. All lung samples were prepared with protease inhibitor cocktail and lysis buffer prepared with RIPA buffer (Thermo Fisher Scientific). Lung tissue aliquots from all groups were weighed and homogenized with lysis buffer. The centrifuge was centrifuged at 8200 rpm for 15 minutes and the supernatant was collected and measured using a microplate reader (EZ Read 400, Biochrom, Cambourne, UK).
천식은 과민성면역반응으로 Th1과 Th2의 불균형에 의해 발생하는 질환이며 특히 Th2와 관련된 인자 IL-4가 상승하게 된다.Asthma is a disease caused by an imbalance of Th1 and Th2 due to an irritable immune response, especially the IL-4 related to Th2.
도 38은 퓨리톤에 의한 IL-4의 발현 정도를 관찰하여 나타낸 결과이다. 여기에서 CON은 정상동물군, OVA는 난백 알부민 야기대조군이고, DEX는 천식치료제인 덱사메타손 처리군, 퓨리톤 700 ㎕는 퓨리톤을 700 ㎕ 처리한 군이며 퓨리톤 1400 ㎕는 퓨리톤을 1400 ㎕ 처리한 군을 의미한다. 여기에서 보듯이, IL-4의 발현이 퓨리톤 농도 의존적으로 감소하는 것을 알 수 있었다. FIG. 38 shows the results of observing the degree of expression of IL-4 by puritone. Here, CON is a normal animal group, OVA is an egg white albumin-induced control group, DEX is treated with dexamethasone, which is a therapeutic agent for asthma, 700 μl of purite is treated with 700 μl of purite, 1400 μl of purite is treated with 1400 μl of purite It means a group. As shown here, the expression of IL-4 was found to be decreased in dependence on the purite concentration.
따라서, 본 발명의 미네랄 이온 혼합물을 포함하는 조성물은 천연물질로서 인체에 안전하여 항암, 항균, 알콜분해, 피부상처 치유 또는 피부재생 및 항천식 효과를 가지므로 약학적, 화장료 및 식품 조성물로 유용하게 이용될 수 있다.Therefore, the composition containing the mineral ion mixture of the present invention is safe as a human body and has anticancer, antibacterial, alcohol decomposition, skin wound healing or skin regeneration and anti-asthmatic effect, so that it is useful as a pharmaceutical, cosmetic and food composition Can be used.

Claims (19)

  1. 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물을 유효성분으로 포함하는 항암용 조성물.Biotite, Kaolinite, Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite, and Muscovite ) As an active ingredient.
  2. 제 1 항에 있어서,The method according to claim 1,
    상기 미네랄 이온 혼합물이 브루사이트(Brucite), 일라이트(Illite), 리메스톤(Limestone), 제올라이트(Zeolite), 올소클레이스(Orthoclase) 또는 올소클레이스 펠드스파(Orthoclase feldspar), 베마이트(boehmite), 네펠린(Nepheline), 팔리코르스카이트(Palygorskite) 또는 애터펄자이트(Attapulgite), 마그네사이트(Magnesite), 스페릴라이트(Sperrylite), 크렌네라이트(Krennerite), 페트자이트(Petzite), 기브사이트(Gibbsite), 앨러페인(Allophane), 플로고파이트(Phlogopite), 레피도라이트(Lepidolite), 실바나이트(Sylvanite), 글로코나이트(Glauconite), 돌로마이트(Dolomite), 토르말린(Tourmaline), 카날라이트(Carnallite), 안드라다이트(Andradite) 및 휴마이트(Humite)를 추가로 포함하는 것을 특징으로 하는 항암용 조성물.Wherein said mineral ion mixture is selected from the group consisting of Brucite, Illite, Limestone, Zeolite, Orthoclase or Orthoclase feldspar, boehmite, Nepheline, Palygorskite or Attapulgite, Magnesite, Sperrylite, Krennerite, Petzite, Gibb, (Gibbsite), Allophane, Phlogopite, Lepidolite, Sylvanite, Glauconite, Dolomite, Tourmaline, Canalite, Wherein the composition further comprises Carnallite, Andradite and Humite.
  3. 제 2 항에 있어서,3. The method of claim 2,
    상기 미네랄 이온 혼합물이 카올리나이트 15 내지 25 중량%, 바이오타이트 12 내지 23 중량%, 몬트모릴로나이트 15 내지 25 중량%, 서펜틴 10 내지 13 중량%, 마이카 7 내지 9 중량%, 버미쿨라이트 3 내지 5 중량%, 무스코바이트 2 내지 4 중량%, 클리노클로레 2 내지 5 중량%, 브루사이트 1 내지 3 중량%, 일라이트 1 내지 3 중량%, 리메스톤 1 내지 3 중량%, 제올라이트 0.5 내지 1.5 중량%, 올소클레이스 또는 올소클레이스 펠드스파 0.5 내지 1.5 중량%, 베마이트 0.8 내지 1.0 중량%, 네펠린 0.7 내지 0.9 중량%, 팔리코르스카이트 또는 애터펄자이트 0.7 내지 0.9 중량%, 마그네사이트 0.6 내지 0.8 중량%, 스페릴라이트 0.5 내지 0.7 중량%, 크렌네라이트 0.5 내지 0.7 중량%, 페트자이트 0.4 내지 0.6 중량%, 기브사이트 0.3 내지 0.5 중량%, 앨러페인 0.3 내지 0.5 중량%, 플로고파이트 0.3 내지 0.5 중량%, 레피도라이트 0.2 내지 0.4 중량%, 실바나이트 0.2 내지 0.4 중량%, 글로코나이트 0.2 내지 0.4 중량%, 돌로마이트 0.2 내지 0.4 중량%, 토르말린 0.1 내지 0.3 중량%, 카날라이트 0.1 내지 0.3 중량%, 안드라다이트 0.1 내지 0.3 중량% 및 휴마이트 0.05 내지 0.15 중량%를 포함하는 것을 특징으로 하는 항암용 조성물.Wherein the mineral ion mixture comprises 15 to 25 wt% of kaolinite, 12 to 23 wt% of biotite, 15 to 25 wt% of montmorillonite, 10 to 13 wt% of serpentin, 7 to 9 wt% of mica, 1 to 3% by weight of broomsite, 1 to 3% by weight of ilite, 1 to 3% by weight of limestone, 0.5 to 3% by weight of zeolite, 2 to 4% 0.5 to 1.5% by weight of an isoparaffin, 0.5 to 1.5% by weight of an oligosaccharide or oligosaccharide spandex, 0.8 to 1.0% by weight of boehmite, 0.7 to 0.9% by weight of nephelin, 0.7 to 0.9% The present invention relates to a process for producing a zeolite, comprising the steps of: 0.6 to 0.8 wt% of magnesite, 0.5 to 0.7 wt% of spearylite, 0.5 to 0.7 wt% of crenelite, 0.4 to 0.6 wt% of petzite, 0.3 to 0.5 wt% Flogophite 0.3 to 0.5 0.2 to 0.4 wt.% Of gypsum, 0.1 to 0.3 wt.% Of tourmaline, 0.1 to 0.3 wt.% Of canalite, 0.2 to 0.4 wt. 0.1 to 0.3% by weight of undiluted and 0.05 to 0.15% by weight of humite.
  4. 제 1 항 내지 제 3 항 중 어느 한 항에 있어서,4. The method according to any one of claims 1 to 3,
    상기 암은 갑상선암, 위암, 대장암, 폐암, 난소암, 유방암, 직장암, 간암, 전립선암, 췌장암, 담낭암, 혈액암, 피부암, 신장암 또는 담도암인 것을 특징으로 하는 항암용 조성물.Wherein the cancer is cancer of the thyroid, gastric cancer, colon cancer, lung cancer, ovarian cancer, breast cancer, rectum cancer, liver cancer, prostate cancer, pancreatic cancer, gallbladder cancer, blood cancer, skin cancer, kidney cancer or bile duct cancer.
  5. 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물을 유효성분으로 포함하는 항균용 조성물.Biotite, Kaolinite, Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite, and Muscovite ) As an active ingredient.
  6. 제 5 항에 있어서,6. The method of claim 5,
    상기 미네랄 이온 혼합물이 브루사이트(Brucite), 일라이트(Illite), 리메스톤(Limestone), 제올라이트(Zeolite), 올소클레이스(Orthoclase) 또는 올소클레이스 펠드스파(Orthoclase feldspar), 베마이트(boehmite), 네펠린(Nepheline), 팔리코르스카이트(Palygorskite) 또는 애터펄자이트(Attapulgite), 마그네사이트(Magnesite), 스페릴라이트(Sperrylite), 크렌네라이트(Krennerite), 페트자이트(Petzite), 기브사이트(Gibbsite), 앨러페인(Allophane), 플로고파이트(Phlogopite), 레피도라이트(Lepidolite), 실바나이트(Sylvanite), 글로코나이트(Glauconite), 돌로마이트(Dolomite), 토르말린(Tourmaline), 카날라이트(Carnallite), 안드라다이트(Andradite) 및 휴마이트(Humite)를 추가로 포함하는 것을 특징으로 하는 항균용 조성물.Wherein said mineral ion mixture is selected from the group consisting of Brucite, Illite, Limestone, Zeolite, Orthoclase or Orthoclase feldspar, boehmite, Nepheline, Palygorskite or Attapulgite, Magnesite, Sperrylite, Krennerite, Petzite, Gibb, (Gibbsite), Allophane, Phlogopite, Lepidolite, Sylvanite, Glauconite, Dolomite, Tourmaline, Canalite, Wherein the composition further comprises Carnallite, Andradite and Humite.
  7. 제 6 항에 있어서,The method according to claim 6,
    상기 미네랄 이온 혼합물이 카올리나이트 15 내지 25 중량%, 바이오타이트 12 내지 23 중량%, 몬트모릴로나이트 15 내지 25 중량%, 서펜틴 10 내지 13 중량%, 마이카 7 내지 9 중량%, 버미쿨라이트 3 내지 5 중량%, 무스코바이트 2 내지 4 중량%, 클리노클로레 2 내지 5 중량%, 브루사이트 1 내지 3 중량%, 일라이트 1 내지 3 중량%, 리메스톤 1 내지 3 중량%, 제올라이트 0.5 내지 1.5 중량%, 올소클레이스 또는 올소클레이스 펠드스파 0.5 내지 1.5 중량%, 베마이트 0.8 내지 1.0 중량%, 네펠린 0.7 내지 0.9 중량%, 팔리코르스카이트 또는 애터펄자이트 0.7 내지 0.9 중량%, 마그네사이트 0.6 내지 0.8 중량%, 스페릴라이트 0.5 내지 0.7 중량%, 크렌네라이트 0.5 내지 0.7 중량%, 페트자이트 0.4 내지 0.6 중량%, 기브사이트 0.3 내지 0.5 중량%, 앨러페인 0.3 내지 0.5 중량%, 플로고파이트 0.3 내지 0.5 중량%, 레피도라이트 0.2 내지 0.4 중량%, 실바나이트 0.2 내지 0.4 중량%, 글로코나이트 0.2 내지 0.4 중량%, 돌로마이트 0.2 내지 0.4 중량%, 토르말린 0.1 내지 0.3 중량%, 카날라이트 0.1 내지 0.3 중량%, 안드라다이트 0.1 내지 0.3 중량% 및 휴마이트 0.05 내지 0.15 중량%를 포함하는 것을 특징으로 하는 항균용 조성물.Wherein the mineral ion mixture comprises 15 to 25 wt% of kaolinite, 12 to 23 wt% of biotite, 15 to 25 wt% of montmorillonite, 10 to 13 wt% of serpentin, 7 to 9 wt% of mica, 1 to 3% by weight of broomsite, 1 to 3% by weight of ilite, 1 to 3% by weight of limestone, 0.5 to 3% by weight of zeolite, 2 to 4% 0.5 to 1.5% by weight of an isoparaffin, 0.5 to 1.5% by weight of an oligosaccharide or oligosaccharide spandex, 0.8 to 1.0% by weight of boehmite, 0.7 to 0.9% by weight of nephelin, 0.7 to 0.9% The present invention relates to a process for producing a zeolite, comprising the steps of: 0.6 to 0.8 wt% of magnesite, 0.5 to 0.7 wt% of spearylite, 0.5 to 0.7 wt% of crenelite, 0.4 to 0.6 wt% of petzite, 0.3 to 0.5 wt% Flogophite 0.3 to 0.5 0.2 to 0.4 wt.% Of gypsum, 0.1 to 0.3 wt.% Of tourmaline, 0.1 to 0.3 wt.% Of canalite, 0.2 to 0.4 wt. 0.1 to 0.3% by weight of undiluted and 0.05 to 0.15% by weight of humite.
  8. 제 5 항 내지 제 7 항 중 어느 한 항에 따른 항균용 조성물을 포함하는 항바이러스제.An antiviral agent comprising the antimicrobial composition according to any one of claims 5 to 7.
  9. 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물을 유효성분으로 포함하는 알콜분해용 조성물.Biotite, Kaolinite, Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite, and Muscovite ) As an active ingredient.
  10. 제 9 항에 있어서,10. The method of claim 9,
    상기 미네랄 이온 혼합물이 브루사이트(Brucite), 일라이트(Illite), 리메스톤(Limestone), 제올라이트(Zeolite), 올소클레이스(Orthoclase) 또는 올소클레이스 펠드스파(Orthoclase feldspar), 베마이트(boehmite), 네펠린(Nepheline), 팔리코르스카이트(Palygorskite) 또는 애터펄자이트(Attapulgite), 마그네사이트(Magnesite), 스페릴라이트(Sperrylite), 크렌네라이트(Krennerite), 페트자이트(Petzite), 기브사이트(Gibbsite), 앨러페인(Allophane), 플로고파이트(Phlogopite), 레피도라이트(Lepidolite), 실바나이트(Sylvanite), 글로코나이트(Glauconite), 돌로마이트(Dolomite), 토르말린(Tourmaline), 카날라이트(Carnallite), 안드라다이트(Andradite) 및 휴마이트(Humite)를 추가로 포함하는 것을 특징으로 하는 알콜분해용 조성물.Wherein said mineral ion mixture is selected from the group consisting of Brucite, Illite, Limestone, Zeolite, Orthoclase or Orthoclase feldspar, boehmite, Nepheline, Palygorskite or Attapulgite, Magnesite, Sperrylite, Krennerite, Petzite, Gibb, (Gibbsite), Allophane, Phlogopite, Lepidolite, Sylvanite, Glauconite, Dolomite, Tourmaline, Canalite, Wherein the composition further comprises Carnallite, Andradite and Humite.
  11. 제 10 항에 있어서,11. The method of claim 10,
    상기 미네랄 이온 혼합물이 카올리나이트 15 내지 25 중량%, 바이오타이트 12 내지 23 중량%, 몬트모릴로나이트 15 내지 25 중량%, 서펜틴 10 내지 13 중량%, 마이카 7 내지 9 중량%, 버미쿨라이트 3 내지 5 중량%, 무스코바이트 2 내지 4 중량%, 클리노클로레 2 내지 5 중량%, 브루사이트 1 내지 3 중량%, 일라이트 1 내지 3 중량%, 리메스톤 1 내지 3 중량%, 제올라이트 0.5 내지 1.5 중량%, 올소클레이스 또는 올소클레이스 펠드스파 0.5 내지 1.5 중량%, 베마이트 0.8 내지 1.0 중량%, 네펠린 0.7 내지 0.9 중량%, 팔리코르스카이트 또는 애터펄자이트 0.7 내지 0.9 중량%, 마그네사이트 0.6 내지 0.8 중량%, 스페릴라이트 0.5 내지 0.7 중량%, 크렌네라이트 0.5 내지 0.7 중량%, 페트자이트 0.4 내지 0.6 중량%, 기브사이트 0.3 내지 0.5 중량%, 앨러페인 0.3 내지 0.5 중량%, 플로고파이트 0.3 내지 0.5 중량%, 레피도라이트 0.2 내지 0.4 중량%, 실바나이트 0.2 내지 0.4 중량%, 글로코나이트 0.2 내지 0.4 중량%, 돌로마이트 0.2 내지 0.4 중량%, 토르말린 0.1 내지 0.3 중량%, 카날라이트 0.1 내지 0.3 중량%, 안드라다이트 0.1 내지 0.3 중량% 및 휴마이트 0.05 내지 0.15 중량%를 포함하는 것을 특징으로 하는 알콜분해용 조성물.Wherein the mineral ion mixture comprises 15 to 25 wt% of kaolinite, 12 to 23 wt% of biotite, 15 to 25 wt% of montmorillonite, 10 to 13 wt% of serpentin, 7 to 9 wt% of mica, 1 to 3% by weight of broomsite, 1 to 3% by weight of ilite, 1 to 3% by weight of limestone, 0.5 to 3% by weight of zeolite, 2 to 4% 0.5 to 1.5% by weight of an isoparaffin, 0.5 to 1.5% by weight of an oligosaccharide or oligosaccharide spandex, 0.8 to 1.0% by weight of boehmite, 0.7 to 0.9% by weight of nephelin, 0.7 to 0.9% The present invention relates to a process for producing a zeolite, comprising the steps of: 0.6 to 0.8 wt% of magnesite, 0.5 to 0.7 wt% of spearylite, 0.5 to 0.7 wt% of crenelite, 0.4 to 0.6 wt% of petzite, 0.3 to 0.5 wt% Flogophite 0.3 to 0.5 0.2 to 0.4 wt.% Of gypsum, 0.1 to 0.3 wt.% Of tourmaline, 0.1 to 0.3 wt.% Of canalite, 0.2 to 0.4 wt. 0.1 to 0.3% by weight of andrapid and 0.05 to 0.15% by weight of humite.
  12. 제 9 항 내지 제 11 항 중 어느 한 항에 따른 알콜분해용 조성물을 포함하는 숙취해소용, 간기능 보호용 또는 알콜성 간질환 치료 또는 예방용 조성물.11. A composition for alcohol use, comprising a composition for alcohol decomposition according to any one of claims 9 to 11, for the protection of liver function or for the treatment or prevention of alcoholic liver disease.
  13. 제 12 항에 있어서,13. The method of claim 12,
    상기 알콜성 간질환이 알콜성 지방간, 알콜성 간염 또는 알콜성 간경변증인 것을 특징으로 하는 숙취해소용, 간기능 보호용 또는 알콜성 간질환 치료 또는 예방용 조성물.Wherein the alcoholic liver disease is alcoholic fatty liver disease, alcoholic hepatitis, or alcoholic cirrhosis, or a composition for treating or preventing hangover, for the protection of liver function or for the treatment or prevention of alcoholic liver disease.
  14. 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물을 유효성분으로 포함하는 피부상처 치유 또는 피부재생 촉진용 조성물.Biotite, Kaolinite, Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite, and Muscovite ) As an active ingredient. The composition for accelerating skin wound healing or skin regeneration.
  15. 제 14 항에 있어서,15. The method of claim 14,
    상기 미네랄 이온 혼합물이 브루사이트(Brucite), 일라이트(Illite), 리메스톤(Limestone), 제올라이트(Zeolite), 올소클레이스(Orthoclase) 또는 올소클레이스 펠드스파(Orthoclase feldspar), 베마이트(boehmite), 네펠린(Nepheline), 팔리코르스카이트(Palygorskite) 또는 애터펄자이트(Attapulgite), 마그네사이트(Magnesite), 스페릴라이트(Sperrylite), 크렌네라이트(Krennerite), 페트자이트(Petzite), 기브사이트(Gibbsite), 앨러페인(Allophane), 플로고파이트(Phlogopite), 레피도라이트(Lepidolite), 실바나이트(Sylvanite), 글로코나이트(Glauconite), 돌로마이트(Dolomite), 토르말린(Tourmaline), 카날라이트(Carnallite), 안드라다이트(Andradite) 및 휴마이트(Humite)를 추가로 포함하는 것을 특징으로 하는피부상처 치유 또는 피부재생 촉진용 조성물.Wherein said mineral ion mixture is selected from the group consisting of Brucite, Illite, Limestone, Zeolite, Orthoclase or Orthoclase feldspar, boehmite, Nepheline, Palygorskite or Attapulgite, Magnesite, Sperrylite, Krennerite, Petzite, Gibb, (Gibbsite), Allophane, Phlogopite, Lepidolite, Sylvanite, Glauconite, Dolomite, Tourmaline, Canalite, Wherein the composition further comprises Carnallite, Andradite and Humite. &Lt; Desc / Clms Page number 20 &gt;
  16. 제 15 항에 있어서,16. The method of claim 15,
    상기 미네랄 이온 혼합물이 카올리나이트 15 내지 25 중량%, 바이오타이트 12 내지 23 중량%, 몬트모릴로나이트 15 내지 25 중량%, 서펜틴 10 내지 13 중량%, 마이카 7 내지 9 중량%, 버미쿨라이트 3 내지 5 중량%, 무스코바이트 2 내지 4 중량%, 클리노클로레 2 내지 5 중량%, 브루사이트 1 내지 3 중량%, 일라이트 1 내지 3 중량%, 리메스톤 1 내지 3 중량%, 제올라이트 0.5 내지 1.5 중량%, 올소클레이스 또는 올소클레이스 펠드스파 0.5 내지 1.5 중량%, 베마이트 0.8 내지 1.0 중량%, 네펠린 0.7 내지 0.9 중량%, 팔리코르스카이트 또는 애터펄자이트 0.7 내지 0.9 중량%, 마그네사이트 0.6 내지 0.8 중량%, 스페릴라이트 0.5 내지 0.7 중량%, 크렌네라이트 0.5 내지 0.7 중량%, 페트자이트 0.4 내지 0.6 중량%, 기브사이트 0.3 내지 0.5 중량%, 앨러페인 0.3 내지 0.5 중량%, 플로고파이트 0.3 내지 0.5 중량%, 레피도라이트 0.2 내지 0.4 중량%, 실바나이트 0.2 내지 0.4 중량%, 글로코나이트 0.2 내지 0.4 중량%, 돌로마이트 0.2 내지 0.4 중량%, 토르말린 0.1 내지 0.3 중량%, 카날라이트 0.1 내지 0.3 중량%, 안드라다이트 0.1 내지 0.3 중량% 및 휴마이트 0.05 내지 0.15 중량%를 포함하는 것을 특징으로 하는 피부상처 치유 또는 피부재생 촉진용 조성물.Wherein the mineral ion mixture comprises 15 to 25 wt% of kaolinite, 12 to 23 wt% of biotite, 15 to 25 wt% of montmorillonite, 10 to 13 wt% of serpentin, 7 to 9 wt% of mica, 1 to 3% by weight of broomsite, 1 to 3% by weight of ilite, 1 to 3% by weight of limestone, 0.5 to 3% by weight of zeolite, 2 to 4% 0.5 to 1.5% by weight of an isoparaffin, 0.5 to 1.5% by weight of an oligosaccharide or oligosaccharide spandex, 0.8 to 1.0% by weight of boehmite, 0.7 to 0.9% by weight of nephelin, 0.7 to 0.9% The present invention relates to a process for producing a zeolite, comprising the steps of: 0.6 to 0.8 wt% of magnesite, 0.5 to 0.7 wt% of spearylite, 0.5 to 0.7 wt% of crenelite, 0.4 to 0.6 wt% of petzite, 0.3 to 0.5 wt% Flogophite 0.3 to 0.5 0.2 to 0.4 wt.% Of gypsum, 0.1 to 0.3 wt.% Of tourmaline, 0.1 to 0.3 wt.% Of canalite, 0.2 to 0.4 wt. 0.1 to 0.3% by weight of undiluted and 0.05 to 0.15% by weight of humite.
  17. 바이오타이트(Biotite), 카올리나이트(Kaolinite), 몬트모릴로나이트(Montmorillonite), 서펜틴(Serpentine), 마이카(Mica), 클리노클로레(Clinochlore), 버미쿨라이트(Vermiculite) 및 무스코바이트(Muscovite)를 포함하는 미네랄 이온 혼합물을 유효성분으로 포함하는 항천식용 조성물.Biotite, Kaolinite, Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite, and Muscovite ) As an active ingredient.
  18. 제 17 항에 있어서,18. The method of claim 17,
    상기 미네랄 이온 혼합물이 브루사이트(Brucite), 일라이트(Illite), 리메스톤(Limestone), 제올라이트(Zeolite), 올소클레이스(Orthoclase) 또는 올소클레이스 펠드스파(Orthoclase feldspar), 베마이트(boehmite), 네펠린(Nepheline), 팔리코르스카이트(Palygorskite) 또는 애터펄자이트(Attapulgite), 마그네사이트(Magnesite), 스페릴라이트(Sperrylite), 크렌네라이트(Krennerite), 페트자이트(Petzite), 기브사이트(Gibbsite), 앨러페인(Allophane), 플로고파이트(Phlogopite), 레피도라이트(Lepidolite), 실바나이트(Sylvanite), 글로코나이트(Glauconite), 돌로마이트(Dolomite), 토르말린(Tourmaline), 카날라이트(Carnallite), 안드라다이트(Andradite) 및 휴마이트(Humite)를 추가로 포함하는 것을 특징으로 하는 항천식용 조성물Wherein said mineral ion mixture is selected from the group consisting of Brucite, Illite, Limestone, Zeolite, Orthoclase or Orthoclase feldspar, boehmite, Nepheline, Palygorskite or Attapulgite, Magnesite, Sperrylite, Krennerite, Petzite, Gibb, (Gibbsite), Allophane, Phlogopite, Lepidolite, Sylvanite, Glauconite, Dolomite, Tourmaline, Canalite, Wherein the composition further comprises Carnallite, Andradite and Humite.
  19. 제 18 항에 있어서,19. The method of claim 18,
    상기 미네랄 이온 혼합물이 카올리나이트 15 내지 25 중량%, 바이오타이트 12 내지 23 중량%, 몬트모릴로나이트 15 내지 25 중량%, 서펜틴 10 내지 13 중량%, 마이카 7 내지 9 중량%, 버미쿨라이트 3 내지 5 중량%, 무스코바이트 2 내지 4 중량%, 클리노클로레 2 내지 5 중량%, 브루사이트 1 내지 3 중량%, 일라이트 1 내지 3 중량%, 리메스톤 1 내지 3 중량%, 제올라이트 0.5 내지 1.5 중량%, 올소클레이스 또는 올소클레이스 펠드스파 0.5 내지 1.5 중량%, 베마이트 0.8 내지 1.0 중량%, 네펠린 0.7 내지 0.9 중량%, 팔리코르스카이트 또는 애터펄자이트 0.7 내지 0.9 중량%, 마그네사이트 0.6 내지 0.8 중량%, 스페릴라이트 0.5 내지 0.7 중량%, 크렌네라이트 0.5 내지 0.7 중량%, 페트자이트 0.4 내지 0.6 중량%, 기브사이트 0.3 내지 0.5 중량%, 앨러페인 0.3 내지 0.5 중량%, 플로고파이트 0.3 내지 0.5 중량%, 레피도라이트 0.2 내지 0.4 중량%, 실바나이트 0.2 내지 0.4 중량%, 글로코나이트 0.2 내지 0.4 중량%, 돌로마이트 0.2 내지 0.4 중량%, 토르말린 0.1 내지 0.3 중량%, 카날라이트 0.1 내지 0.3 중량%, 안드라다이트 0.1 내지 0.3 중량% 및 휴마이트 0.05 내지 0.15 중량%를 포함하는 것을 특징으로 하는 항천식용 조성물.Wherein the mineral ion mixture comprises 15 to 25 wt% of kaolinite, 12 to 23 wt% of biotite, 15 to 25 wt% of montmorillonite, 10 to 13 wt% of serpentin, 7 to 9 wt% of mica, 1 to 3% by weight of broomsite, 1 to 3% by weight of ilite, 1 to 3% by weight of limestone, 0.5 to 3% by weight of zeolite, 2 to 4% 0.5 to 1.5% by weight of an isoparaffin, 0.5 to 1.5% by weight of an oligosaccharide or oligosaccharide spandex, 0.8 to 1.0% by weight of boehmite, 0.7 to 0.9% by weight of nephelin, 0.7 to 0.9% The present invention relates to a process for producing a zeolite, comprising the steps of: 0.6 to 0.8 wt% of magnesite, 0.5 to 0.7 wt% of spearylite, 0.5 to 0.7 wt% of crenelite, 0.4 to 0.6 wt% of petzite, 0.3 to 0.5 wt% Flogophite 0.3 to 0.5 0.2 to 0.4 wt.% Of gypsum, 0.1 to 0.3 wt.% Of tourmaline, 0.1 to 0.3 wt.% Of canalite, 0.2 to 0.4 wt. 0.1 to 0.3% by weight of andradite, and 0.05 to 0.15% by weight of humite.
PCT/KR2018/015205 2017-12-01 2018-12-03 Anticancer, antibacterial, alcohol-degrading, skin wound-healing, skin-regenerating, or antiasthmatic composition comprising mineral ion mixture WO2019108049A2 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
KR10-2017-0164585 2017-12-01
KR20170164585 2017-12-01
KR10-2018-0005734 2018-01-16
KR20180005734 2018-01-16
KR10-2018-0086173 2018-07-24
KR1020180086173A KR101996383B1 (en) 2017-12-01 2018-07-24 An anticancer composition comprising purtiton
KR1020180107033A KR101973198B1 (en) 2018-01-16 2018-09-07 Composition for preventing and treating asthmatic disease comprising mineral ion complex
KR10-2018-0107032 2018-09-07
KR10-2018-0107033 2018-09-07
KR1020180107032A KR101963614B1 (en) 2018-09-07 2018-09-07 A composition for reducing hangover comprising complex containing mineral ion complex
KR10-2018-0135373 2018-11-06
KR1020180135373A KR102022671B1 (en) 2018-11-06 2018-11-06 Composition for skin wound healing and regeneration comprising mineral ion complex
KR10-2018-0152879 2018-11-30
KR1020180152879A KR102037431B1 (en) 2018-11-30 2018-11-30 An antibacterial composition comprising plant extracts and the antiviral agent comprising the same

Publications (2)

Publication Number Publication Date
WO2019108049A2 true WO2019108049A2 (en) 2019-06-06
WO2019108049A3 WO2019108049A3 (en) 2019-08-08

Family

ID=66665149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/015205 WO2019108049A2 (en) 2017-12-01 2018-12-03 Anticancer, antibacterial, alcohol-degrading, skin wound-healing, skin-regenerating, or antiasthmatic composition comprising mineral ion mixture

Country Status (1)

Country Link
WO (1) WO2019108049A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112441825A (en) * 2019-08-28 2021-03-05 延世大学原州产学合作团 Ceramic composition for relieving or improving inflammation and preparation method thereof
CN113952462A (en) * 2021-11-18 2022-01-21 中南大学湘雅三医院 New application of synthetic fiber-like serpentine nano material

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217853B2 (en) * 2002-05-24 2007-05-15 Corium International, Inc. Composition for cushions, wound dressings and other skin-contacting products
KR100992216B1 (en) * 2008-04-22 2010-11-04 순천향대학교 산학협력단 Mineral Composition For Treating Wound
KR20100025435A (en) * 2008-08-27 2010-03-09 순천향대학교 산학협력단 Inhibitory effect of ore mineral mixtrue on the allergic inflammation
US8465731B2 (en) * 2010-03-12 2013-06-18 Elc Management, Llc Probiotic color cosmetic compositions and methods
KR20170030245A (en) * 2015-09-09 2017-03-17 이대훈 An manufacturing method of far infrared ray radiation material with phyllosilicate

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112441825A (en) * 2019-08-28 2021-03-05 延世大学原州产学合作团 Ceramic composition for relieving or improving inflammation and preparation method thereof
CN113952462A (en) * 2021-11-18 2022-01-21 中南大学湘雅三医院 New application of synthetic fiber-like serpentine nano material

Also Published As

Publication number Publication date
WO2019108049A3 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
WO2012074183A1 (en) Pharmaceutical composition for preventing or treating inflammatory diseases comprising trachelospermi caulis extract and paeonia suffruticosa andrews extract, and method for preparing the same
WO2017048028A1 (en) Novel antimicrobial peptide derived from myxinidin peptide, and use thereof
WO2016060525A1 (en) Composition containing extract or fraction of genus justicia plant
WO2020091440A9 (en) Composition for improving skin barrier damage and/or alleviating skin inflammation, containing 3,5-dicaffeoylquinic acid as active ingredient
WO2015002393A1 (en) Composition for treating or preventing inflammatory skin disease, comprising, as active ingredient, immature citrus fruit extract, or synephrine or salt thereof
WO2019108049A2 (en) Anticancer, antibacterial, alcohol-degrading, skin wound-healing, skin-regenerating, or antiasthmatic composition comprising mineral ion mixture
WO2019103541A1 (en) Anti-inflammatory composition comprising graphene nano-structure
WO2017179931A1 (en) Pharmaceutical composition for preventing or treating respiratory disease comprising extract of justicia procumbens l.
WO2015037778A1 (en) Composition containing lignan compound as active ingredient for preventing or treating cancer
WO2022260454A1 (en) Composition for atopic dermatitis treatment or skin barrier strengthening or skin aging prevention, comprising forsythia velutina nakai extract
WO2020067748A1 (en) Composition having anti-stress, anti-depressant or anxiolytic effect comprising at least one compound selected from the group consisting of undecanal, dodecanal, and pharmaceutically acceptable salts thereof as active ingredient
WO2013172525A1 (en) Cosmetics, pharmaceuticals, and food composition containing pieces or extract from fish eyes
WO2020032365A1 (en) Composition, comprising ginsenoside compound, for preventing or treating inflammasome-mediated inflammatory disease
WO2015111832A1 (en) Composition for preventing or treating prostate-related diseases, containing poncirus trifoliate extract
WO2016010340A1 (en) Composition for preventing and treating inflammation or allergic diseases, containing gynura procumbens extract as active ingredient, and use thereof
WO2020085826A1 (en) Composition for alleviation of skin irritation induced by environmental pollution factors or for skin protection, containing nutmeg extract or macelignan as active ingredient
WO2018106009A1 (en) Composition containing maple tree leaf extract or fractions thereof for preventing or treating inflammatory ocular diseases
WO2015037855A1 (en) A composition comprising an extract of combined herbs consisting of acanthopanax koreanum nakai and crinum asiaticum var. japonicum showing preventing activity of baldness and stimulating activity of hair growth
WO2021002642A1 (en) Composition for preventing or treating rheumatoid arthritis, comprising snake venom
WO2015105373A1 (en) Composition for prevention or treatment of asthma, comprising e uonymus alatus extract or fraction thereof
WO2013024960A1 (en) Medical composition containing stauntonia hexaphylla extract
WO2016122091A1 (en) Pharmaceutical composition for prevention and treatment of allergic disease or contact dermatitis, comprising cymbidium extract as active ingredient
WO2020027534A1 (en) Composition comprising punicalagin for inhibiting par2 activity
WO2023182540A1 (en) Composition for preventing and ameliorating viral disease
WO2012096463A2 (en) Composition containing a mixed herbal extract as an active ingredient for preventing and improving allergic or non-allergic skin disease, and uses thereof

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18883605

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 01/02/2021)

122 Ep: pct application non-entry in european phase

Ref document number: 18883605

Country of ref document: EP

Kind code of ref document: A2